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ABSTRACT 
There is increasing evidence demonstrating a determinant role of gut microbiota in 
host health, and one underlying mechanism is via gut-microbial metabolites-host 
interaction in modulating host’s cellular functions. SCFAs, main fermentation products of 
dietary fibres by gut microbiota in GI tract, are considered to be generally beneficial to the 
host. It has been shown that SCFAs act as substrates for energy metabolism, receptor 
agonists, and as histone deacetylase (HDAC) inhibitors. However, there are still gaps in the 
knowledge of their biological effects. It has been hypothesised that SCFAs may act as 
substrate for energy metabolism as well as ligand for several GPCRs, thus play roles in many 
cellular functions. Combining 1H nuclear magnetic resonance (NMR) spectroscopy with 
multivariate statistical analysis of the effect of SCFAs on the hepatic cancer metabolic 
network identified a metabolic signature associated dose- and time- related SCFA 
exposure. TCA cycle intermediate, α-keto-β-methylvalerate was strongly correlated with 
the treatment of SCFAs suggesting the preferential of the cells to SCFAs for energy 
production. This signature further confirms that SCFAs play direct role in host energy 
metabolism. Having implemented a harmonised pharmacological assessment of a 
comprehensive SCFA panel on FFAR2, FFAR3, and GPR109A, this study is the first to reveal 
that isobutyrate and isovalerate are novel partial agonists for GPR109A. Furthermore, 
niacin, a classical agonist for GPR109A also has been shown to activate FFAR2 and FFAR3 
but with much lower affinity. In another study, the effect of SCFAs on 3T3-L1 adipogenesis 
and adipocytes lipolysis has been characterised. Dosing the 3T3-L1 cells with isobutyrate, 
valerate, and isovalerate significantly induce the adipogenesis of the cells. In contrast, 
other SCFAs have no effect of the 3T3-L1 cell differentiation. Subsequent study focused on 
the effect of SCFAs on basal adipocyte lipolysis. Mature adipocytes were treated with 100 
µM of SCFAs for 3hr and glycerol release was measured. This study revealed the anti-
lipolytic property of propionate, butyrate, and valerate by significantly inhibits lipolysis in 
mature 3T3-L1 adipocytes. Thus, the role of SCFAs in regulating adipocytes functions may 
be particular important and beneficial in regulating plasma lipid profile and possibly 
aspects of metabolic syndrome. Together, these data enhance our understanding on the 
role of SCFAs on important metabolic tissues, which are hepatocyte and adipocyte. 
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CHAPTER 1  
 
1.  INTRODUCTION 
 
1.1 Obesity 
Obesity is one of the most important health problems in the world right now. The 
worldwide prevalence of obesity has increased drastically since 1980, and according to the 
data from World Health Organisation (WHO) in 2014, there are more than 1.9 billion 
overweight adults with 600 million classified as clinically obese. Overall, approximately 13% 
of the adult population in the world were obese (11% of men and 15% of women). Children 
are not excluded from this problem with 42 million children under the age of 5 were obese 
or overweight in 2013 (WHO, 2015). The occurrence of obesity in developed countries to 
increase in part due to inactive lifestyle.  
Obesity is the results of a long-term imbalance between energy intake and 
expenditure, which is regulated by a number of pathways involving metabolites and 
hormones (Greenwood et al., 2011). In addition, its development also depends on genetic 
and environmental factors. Moreover, this epidemic also increases the chance of having 
other health problems including type 2 diabetes, hypertension, respiratory problems, 
cardiovascular diseases (CVDs), and cancer (van Greevenbroek et al., 2013; Liu et al., 2010; 
Wildman et al., 2011). The healthcare cost for obesity costs the world economy around $2 
trillion in economic burden (Dobbs and Manyika, 2015). Therefore, reversing the obesity 
trend is crucial as it could greatly save world economy.   
 
22 
 
1.1.1 Definition of obesity and metabolic syndrome. 
Obesity is a medical condition characterised by an accumulation of excess body fat 
to the magnitude that it may affect health. A person is considered obese when having body 
mass index (BMI) of 30 or more (http://www.who.int/topics/obesity/en/). However, BMI 
cannot be used as the only method to definitively diagnose obesity. A very muscular person 
for example, can have a high BMI without having an excess of body fat, and can easily be 
misclassified (Seidell and Flegal, 1997). Therefore, a waist circumference measurement is 
a better method to define obesity as it measures the proportion of abdominal fat. 
Obesity is commonly associated with an array of additional chronic metabolic 
problems, including hyperglycaemia, hypertriglyceridemia, low high-density lipoprotein 
cholesterol (HDL), and high blood pressure (Alberti et al., 2005). The epidemiological 
clustering of these conditions led to the introduction of the `metabolic syndrome’ concept, 
defined by the presence of three or more of these conditions (Alberti et al., 2005).   
Metabolic syndrome is a strong predictor of the development and progression of CVDs, the 
leading cause of mortality and morbidity worldwide (Després and Lemieux, 2006; Kim and 
Reaven, 2004). 
 
1.1.2 Aetiology of obesity and metabolic syndrome 
Despite a growing knowledge on the signalling pathways involved in obesity and 
metabolic syndrome, their causes and regulatory checkpoints remain unclear. Most of the 
evidence suggests that the aetiology for obesity as well as metabolic syndrome is resulted 
from complex interaction between genetic and environmental factors (Bleich et al., 2008). 
Factors, such as eating habits, genetics, environment, metabolism, and lifestyle play 
an important role in the development of obesity. Obesity is a highly heritable trait. Studies 
focusing on the inheritance pattern rather than on the specific genes have demonstrated 
that child from obese parents has ~70% chances to get obese compared to the child of 
normal weight parents (Barsh et al., 2000).    
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However, over 90% of obesity cases are still of uncertain origin and less than 10% 
are associated with genetic and hormonal causes (Xu and Xue, 2015). For instance, a study 
performed to characterise causative genes for obesity and metabolic syndrome has 
demonstrated that the obese (ob) gene in C57BL/6 mouse model and its product, leptin, 
regulate both food intake and energy expenditure (Zhang et al., 1994). However, the 
frequency of this mutation on human obese gene is very rare, and the obesity pandemic in 
human is not primarily caused by dysregulation of leptin production (Pi-Sunyer et al., 
1999).  
In the Western world, as well as in developing countries, sedentary lifestyles and 
high-carbohydrate and high-fat diets frequently lead to obesity as a consequences of the 
imbalance between energy intake and energy expenditure. Environmental stimuli, such as 
diet or stress, can trigger epigenetic mechanisms (e.g. histone acetylation, DNA 
methylation) that regulate the expression of several genes involved in cell differentiation 
and energy homeostasis (Musri and Párrizas, 2012; Pjetri et al., 2012). An animal study 
showed that high fat diet (HF) causes DNA methylation of gene promoters in specific brain 
areas, thus decreasing gene expression in the reward-related brain regions (Pjetri et al., 
2012). 
There is growing evidence that the gut microbiota can also play a role in systemic 
metabolism, making the host more prone or resistant to obesity and its related diseases. It 
has been shown that mammalian host-gut microbiota interaction plays an important role 
in the host’s physiological processes such as in nutrients digestion and absorption, increase 
energy harvest, and can play a pivotal role in the development of metabolic diseases 
(Holmes et al., 2011). Previously, a study has revealed that obesity is associated with 
changes in the composition of specific gut microbiota and their activity, which cause an 
increase in efficiency to extract energy from the diet (Turnbaugh et al., 2006). These results 
highlight that the gut microbiota could play a significant factors in the development of 
obesity. 
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1.1.3 Adipocytes dysfunction and obesity. 
Energy balance or homeostasis can be explained by the energy equation. Under 
normal conditions in which there is sufficient energy availability, the amount of energy 
intake is equal with energy expenditure. Thus, the amount of energy stored in the form of 
adipose tissues remains constant. The maintenance of energy balance requires complex 
communication between central nervous system (CNS) and other tissues. This takes place 
through a number of mechanisms, including hormonal control, neural, and nutritional 
signals. Obesity develops as a result of a long-term imbalance in these processes. It is 
characterised by an increase in the accumulation of triglyceride (TG) storage in adipose 
tissues and peripheral tissues. Adipogenesis is a tightly regulated process in which 
preadipocytes are differentiated into mature adipocytes and become highly specialised 
cells. Mature adipocytes are spherical cells with the majority cellular component being lipid 
droplet. Normal adipocytes are metabolically active and dynamic in response to different 
hormones (Kersten, 2001). Adipose tissue is a site where excess energy is stored in the 
form of TGs, and when needed somewhere else in the body, the TGs are then mobilised 
and then hydrolysed to generate fatty acids (FAs), which is subsequently transported into 
mitochondria to undergo β-oxidation (Duncan et al., 2007a). During development of 
obesity, there is an accumulation of fat mass attributed to both adipocyte hypertrophy and 
hyperplasia, usually concomitant with increased angiogenesis and macrophage infiltration 
into adipose tissue as well as an altered secretory profile (Bourlier et al., 2008). 
As a physiological response to chronic nutrient surplus, hyperinsulinemia promotes 
enlargement of the adipocyte by increasing the expression of lipogenic enzymes while 
reducing lipolysis. As adipocytes are full with lipids, if there is an inadequate proliferation 
and differentiation of adipocyte to cope the energy excess, for example due to genetically 
defect in adipocyte differentiation, the upper limit of lipid storage will be reached. This 
results in an increase in the size of adipocyte, resulting in hypertrophic adipocytes (Jankovic 
et al., 2015). Hypertrophic adipocytes are typically seen in obese individuals. These are 
characterised by having elevated circulating level of pro-inflammatory cytokines (e.g. IL-6 
and TNF-α), an altered adipokine secretion profile, and increased lipolytic capacity 
(Hauner, 2005; Laurencikiene et al., 2011; Skurk et al., 2007). These types of adipocytes 
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have been suggested to decrease sensitivity to insulin and impair the insulin-mediated 
effect in adipose tissue, including its anti-lipolytic regulation (Jankovic et al., 2015). 
Impairment of lipolysis regulation results in the increase of free fatty acids (FFAs) and 
glycerol release, which further cause an elevation level of plasma non-esterified fatty acids 
(NEFA). An increase in adipocyte lipolysis in hypertrophic adipocytes causes elevation in 
plasma FFAs, which promotes ectopic fat deposition in non-adipose tissues, including liver, 
pancreas, skeletal muscle, and heart (Snel et al., 2012). Lipid accumulation in these tissues 
impairs insulin sensitivity and cell functions (Snel et al., 2012).  
 
1.1.4 Free FAs and insulin resistance. 
The clinical definition of insulin resistance (IR) is “the inability of a known quantity 
of exogenous or endogenous insulin to increase glucose uptake and utilisation in an 
individual as much as it does in normal population” (Lebovitz, 2001). During fasting, lipids, 
stored in the form of TGs in adipocytes and hepatocytes are broken down and hydrolysed 
into glycerol and free FAs via a process called lipolysis. The resulting free FAs then enter 
blood circulation, bind with serum albumin and are then transported to peripheral tissues, 
such as muscle and kidney for energy production. Disruption of lipolysis causes excess of 
free FAs in circulation, the medical condition known as hyperlipidaemia. There is growing 
evidence demonstrating the deteriorated effects of excess free FAs on both insulin 
sensitivity and insulin secretion, which lead to the development of IR. In a study of non-
obese, normal glucose-tolerant persons with genetic predispositions to type 2 diabetes 
(T2D), prolonged lipid infusion for more than 24 hours to a level that is similar to the plasma 
free FAs level in obese individuals, led to impaired glucose-stimulated insulin secretion 
(GSIS) by pancreatic β-cells, and caused hepatic insulin resistance (Kashyap et al., 2003).  
Skeletal muscle has been identified as an important endocrine organ that produces 
and releases cytokines, which are called “myokines” (Pedersen and Febbraio, 2008). A 
study conducted on lean and healthy individuals without history of T2D in family has 
demonstrated that a prolonged physiological increase in plasma free FAs to the same level 
as can be found in obese person impairs the insulin sensitivity (Kashyap et al., 2004). In 
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different study, increase in plasma free FAs causes a dose-dependent inhibition of insulin-
mediated glucose uptake by skeletal muscle and insulin signalling cascade (Belfort et al., 
2005). Moreover, lean glucose tolerant individuals showed a decrease in insulin sensitivity 
as well as impaired mitochondrial inner membrane potential after short-term increase in 
plasma free FAs levels (Chavez et al., 2010).  
The impairment of insulin action by hyperlipidaemia often associated with other 
disorders such as dyslipidaemia, hypertension, and fat accumulation in adipose tissues. 
This causes deterioration in insulin signalling thus promoting the development of insulin 
resistance (IR) (Delarue and Magnan, 2007; Saltiel and Kahn, 2001). The deterioration in 
insulin signalling has been shown to affect important cellular pathways that are crucial in 
maintaining energy homeostasis (Sharma et al., 2008).  
 
1.2 Obesity and energy homeostasis. 
As mentioned previously, obesity is characterised by increased TG in adipose tissue 
and non-adipose tissues. This condition is a result of an imbalance between energy intake 
and energy expenditure. In order to carry out their functions, all cells require energy. 
Energy can be obtained from diets or in the event of low nutrient supply, it can be obtained 
from source stored within the cell (TGs). The main source of energy substrate for most 
organisms is glucose. It is the key energy source for human body. Besides glucose, our body 
also capable of utilising FAs, and amino acids for fuel as well as for carrying out many 
cellular processes. The right combination of these nutrients allows the body to function 
well and remain healthy. Metabolic pathway is a series of biochemical reactions in a cell 
that build or breakdown molecules for cellular processes. The energy pathways involving 
glucose, FAs, and amino acids are connected due to having many common intermediate 
metabolites which subsequently feed into tricarboxylic acid cycle (TCA cycle) to generate 
ATP (Ramsey Bronk, 1999). 
Plasma glucose concentration is determined by the rate of glucose entering the 
circulation and the rate of glucose utilisation (Aronoff et al., 2004). It requires a precise 
matching of these two processes in order to maintain the normal plasma glucose 
27 
 
concentration (Giugliano et al., 2008).  Circulating glucose is obtained from three sources; 
1) intestinal absorption during the state of digestion of dietary carbohydrate; 2) 
glycogenolysis; 3) and via gluconeogenesis. There is a potential of brain damage due to low 
circulating blood glucose or severe hypoglycaemia, while chronically high glucose levels in 
the circulation (hyperglycaemia) is toxic and has been shown to cause organ damage 
(Adler, 2002). Following high carbohydrate diets, human body stores glucose in the liver 
and the skeletal muscle in the form of glycogen. When glucose is not being used for energy, 
it is converted into glycogen by the process called glycogenosis. Glycogen acts as the 
secondary energy storage, fat being the body’s primary energy storage in adipose tissue. 
In addition, the catabolism of glucose produces acetyl-CoA, an intermediate metabolite. 
Acetyl-CoA is used for FA synthesis, the process known as lipogenesis. Lipogenesis includes 
both the synthesis of FA and TG synthesis, where the latter is produced by the esterification 
of glycerol and FAs (Kersten, 2001).  
During starvation or low energy levels, human body undergoes glycogenolysis and 
lipolysis, breaking down glycogen and TGs to generate glucose and free FAs, respectively 
which supply energy for other tissues. The glucose produced in this manner is then 
metabolised to produce pyruvate via glycolysis, while the FAs undergo β-oxidation forming 
acetyl-CoA. Moreover, amino acids, produced from the catabolism of proteins also can 
generate intermediate metabolites for TCA cycle and generate energy for the cell. The 
human body can also undergo gluconeogenesis, a metabolic process that can generate 
glucose from non-carbohydrate carbon substrate such as pyruvate, glycerol, and 
glucogenic amino acids. In humans, only two organs have sufficient gluconeogenic 
enzymes activity and glucose-6-phosphatase (G6Pase) activity, which are the liver and the 
kidney. These two enzymes allow them to release glucose into the bloodstream as a result 
of gluconeogenesis (Gerich et al., 2001).  
Pyruvate, acetyl-CoA, and other intermediate metabolites produced in the manners 
explain above will then use to generate energy via incorporating in the TCA cycle. The series 
of reactions of the TCA cycle generate reduced coenzymes (3 NADH and 1 FADH2), which 
will then use by the oxidative phosphorylation to form energy-rich adenosine triphosphate 
(ATP). Energy homeostasis is largely controlled by hormonal excretion. In human body, the 
glucoregulatory hormones are responsible in maintaining normal circulation of glucose. In 
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particular, insulin is the main glucoregulatory hormone (Giugliano et al., 2008). Ingestion 
of carbohydrate causes a rise in insulin secretion and stimulates glucose uptake by the cell. 
It also increases glycogenesis and FAs synthesis activity, while at the same time inhibiting 
protein degradation. In the fasting state, insulin secretion is reduced and simultaneously 
increased the secretion of glucagon from α-cells of the islets of Langerhans of the pancreas. 
Glucagon increases circulating glucose by promoting glycogenolysis and gluconeogenesis. 
In this condition, lipolysis activity is also increased while decreasing the lipogenesis. 
 
 
Figure 1.1: Amino acid catabolism showing the fate of carbon skeletons and how they enter the 
TCA cycle. Figure was adapted from Ramsey Bronk, (1999). 
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1.2.1 Amino acid metabolism. 
Proteins are an integral part of the human body and are involved in many of the 
biosynthetic pathways. A number of evidences show that amino acids directly involve in 
cell-specific nutrient metabolism (Jobgen et al., 2006), cell signalling (Marc Rhoads and Wu, 
2009), oxidative defence (Wu et al., 2004), as well as increase the efficiency of utilising 
dietary proteins (Wang et al., 2008). Dietary proteins and amino acids are essential 
nutrients as they supply the nitrogen source for the synthesis of nitrogenous compounds 
(protein, amino acids, and nucleic acids) for cells. Due to the needs for nitrogen balance 
and cell growth, amino acids can be supplied from diet. They are classified in two main 
groups; 1) nutritionally essential, and 2) non-essential (Wu, 2009). Essential amino acids 
(EAAs) are amino acids that cannot be synthesised by body and must be supplied from the 
diet, while non-essential amino acids (NEAAs) can be synthesized de novo from a non–
amino acid source of nitrogen (Table 1.1).  
Protein and amino acid degradation can produce intermediate metabolites for 
energy production. The catabolism of amino acids provides up to 15% of the human body’s 
energy requirement. Dietary protein digestion in the stomach occurs through the action of 
pepsins, and continues within the lumen of duodenum. There are two main pancreatic 
enzymes responsible in the digestion of protein in small intestine, which are trypsin and 
chymotrypsin (Rawlings and Barrett, 1994; Wilcox, 1970). Protein breakdown, or 
proteolysis, generates amino acids and peptides, which are then absorbed by enterocytes 
via peptide transporters (PepT1). Inside the enterocyte, the peptides are further 
hydrolysed into amino acids by the action of cytoplasmic peptidase. The resulting amino 
acids are then shuffled across intestinal mucosa by basolateral amino acids transporter and 
enter the blood circulation (Ramsey Bronk, 1999). Amino acids are distributed into other 
tissues where they can have a number of fates; 1) to synthesise new amino acids, 2) used 
for protein biosynthesis, or 3) degraded to provide nitrogen. In the organism, amino acids 
catabolism is strongly regulated in order to maintain the balance between nitrogen intake 
and nitrogen excretion levels. The balance between nitrogen intake and excretion is strictly 
controlled to keep a constant nitrogen level in the organism. 
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Table 1.1: Amino acids in human 
Essential amino acids Non-essential amino acids 
Histidine* Alanine 
Isoleucine Arginine* 
Leucine Aspartic acid 
Lysine Cysteine 
Methionine Glutamic acid 
Phenylalanine Glutamine 
Threonine Glycine 
Tryptophan Proline 
Valine Serine 
 Tyrosine 
 Asparagine 
(*) Essential in certain cases. (Fürst and Stehle, 2004; Reeds, 2000; Wu, 2009). 
 
The initial stage in the catabolism of many amino acids (phenylalanine, tyrosine, 
leucine, isoleucine, valine) is transamination. Transamination is a process in which α-keto 
acids are converted into 2-oxo acids by the action of aminotransferase enzymes (Ramsey 
Bronk, 1999). In this process, α-amino groups are transferred to either oxaloacetate or 2-
oxoglutarate producing aspartate or glutamate, respectively. These two amino acids then 
participate in urea cycle. Glutamate needs to be deaminated by glutamate dehydrogenase 
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to provide ammonia, which is used to synthesis another urea cycle intermediate, citrulline. 
On the other hand, aspartate participates directly in urea synthesis (Ramsey Bronk, 1999). 
For other amino acids (such as arginine, lysine, proline, threonine, and tryptophan), there 
is no transamination reaction process for during their catabolism process. Instead, the 
major pathway for the degradation of these amino acids involves the conversion into 
different amino acids.  
Following nitrogen removal, most of the carbon atoms from amino acid carbon 
skeletons are degraded to TCA cycle intermediates, pyruvate, and acetyl-CoA which are 
used to generate ATP and CO2 (Figure 1.1). Amino acids can form glucose via pyruvate in 
tissues capable of gluconeogenesis and can be converted into FAs or ketone bodies via 
acetyl-CoA production. However, leucine and lysine do not form glucose as they are 
exclusively ketogenic and can only yield acetyl-CoA (Ramsey Bronk, 1999; Wu, 2009). 
Although protein is not the primary energy source for human body, it is still important to 
consider the dietary significance of proteins in the energy supply. The balance of nitrogen 
in the body is tightly regulated by the rate of protein turnover and the production of urea. 
Due to this reason, a diet high in protein can promote amino acid degradation, which can 
cause excess in FAs synthesis, increase TGs storage, and thus promote obesity.  
 
1.3 Host-gut microbiota interactions. 
The human body is a habitat for diverse microbial organisms. These microbial 
organisms live at various sites all over the human body (Camp et al., 2009; Eckburg et al., 
2005). The major site where the most microbial populations reside is at the human 
intestinal tract, where the population is up to 100 trillion bacteria, far more than all other 
microbial population in body’s surface (Bäckhed et al., 2005). The human gut microbiome 
is considered as a microbial organ inside the host. It is a collection of different cell lineages 
that are capable of communicating with each other and the host, and has an ability to 
undergo self-replication for its repair and maintenance. Moreover, it also consumes, 
stores, and redistributes energy, as well as regulating many important physiological 
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processes (Bäckhed et al., 2005). The human gut microbiota may contain approximately 
100 times as many genes as the host’s genome (Bäckhed et al., 2005). 
 
1.3.1 Gut microbial ecology. 
There are more than 800 different species of bacteria incorporated in human gut, 
with the highest number of bacteria can be found in the colon (up to 1012 cells/gram of 
faeces) (Eckburg et al., 2005). The composition and number of the bacteria reside along 
the GI tract is increase from the stomach to the colon (Figure 1.2). There is growing 
evidence that suggest the colonisation of human gut starts before birth. After birth, at first 
the infant’s microbiota shows low diversity and stability, but increase and converges 
towards an adult-type microbiota by the end of the first 36-60 months of life (Rodríguez et 
al., 2015). The establishment of the microbiota is strongly dependent on external factors 
(DiBaise et al., 2008). In the first month of life, Bifidobacterium is the main genus especially 
in breast-fed infants (up to 90% of total faecal bacteria), while more diverse bacteria are 
found in formula-fed infant as well as in weaning children (Laparra and Sanz, 2010).  
Moreover, metagenomic analysis of human faecal samples show that in adults and weaned 
children, the major constituents of colonic microbiota are Bacteroides, followed by several 
genera from the Firmicutes, such as Eubacterium, Ruminococcus, and Clostridium, and the 
genus Bifidobacterium. In contrast, in the infants, Bifidobacterium and/or a few genera 
from the family Enterobacteriaceae, such as Escherichia, Raoultella, and Klebsiella are 
predominant (Kurokawa et al., 2007). The changes of this bacterial ecosystem occur 
throughout an individual's lifetime through the influence of several factors including diet, 
environmental, and disease conditions, and led to the alteration of bacterial-host symbiosis 
(Nazli et al., 2004; Xu et al., 2007). 
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Figure 1.2: Microbial numbers and composition in the gastrointestinal tract. Information taken 
from Sartor, (2008) and Sekirov et al., (2010). 
 
1.3.2 Roles of the gut microbiota in host physiology and health. 
The human intestinal tract provides the trillions of bacteria with a nutrient-rich 
environment for them to live and in exchange the host benefits from them as the gut 
microbiota help process nutrients for our body needs. This relationship between the 
human intestinal tract and its gut microbiota is often described as mutualism interaction, 
as both the bacteria and the host benefit from the interaction (Figure 1.3). For example, a 
highly-adaptive glycophile, Bacteroides thetaiotaomicron, is one of the most common 
known microbes in human intestine, capable of degrading the indigestible dietary 
polysaccharides that serve the host with 10-15% of their calorific requirement (Bäckhed et 
al., 2005). 
Gut microbiota is involved in the development of intestinal mucosa and systemic 
immune system throughout the life of the host (Macpherson and Harris, 2004). Studies 
conducted on Germ Free (GF) animals revealed that gut microbiota plays an important role 
in regulating physiological, biochemical, and immunological development of the host. GF 
animals have abnormal numbers of immune cell types and immune products. Moreover, 
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in GF animals, the formation of the spleens and lymph nodes are also impaired, with poorly 
formed B- and T-cell zones (Bauer et al., 1963). The GF mice also have a lower levels of 
serum immunoglobulin (IgG2 and IgG1) compared to holoxenic mice (Benveniste et al., 
1971). Reduction in the efficiency of the immune system and in inflammatory responses 
also observed in GF animals (Berg, 1996). Furthermore, commensal bacterium are also 
involved in many important intestinal functions by modulating the gene-expression profile 
of the intestinal epithelial-cell layer (Hooper, 2001). Therefore, the presence of gut 
microbial community is vital to the host as it helps in maintaining the gut formation and 
assisting in pathogen colonisation resistance (Nicholson et al., 2005).  
A large number of the microbiota cell metabolic processes beneficial to the host are 
involved in the digestion and degradation of indigestible dietary fibres. A number of gut 
microbiota species have been shown to involve in the metabolism of dietary fibres to short-
chain fatty acids (SCFAs), generating energy substrates for the host. Interestingly, the 
metabolism of nutrients by the bacteria is not only for the host’s benefit, but also benefit 
the microbiota itself, to maintain its population and activity. In addition, resident microbes 
also regulate fat storage by modulate the uptake of dietary lipids. It has been demonstrated 
that gut microbiota promotes de novo lipogenesis by increasing the activity of lipoprotein 
lipase (LPL) in adipose tissue, leading to an increase of hepatic triglyceride production. 
Previous study by Bäckhed et al found that conventionalisation of GF mice with normal 
mice cecal microbiota, produces a 60% increase in total body fat content even with reduced 
food intake (Bäckhed et al., 2004). As the gut microbiota is involved in many processes in 
host growth and development, the imbalance in its composition and number may lead to 
many diseases and dysfunctional in human body. Therefore, the balance of the microbiota 
species is very important and can determine the health of the host. 
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Figure 1.3: Gut microbiota and host symbiosis. Constructed based on idea taken from Neves et al., 
(2015). 
 
1.4 Production of SCFAs from fermentable substrates. 
Dietary fibres are defined as non-digestible carbohydrates and lignin that are 
intrinsic and intact in plant (IOM (Institute of Medicine), 2002).This means almost 100% of 
dietary fibres escape the digestion in the small intestine and reach the colon relatively 
intact, making them the main fermentable substrate available to the gut microbiota. 
Fermentation of the dietary fibres occurs predominantly in the proximal colon where 
substrate availability and bacterial activity are the highest. Toward the distal colon, 
substrate availability is limited and diffusion of substrates and microbial fermentation 
products is reduced because of the extraction of free water (den Besten et al., 2014). The 
main by-products of the microbial fermentation of carbohydrate including CO2, CH4, H2, 
SCFAs, bacterial cell mass, and heat (Cummings et al., 2001; Topping and Clifton, 2001).  
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Polysaccharides that enter the large intestine contain insoluble fibres of plant-wall 
polysaccharides, resistant starch, inulin, and oligosaccharides. It is estimated that 
approximately 10% of human caloric requirements are derived from the fermentation of 
dietary fibres by gut microbiota (Bergman, 1990a). SCFAs are organic acids with 1 to 6 
carbon atoms, and are the principal anions produced from this fermentation process along 
with the gasses H2, CH2, and CH4 (Cummings, 1981; Macfarlane and Gibson, 1995). The 
main SCFAs produced are acetate, propionate, and butyrate. Being the major SCFAs 
produced in this manner, they are released at high concentrations in ascending colon (70-
140 mM), while their concentration are declining in the transverse colon (20-70 mM) and 
in the descending colon (20-40 mM)(Topping and Clifton, 2001). The molar ratio of acetate, 
propionate, and butyrate production in the colonic lumen is 60:25:15, respectively (Tazoe 
et al., 2008). However, this ratio can change depending on several factors such as diet, 
microbial composition, and the site of fermentation (Fredstrom et al., 1994). The pathway 
of SCFAs production by anaerobic system are summarised in Figure 1.4 and the chemical 
formula for the main SCFAs is presented in Table 1.2.  
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Figure 1.4: Functional/phylogenetic groups involved with the formation and conversion of SCFA in 
the human large intestine. Diagram above simplified the main routes of carbohydrate fermentation 
in the human large intestine. Two distinct cross-feeding mechanisms operate in the GI tract: (1) 
due to the consumption of fermentation end-products (lactate and acetate), and (2) due to cross-
feeding of partial breakdown products from complex substrates (Belenguer et al., 2007; Falony et 
al., 2006). Both mechanisms contribute to the production of butyrate. Adapted from Macfarlane 
and Macfarlane (2003) and Flint (2006). PEP, Phosphoenolpyruvate. 
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1.4.1 Acetate 
Endogenous production of acetate in human body originates from the cells 
producing and utilising SCFAs (Pouteau et al., 2003). Under fasting condition, endogenous 
acetate contributes approximately 6.5% of resting energy expenditure in human (Pouteau 
et al., 2003). Colonic production of acetate (exogenous) is the major source of circulating 
SCFAs in human, accounting 60-70% of total SCFAs produced from carbohydrate 
fermentation (Pouteau et al., 2003). This is also the principal route by which the body 
obtains energy from carbohydrate that escapes digestion in small intestine (6.3-8.4 kJ g-1, 
1.5-2 kcal g-1) (Livesey, 1990; Roberfroid et al., 1993). Moreover, in animal studies, it has 
been demonstrated that acetate is secreted by the liver when the portal blood levels fall 
below a critical level (Salminen et al., 1998).   
Almost all heterotrophic anaerobic gut bacteria are able to produce acetate. 
However, up to one-third of all acetate in the large intestine can come from reductive 
acetogenesis (Miller and Wolin, 1996). Hydrogen produced during the fermentation 
process of the fibre is either released as gas or used by hydrogen-utilising species including 
methanogenic archaea, sulphate reducers, and acetogens (Macfarlane and Gibson, 1995). 
Species such as Ruminococcus productus and Rumminoccoccus hydrogenotrophicus are 
able produce acetate from H2 and CO2 (Bernalier et al., 1996; Ohashi et al., 2007) (Figure 
1.4). Apart from being taken up by colonic mucosa, butyrate-producing bacteria found in 
the human colon can be net utilisers of acetate. In particular, bacteria such as Anaerostipes 
caccae, Roseburia intestinalis, Roseburia sp. A2-181, Roseburia sp. A2-183, Coprococcus sp. 
Strain L2-50, and Faecalibacterium prausnitzii are able to produce butyrate from acetate 
(Duncan et al., 2002, 2004a; Falony et al., 2006). Roseburia intestinalis, Faecalibacterium 
prausnitzii, and Eubacterium hallii are the most abundant butyrate-producing bacteria in 
human colon with a mean populations of 2.3, 3.8, and 0.6%, of faecal microbiota, 
respectively. Among this, Faecalibacterium prausnitzii and Roseburia spp. generate much 
of their butyrate carbon from exogenously derived acetate via the action of butyryl-
CoA:acetyl-CoA transferase (Duncan et al., 2002). Formation of acetate benefits bacteria 
because it produces ATP via substrate-level phosphorylation (Macfarlane and Gibson, 
1997).  
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1.4.2 Propionate 
Intestinal bacteria produce propionate through two major routes; the first is 
directly from sugar in a single species, while the second route is indirect formation by cross-
feeding from succinate and lactate producers. It has been suggested that there are two 
main metabolic pathways of propionate production; the `randomising’ pathway via 
succinate and the acrylate pathway. Belenguer et al (2007) established that the dominant 
route of propionate formation was via the acrylate pathway, by which lactate was 
converted to propionate, so presumably the same applies for propionate formation via 
conversation of sugars (Belenguer et al., 2007) (Figure 1.5). If this assumption is correct, 
based on the process in rumen, the main species responsible for the formation of 
propionate from sugars and lactate would probably be Megasphaera elsdenii (Counotte et 
al., 1981). Furthermore, members of the Clostidium cluster IX such as Selenomonas, 
Megasphaera, and Veillonella spp. are capable of producing propionate through 
decarboxylation succinate (Flint, 2006).  
 
 
Figure 1.5: Acrylate pathway of propionate formation from lactate. Gut microbiota can increase 
the production of propionate via this pathway based from the in vitro fermentations of human 
faeces in the presence of lactate and the absence of carbohydrate. Information taken from 
Belenguer et al., (2007). 
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1.4.3 Butyrate  
Roseburia spp. and Faecalibacterium prausnitzii are the two most abundant groups 
of butyrate-producing bacteria isolated from human faecal samples (Duncan et al., 2006; 
Flint, 2006; Walker et al., 2005). As discussed earlier (section 1.4.1), butyrate is also 
produced by acetate-utilising bacteria. In addition, it has been reported that a significant 
amount of lactate can be converted into butyrate in the human colon by the action of 
lactate-utilising bacteria, Eubacterium hallii and Anaerostipes caccae (Duncan et al., 
2004b). There are two metabolic routes in which gut microbiota can produce butyrate. The 
first one is the conversion of butyryl-CoA to butyrate via butyrate kinase, and the second 
one is via acetyl-CoA transferase (Duncan et al., 2002; Louis et al., 2004). It has been 
suggested that the supply of butyrate in the colon can be influenced by diet and variations 
in the dominant metabolic type of butyrate-producer among individuals (Duncan et al., 
2004b).(Duncan et al., (2007) further validated this hypothesis in relation to dietary 
variations, which shows a significant decrease in members from Clostridium cluster XIVa 
(Roseburia spp. and Eubacterium rectale) that associated with butyrate production, caused 
by the decreasing of dietary carbohydrate intake. 
Despite producing acetate, propionate, and butyrate as it main fermentation 
products, gut-microbial fermentation of dietary fibres also resulted in the production 
several other metabolites but in much lower amounts. 
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Table 1.2: The chemical formula for the main SCFAs produced from the fermentation of dietary 
fibres by gut microbiota. 
 
 
1.4.4 Other fermentation products 
As mentioned previously, acetate, propionate and butyrate are the three major 
SCFAs produced by gut microbiota fermentation of dietary fibres. Other SCFAs also 
present, but in much lower amounts including formate, valerate, caproate, and branched 
chain fatty acids (BCFAs) 2-methylbutyrate, isobutyrate, and isovalerate. It has been shown 
that 2-methylbutyrate, isobutyrate, and isovalerate are formed by the fermentation of 
branched amino acids (BCAAs) (isoleucine, valine, and leucine, respectively) by the faecal 
microbiota (Macfarlane and Gibson, 1995). The levels of BCFAs are higher than other FAs 
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in the descending colon. This is caused by the higher rate of protein fermentation 
compared to carbohydrate fermentation due to substrates availability and increased of pH 
in this region (Cummings et al., 1987). Higher level (25%) of BCFAs production was 
observed after inoculation with gut microbiota from individuals with inflammatory bowel 
disease (IBD) compared with inoculation with microbiota from healthy individuals (van 
Nuenen et al., 2004). Based on this findings, high level of metabolites produced from 
proteolytic fermentation may play a role in the aetiology of IBD, but more data is needed 
to support this hypothesis. 
While majority of SCFAs especially butyrate are being used in the gut, however 
there is still small amount of these SCFAs being transported from the intestinal lumen into 
the portal blood where they are taken up by organs.   
 
1.5 Transport of SCFAs 
As mentioned previously, while the majority of SCFAs produced is utilised within 
the gut, a small proportion of these SCFAs reached the liver and peripheral tissues where 
they can be used as substrates and/or signalling molecules. As small proportion of SCFAs 
present in the gut in unionised forms, they can cross the apical membrane through passive 
diffusion. However, the major part of SCFAs exists in an ionised form and transport across 
the intestinal mucosa is mediated by two main protein transporters: 1) monocarboxylate 
transporter 1 (MCT-1) (Hadjiagapiou et al., 2000; Vidyasagar, 2005), and 2) sodium-coupled 
monocarboxylate transporter 1 (SMCT-1) (Gupta et al., 2006; Takebe et al., 2005). High 
expression of both transporters has been found on colonocytes (Takebe et al., 2005; 
Teramae et al., 2010). In addition, MCT-1 also expressed abundantly on lymphocytes 
(Halestrap and Meredith, 2004), while SMCT-1 is expressed in kidney and thyroid gland 
(Ganapathy et al., 2005). 
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1.6 SCFAs are G-protein coupled receptor (GPCR) agonists. 
Next to its role as substrate for energy production, previous studies indicate that 
SCFAs can act as signalling molecules through cell surface receptors known as G-protein 
coupled receptors (GPCRs). This group of protein receptors constitutes a large and diverse 
family of proteins that sense molecules outside the cell and activate intracellular signalling 
cascades. GPCRs are also known as seven-transmembrane (7TM) receptors with an 
extracellular N-terminus and an intracellular C-terminus (Palczewski et al., 2000). Several 
endogenous ligands, such as hormones, peptides, protein, neurotransmitters, and fatty 
acids are able to activate GPCRs (Howard et al., 2001; Kirkham et al., 1992). Upon ligand 
binding, the structural changes within GPCRs allow the receptors to activate guanine-
nucleotide binding protein (G protein) inside the cell. G protein is a heterotrimeric protein 
that made up of an alpha (α), beta (β), and gamma (γ) subunits (Hurowitz et al., 2000), the 
activation of which regulates cellular responses via a variety of second messenger cascades 
(Lefkowitz, 2007; Oldham and Hamm, 2007; Wettschureck and Offermanns, 2005). In 2003, 
three independent groups have successfully deorphanised G-protein coupled receptor 41 
(GPR41) and 43 (GPR43), and revealed that SCFAs act as a ligand for these receptors (Brown 
et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003). The receptors were later renamed to 
free-fatty acid receptor 2 (FFAR2) and 3 (FFAR3), for GPR43 and GPR41, respectively. These 
two receptors share 42% amino acid identity and belong to the same family (Brown et al., 
2003). Another type of GPCR, called GPR109A (also known as hydroxycarboxylic acid 
receptor 2 or HCA2) is a high affinity receptor for niacin which also can be activated by 
butyrate (Thangaraju et al., 2009a). 
 
1.6.1 FFAR2 
FFAR2, also known as GPR43 is activated by high micromolar or millimolar 
concentrations of SCFAs, most notably acetate, propionate, and butyrate with varying 
potency. This receptor responds somewhat more strongly to shorter chain length SCFAs, 
while propionate was reported to be the most potent agonist, acetate is the most selective 
(Le Poul et al., 2003). FFAR2 couples primarily to Gαi and Gαq proteins family (Figure 1.6-
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B). FFAR2 activation following ligand binding activates a series of second messenger 
cascades regulating intracellular responses. Gαi family were first identified as the inhibitory 
G proteins (Bokoch et al., 1984). Activation of Gαi protein subunit inhibits the production 
of  cyclic adenosine monophosphate (cAMP)-dependent pathway by adenylate cyclase, 
resulting in the reduction in intracellular cAMP production from ATP (Birnbaumer, 2007; 
Le Poul et al., 2003). As for the Gαq, this protein family activates phospholipase Cβ (PLCβ) 
isoforms. Activated PLCβ then hydrolyses phosphatidylinositol 4,5 bisphosphate into 1,2 
diacylglycerol (DAG) and inositol 1,4,5 triphosphate (IP3). While DAG acts as a second 
messenger that activate protein kinase C (PKC), IP3 binds to specific IP3 receptor (calcium 
(Ca2+) release channels in the endoplasmic reticulum, thus increase Ca2+ release (Le Poul et 
al., 2003).  
FFAR2 was shown to be highly expressed in immune cells such as 
polymorphonuclear (PMN) cells and peripheral blood mononuclear (PBMC) cells, with high 
expression was observed in neutrophils (Brown et al., 2003; Le Poul et al., 2003; Nilsson et 
al., 2003). A number of studies have demonstrated that FFAR2 acts as a chemoattractant 
receptor for SCFAs in neutrophils (Le Poul et al., 2003; Maslowski et al., 2009; Vinolo et al., 
2011). A study conducted by(Maslowski et al., (2009) demonstrated that FFAR2-deficient 
mice show  exacerbated or unresolving inflammation in model of colitis, arthritis, and 
asthma. In addition, germ-free mice which are unable to produce SCFAs from fibre, display 
similar dysregulation of inflammatory responses, which suggests that SCFAs and FFAR2 are 
likely to have a molecular link between fibre-rich diet, gut microbial metabolism, and 
inflammatory immune responses (Maslowski et al., 2009).  
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Figure 1.6: Role of butyrate in colonocytes metabolism and schematic overview of receptors 
activation by short-chain fatty acids (SCFA). (A) Fate of butyrate after being produced from 
microbial fermentation of dietary fibre. (B) FFAR2, and (C) FFAR3, and GPR109A signalling 
pathways. Part of illustrations was designed using Servier Medical Art used under CC BY 3.0. 
Adapted from Neves et al., 2015). 
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It has been shown previously that SCFAs, in particular propionate and butyrate are 
able to inhibit the growth of colon cancer cells in in vitro model (Gamet et al., 1992). More 
recently, a study shows that the expression of FFAR2 is frequently reduced or abolished in 
colon cancer cells, and that the restoration in the FFAR2 expression followed by propionate 
treatment induced G0/G1 cell cycle arrest and activated caspases, and increased apoptotic 
cell death (Tang et al., 2011).  Therefore, it is suggested that there is a possible link between 
the gut microbial fermentation products and FFAR2 in lowering colon cancer incidence. 
FFAR2 is also found to be expressed in peptide YY (PYY)-expressing enteroendocrine cells 
(L cells) (Karaki et al., 2006). These cells produce glucagon like peptide (GLP-1), a hormone 
which regulates insulin secretion from pancreatic β-cells and increase insulin sensitivity in 
target tissue. A study using in vitro colonic cultures shows that the regulation of GLP-1 
release by SCFAs is FFAR2 mediated (Tolhurst et al., 2012). Hong et al., (2005) reported 
FFAR2 expression in adipose tissue. The results of their study highlight the vital role of 
FFAR2 expression during the adipogenesis process and that acetate and propionate 
mediated differentiation of 3T3-L1 cells from preadipocytes into adipocytes. However, 
studies on human adipocyte differentiation were not able to draw a relationship between 
FFAR2 and human adipogenesis as its ligands were not able to induce differentiation of 
preadipocytes, unlike what was reported in mice (Dewulf et al., 2013). SCFAs have 
previously been shown to inhibit lipolysis in human (Laurent et al., 1995). In 3T3-L1 
adipocytes, inhibition of lipolysis by SCFAs has been shown to be mediated by FFAR2 (Ge 
et al., 2008). Based on this observation, this receptor could be used as a target for 
treatment of dyslipidaemia. 
 
1.6.2 FFAR3 
FFAR3 was deorphanised at the same time as FFAR2 by two independent groups 
(Brown et al., 2003; Le Poul et al., 2003). FFAR3 is a receptor for SCFAs, particularly acetate, 
propionate, and butyrate, with propionate being the most potent agonist. This receptor 
also can be activated by other SCFAs including caproate and valerate, but to a lesser degree 
(Xiong et al., 2004). FFAR3 couples to Gi protein pathway (Brown et al., 2003; Le Poul et al., 
2003; Nilsson et al., 2003) (Figure 1.6-C). This receptor has been shown to be expressed in 
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various tissues, including PBMC, spleen, adipose tissue, and pancreas (Brown et al., 2003; 
Le Poul et al., 2003). Stimulation of the anorexigenic hormone secretion, leptin, in 
adipocytes has been shown to be mediated by FFAR3 (Xiong et al., 2004). Overexpression 
of FFAR3 in adipocytes increased SCFAs-mediated leptin secretion, while reduced secretion 
of leptin was observed in FFAR3-knockdown adipocytes. The expression of FFAR3 on 
adipocyte is still controversial as(Hong et al., (2005) and(Frost et al., (2014) were unable to 
detect FFAR3 expression in adipocytes, but high levels of FFAR2 were observed (Hong et 
al., 2005). Another group was also not able to detect FFAR3 mRNA in mouse adipose tissue, 
which then observed consistent reduction on FFAR2 expression in adipose tissue of FFAR3-
knockout mice compared to wild-type mice (Zaibi et al., 2010). Furthermore, they also 
demonstrated that SCFAs promotes leptin secretion in wild-type mice, and found that the 
secretion was reduced in FFAR3-knockout mice, which then suggests that this effect may 
be associated with the down-regulation of FFAR2 in the FFAR3-knockout mice (Zaibi et al., 
2010). Similar to FFAR2, FFAR3 is also expressed in enteroendocrine cells secreting PYY 
hormone. The release of this satiety hormone may also be regulated by FFAR3 (Karaki et 
al., 2006). 
FFAR3 is highly expressed in sympathetic ganglia in both human and mouse (Kimura 
et al., 2011). It has been demonstrated that SCFAs and ketone bodies were able to regulate 
the sympathetic nervous system (SNS) directly via FFAR3 at the sympathetic ganglion. 
Under fed conditions, propionate stimulates sympathetic ganglion through FFAR3 
activation. However, β-hydroxybutyrate, a ketone body produced during starvation or 
diabetes, antagonised FFAR3 and suppressed the SNS activity (Kimura et al., 2011). This 
finding suggests that FFAR3 could play an important role in maintaining energy balance, 
and that FFAR3 agonists could potentially be used for the treatment of obesity.  
 
1.6.3 GPR109A 
GPR109A (hydroxycarboxylic acid receptor 2 or HCA2), also known as Niacin 
receptor 1, is a high affinity niacin receptor. GPR109A is found to be expressed most 
abundantly in adipocytes of white and brown adipose tissue (Soga et al., 2003; Tunaru et 
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al., 2003; Wise et al., 2003). In addition, this receptor is also expressed in keratinocytes 
(Hanson et al., 2010) and immune cells, including dendritic cells, macrophages, and 
neutrophils (Benyó et al., 2005), but to a lesser degree. GPR109A couples to the Gαi protein 
pathway, the activation of which leads to an inhibition of adenylate cyclase, thus reducing 
the production of intracellular cAMP (Wise et al., 2003) (Figure 1.6-C). The agonist activity 
of niacin on this receptor is really important as niacin has been used for more than half a 
century in treating dyslipidaemia (Knopp, 1999). While working on the lipid-lowering effect 
of niacin, two independent groups have discovered that the anti-lipolytic and lipid-lowering 
effects of niacin are mediated by GPR109A activation (Tunaru et al., 2003; Wise et al., 
2003). The niacin-induced decrease in free fatty acids (FFAs) and plasma TG levels were 
abolished in GPR109A-deficient mice (Tunaru et al., 2003). 
GPR109A is expressed in the lumen-facing apical membrane of colonic and 
intestinal epithelial cells. Recently, it has been show that this receptor also can be activated 
by butyrate (Thangaraju et al., 2009b). A previous study has shown that the expression of 
GPR109A is abolished in colon cancer in human and mouse model, as well as in colon 
cancer cell lines. In the presence of its ligands, butyrate and niacin, the re-expression of 
this receptor has been shown to induce apoptosis in colon cancer (Thangaraju et al., 
2009b). Another study by the same group further demonstrated that the activation of 
GPR109A by butyrate promotes anti-inflammatory responses in colonic macrophages and 
dendritic cells. This resulted in the differentiation of Treg cells and IL-10-producing T cells, 
thus suppressing colonic inflammation and carcinogenesis (Singh et al., 2014a). More 
recently, it has been reported that the beneficial effects of high-fibre diet involves the 
activation of GPR109A and GPR43 in the gut epithelium, which promote gut epithelium 
homeostasis via inflammasome pathway (Macia et al., 2015).  
Present evidence indicates that GPR109A activation by its ligands acts on multiple 
sites to modulate anti-inflammatory responses and lipid profile. However, as this receptor 
is also involved in a niacin-induced flushing effect (Benyó et al., 2005), it is controversial as 
to whether the development of new agonists for GPR109A for treating atherosclerosis 
would be therapeutically important. 
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Table 1.3: Summary of the GPCRs activation, including its ligands, expression, and functions 
 
 
It has been shown that SCFAs play a crucial role in many physiological processes in 
humans, via acting as substrate for energy production, ligand for GPCRs activation, and as 
HDAC inhibitors (Figure 1.7). Thus these small metabolites are important in maintaining 
human health as well as might be associated in the development of some diseases. 
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1.7 SCFAs in human health and disease 
Acetate is the principal SCFAs in the gut. Acetate, which is produced via the 
fermentation of carbohydrate by intestinal bacteria, is taken up by the gastrointestinal (GI) 
epithelium, appears in portal blood, and eventually passes through the liver to peripheral 
tissues where it is metabolised by muscle (Salminen et al., 1998). After crossing the blood 
brain barrier, it has been shown that acetate modified acetyl-CoA carboxylase activation 
and expression of neuropeptides responsible for appetite suppression by suppressing 
appetite and inducing hypothalamic neuronal activation (Frost et al., 2014b). Moreover, 
acetate has also been demonstrated as the primary substrate for cholesterol synthesis, and 
may interfere directly in lipid metabolism (Day and Fidge, 1964). High concentrations of 
acetate provide substrate for hepatic lipogenesis (Jenkins et al., 1991).  
In humans, propionate produced from the fermentation of carbohydrate is largely 
cleared by the liver (Salminen et al., 1998). The liver clears majority of propionate and 
butyrate from the portal circulation to prevent high SCFAs concentrations in blood 
(Bloemen et al., 2009). Propionate is a precursor for liver gluconeogenesis (Roy et al., 
2006).  SCFAs, propionate in particular contributes about 80% of ruminants energy need. 
However it is unclear if the human uses propionate in a similar manner to ruminants 
(Bergman, 1990a). Propionate enters TCA cycle via the succinyl-CoA entry point. In brief, 
propionate is first converted into propionyl-CoA by propionyl-CoA synthetase. Propionyl-
CoA is then converted to succinyl-CoA via three successive reactions. The resulting succinyl-
CoA enters the TCA cycle and is converted to oxaloacetate, the gluconeogenesis precursor 
(Bloemen et al., 2010). It has been shown that approximately 50% of propionate is used by 
humans as a substrate for hepatic gluconeogenesis (Reilly and Rombeau, 1993). Moreover, 
in another study, the concentrations of propionate in both portal blood and hepatic vein 
suggest the greater uptake of propionate by the liver (Cummings et al., 1987). These 
accumulating evidences point out that the liver clears a large amount of propionate from 
the portal blood.  
In human subjects, it has been shown that the effect of propionate on hepatic 
carbohydrate metabolism was mediated by its role in improving glucose tolerance and 
insulin sensitivity, as well as increasing high density lipoprotein (HDL)(Venter et al., 1990). 
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Moreover, it has been demonstrated that propionate is converted into glucose by intestinal 
gluconeogenesis (IGN), thus improving energy homeostasis (De Vadder et al., 2014). 
Moreover, another study shows that the consumption of propionate-enriched bread 
decreased high-density lipoprotein while increasing serum triglyceride and improving 
carbohydrate tolerance (Todesco et al., 1991). The inhibitory effect of propionate on the 
synthesis of cholesterol is rather controversial.(Demigné et al., (1995) demonstrated that 
propionate (0.6 mmol/L) significantly inhibits cholesterol synthesis in isolated rat 
hepatocytes,  but another study using a higher concentration (1 mmol/L) did not (Nishina 
and Freedland, 1990). 
Of the SCFAs produced by gut microbiota in human intestine, butyrate has caught 
the most attention and has been studied extensively. It’s involvement in supressing colonic 
inflammation, causing cell cycle arrest, and apoptosis highlight its role in protecting against 
colon cancer and colitis (Ganapathy et al., 2013; Roediger, 1990; Williams et al., 2003). 
Butyrate is the principal substrate and energy source for colonocytes (Roediger, 1980a). It 
is estimated that butyrate provides at least 60-70% of colonic mucosa energy requirements 
essential for their proliferation and differentiation (Suzuki et al., 2008). Butyrate is 
important in maintaining colonic epithelium formation, and plays role in lipid metabolism, 
as well as possessing an anti-tumorigenic effects on many cancer cell lines (Hamer et al., 
2008). At least part of its beneficial effects is due to its ability to inhibit histone deacetylases 
(HDACs) (Chen et al., 2003). Millimolar concentrations of sodium butyrate have previously 
been shown to inhibit histone deacetylases both in vivo and in vitro and cause an 
accumulation of acetylated histone species (Candido, 1978).  
Most of the butyrate in intestinal lumen present in anionic form. In this form, 
butyrate is transported across the intestinal epithelial via monocarboxylate transporter-1 
(MCT1) and then metabolised by colonocytes (Hadjiagapiou et al., 2000). Inside the cell, 
butyrate enters mitochondria in which it undergoes β-oxidation to acetyl-CoA and enters 
the tricarboxylic acid cycle (TCA cycle) for energy production (Allan et al., 1996) (Figure 1.6-
A). A study conducted by(Donohoe et al., (2011) shows that mitochondrial respiration is 
replenished on the addition of butyrate in colonocytes from germ-free mice culture 
medium, which then prevents autophagy. MCT1 mRNA and protein expression, and 
intracellular butyrate concentrations are significantly reduced during the progression from 
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normal to malign cell in the human colon (Lambert et al., 2002).  In addition, a reduction in 
MCT1-mediated butyrate uptake has also been associated with the deficiency in butyrate 
oxidation in colonocytes of inflamed intestine (Thibault et al., 2007).  
 
Figure 1.7: Roles of gut microbial metabolites (SCFAs) in human. Once absorbed in the colon, 
butyrate serves as energy substrates for colonocytes, and acetate and propionate reach liver and 
peripheral organs. In addition, SCFAs also act as HDAC inhibitor and regulate many physiological 
processes through signalling via GPCRs.  
 
1.8 Overview of metabonomics 
Metabonomics by definition is `the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological stimulation or 
genetic modification’ (Nicholson et al., 1999). This technique examines metabolites within 
a biological samples including urine, plasma, faecal, or cell extracts. It is an important tool 
for studying the microbial-mammalian host metabolic axis and has been widely used in 
research (Nicholson et al., 2002).  
Metabolomics, which is the study of metabolic regulation and fluxes in a living 
system is closely related to metabonomics (Nicholson et al., 1999, 2002). Metabolites 
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measured in biofluids reflect genetic and environmental interactions in the mammalian 
host and symbiosis microbiota. This metabolic profiling (metabonomics/metabolomics) 
technique is one such approach in analysing cellular pathway based on the untargeted 
analysis of the metabolite composition in a biological sample (Nicholson et al., 1999). As a 
global untargeted approach, by using this technique, a high-density data is produced which 
can be analysed using a chemometric approach, multivariate statistical analysis, and 
pattern recognition (Nicholson et al., 2002). Thus, this method serves as an attractive 
strategy in biomarker discovery (Smolinska et al., 2012).  
 
1.8.1 Analytical strategies in metabonomics  
Proton Nuclear Magnetic Resonance (1H NMR) and mass spectrometry (MS) are the 
two most popular tools for metabolic profiling (Dumas and Davidovic, 2013; Fonville et al., 
2010). 1H NMR spectroscopy has been used widely in metabolic profiling as it is highly 
reproducible and requires a simple sample preparation method for liquid samples (e.g. 
biofluids) (Dumas and Davidovic, 2013). Mass spectrometry is a highly sensitive analytical 
technique and is able to detect and measure low concentration metabolites. Because NMR 
is relatively insensitive, NMR is normally used in conjunction with GC/MS or LC/MS to help 
in assigning metabolites in samples (Fonville et al., 2010). 
NMR-based metabonomics studies have been successfully used in identifying 
potential biomarkers that associate to a disease, drug toxicology, and genetic as well as 
environmental variation (Coen et al., 2008). Metabonomics is suitable for investigating the 
microbiome-host interaction as the metabolic profiles provide information on the 
endogenous metabolites as well as the host-gut microbial co-metabolites (Holmes et al., 
2011). Moreover, metabonomics studies also have been successfully used in identifying 
the relationship between choline metabolism and the development of nonalcoholic fatty 
liver disease (NAFDL) and IR in rat model (Dumas et al., 2006). 
Therefore, in this project, 1H -NMR-based metabolic profiling technique will be used 
alongside with the cell-based and molecular approaches in assessing the role of gut-
microbial metabolites (SCFAs) in host metabolism. 
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1.9 Hypothesis and aims  
Although SCFAs have been extensively characterised from a mechanistic point of view 
as fuel for the cell, GPCR agonists, and as HDAC inhibitors, there remains gaps in the 
knowledge. The overall hypothesis of this PhD is that SCFAs may play important role in 
hepatic cancer metabolism by acting as substrate for energy metabolism and may act as 
ligand by activating GPCRs, thus regulating adipocyte differentiation and function.  
Towards this end, a set of project aims have been implemented. 
1) Assessment of the effect of sodium as a SCFA counter ion on hepatocyte 
metabotypes -> see Chapter 3 
2) Characterisation of the hepatocyte metabolic signature of SCFA exposure -> see 
Chapter 4 
3) Implementation of a harmonised pharmacological assessment of a comprehensive 
SCFA panel on their GPCRs, i.e., FFAR2, FFAR3, GPR109A –> see Chapter 5 
4) Systematic Characterisation of the role of a comprehensive SCFA panel on 
adipocyte differentiation and function i.e., adipogenesis and lipolysis –> see 
Chapter 6 
 
In order to develop this, 1H NMR-based metabolic profiling technique is used to 
profile the HepG2 cell culture medium in identifying specific biomarkers related to the 
sodium treatment on the cells. Using the same approach, the effect of SCFAs (propionate 
and butyrate) on hepatic cancer metabolism is then investigated by identifying the 
hepatocytes metabolic signature of SCFAs exposure. As it has been reported on the 
activation of several GPCRs by SCFAs before, here an effort has been made in harmonising 
the pharmacological role of a comprehensive SCFA panel in activating their GPCRs (FFAR2, 
FFAR3, GPR109A) by measuring the accumulation of cellular cAMP. Finally, by combining 
cell-based and molecular approaches, the role of comprehensive SCFA panel on adipocyte 
functions is investigated. 
 
55 
 
CHAPTER 2 
 
2. GENERAL METHODOLOGY 
 
In this PhD, several approaches were applied in order to address the aims of the 
project. In chapter 3 and chapter 4, a 1H NMR-based metabonomics technique was used to 
assess the effect of SCFAs on hepatic metabolic network. In chapter 5, the pharmacological 
assessment of a comprehensive SCFA panel on FFAR2, FFAR3, and GPR109A was carried 
out using kits provided by a service company (Discoveryx, USA). In chapter 6, the role of a 
comprehensive SCFA panel on adipocytes development and function was assessed by using 
a combination of a cell-based assays and molecular approaches. 
 
2.1 Analytical strategy 
Metabolic profiling can be applied for the analysis of complex biological samples 
such as biofluids and tissues. This technique is a unique strategy for analysing cellular 
pathways based on the untargeted profiling of the small metabolites present in a biological 
sample. It provides a powerful tool for obtaining insight into functional biology (Nicholson 
et al., 1999). The combination of an in vitro cell model and metabolic profiling technique 
allows us to study the response of the cells to specific treatment or chemical exposure. It 
has been demonstrated previously that NMR-based approach can be used to profile and 
monitor the endogenous metabolome of an in vitro cell system under various biological 
and toxicological exposures (Ellis et al., 2011; Shintu et al., 2012).  
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2.2 Nuclear Magnetic Resonance (NMR) Spectroscopy 
High resolution NMR spectroscopy is a quantitative, non-destructive, and 
reproducible technique that detects small molecular weight molecules within a complex 
biological matrix such as tissue extracts and biofluids (Beckonert et al., 2007). NMR-based 
metabolic profiling is a robust and reliable method, thus suitable for metabonomics 
applications (Bales et al., 1984; Nicholson et al., 1983). This technique provides a metabolic 
`snapshot’ representative of the sample at a particular time point and requires only simple 
sample preparation steps (Nicholson et al., 1999). With the improvement in spectral 
dispersion and sensitivity, the current version of high-field NMR spectrometer enables the 
detection of metabolites in the micromolar range in a short experiment time (Holmes et 
al., 1997).  
 
2.2.1 Principles of NMR spectroscopy  
Nuclear magnetic resonance (NMR) spectroscopy is a powerful analytical tool. It 
detects the way in which electromagnetic radiation interacts with the spin of atomic nuclei. 
The spin is characterised by a nuclear spin quantum number (I), which is dependent on the 
number of protons (atomic number) and nucleons (atomic mass) present (Jardetzky and 
Roberts, 1981). Nuclei with I=0 are not observable by NMR. Nuclear isotopes with a nuclear 
spin of ½, such as 1H, 13C, 15N, and 31P are preferably used in biological approaches. Among 
these, 1H NMR spectroscopy is the most commonly used due to its natural abundance of 
99.9% (Jardetzky and Roberts, 1981).  
When magnetic field (B0) is applied, the nuclei orientate themselves, and the 
number of possible orientation is given by the equation: 2I+1. Therefore, if I=1/2 like 1H, 
this will generate two spin states in a magnetic field. The spin corresponding to ½ is the 
lower energy state, more stable, and aligned (parallel and same direction) with the applied 
magnetic field, B0 (position α). On the other hand, the spin corresponds to -½ is the higher 
energy state, and oriented in the opposite direction to B0 (position β). For both states, the 
spins move around the magnetic field with an angular frequency called the Larmor 
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precession (Keeler, 2002). The energy transition between both states is given by the 
Boltzmann equation:  
ηβ/ηα = e∆E/kT 
Where ηβ and ηα represent the number of nuclei in the upper or lower energy state. ∆E is 
the difference in energy between the two spin states, α and β. k is the Boltzmann constant 
(1.3805x10-23 J/Kelvin), while T is the temperature in Kelvin (K). ∆E can be calculated by the 
following equation: 
∆E=γhB0/2π 
Where γ is the magnetogyric ratio, h is the Planck’s constant (6.626208x10-34 J S), and B0 is 
the NMR magnetic field. The slight excess of spins in the lower energy state (parallel 
orientation, α) than the higher energy state (β) causes a net absorption of energy which 
results in an NMR signal. If the ∆E value is small, the population between the two spin 
states is correspondingly small, thus the NMR signal is relatively low (Jardetzky and 
Roberts, 1981; Keeler, 2002). 
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Figure 2.1: Theory of NMR spectroscopy. (A) Illustrates the nuclei distribution (*) in the two energy 
states when a magnetic field B0 is applied. (B) Motion of net nuclei magnetisation which relaxes at 
the Larmor frequency in a magnetic field B0. (C) Effect of radio-frequency pulse B1 on M0.  
 
The difference between the two energy states results in the magnetisation vector 
M0 lies along the direction of B0 (along z axis). However, when a specific radio-frequency 
pulse is applied (B1) at frequency ω, nuclear spins are excited to the higher frequency 
leading to a new orientation of M0. Once the pulse has stopped, the spins return back to 
equilibrium – a process known as relaxation. There are two major relaxation processes; the 
longitudinal (spin-lattice) relaxation and the transverse (spin-spin) relaxation. During the 
relaxation period, the NMR signal is detected as free induction decay (FID) and 
subsequently transformed to a NMR spectrum by mathematical process called a Fourier 
transform (Jardetzky and Roberts, 1981; Keeler, 2002). 
59 
 
The electric current around the nuclei produced a local magnetic field in the 
opposite direction to B0 and shield it from the applied field. The magnetic field at the nuclei 
is not equal to the applied magnetic field. The difference between the applied field and the 
field at the nucleus is termed the nuclear shielding. The chemical shift is defined as the 
nuclear shielding divided by the applied magnetic field (Jardetzky and Roberts, 1981; 
Keeler, 2002).  
Interaction between neighbouring groups produces splitting pattern of signals, 
which provides additional spectral information. This splitting pattern provides an idea 
about the connectivity of atoms within the molecule. Active nuclei that are close to another 
nuclei can influence each other’s effective magnetic field. This is called spin-spin coupling 
or J-coupling. Spin-spin couplings from neighbouring groups within the molecule results in 
the splitting of NMR signals into two or more components. These components of the NMR 
signals are shifted from the original chemical shift (in ppm). The complexity of the splitting 
pattern is directly related to the number of neighbouring nuclei. The general rule of n + 1 
is used for the multiplicity of splitting, where n is the number of protons on the adjacent 
atoms. For instance, a nucleus with two neighbouring protons will have their resonance 
signals split into three peaks called triplet. The two peaks in a multiplet are separated by a 
scalar coupling constant termed J-constant, and is independent of the external magnetic 
field (Keeler, 2002).   
 
1.1.1 1D NMR spectroscopy 
A 1D NMR uses a single pulse sequence that contains at least 3 parts: 1) the 
preparation time, also known as relaxation delay (in seconds), 2) the pulse width (in 
microseconds), and 3) the acquisition time (in seconds). The preparation time is the time 
in which the spins reach their equilibrium state. The pulse width is the length of time for a 
radio-frequency pulse to perturb the spin system. This is followed by the spins going back 
to their original state generating FID during the acquisition time (Figure 2.2). In order to 
increase signal to noise ratio, the radio-frequency pulse sequence is repeated multiple 
times to improve the signal to noise ratio. In metabonomics study of tissue extract and 
plasma metabolic profiles that contain a large amount of proteins and/or lipids, the high 
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molecular weight molecules typically produce broader resonances than the smaller 
metabolites. The Carr-Purcell-Meiboom-Gill (CPMG) is one of the examples for 1D NMR 
experiment. This experiment reduces the broad signals of macromolecules and allows a 
better observation of low molecular weight compounds.  
 
 
Figure 2.2: Standard one pulse sequence (RD: relaxation delay, pw: pulse width) 
 
1.1.2 2D NMR spectroscopy 
In 1D NMR metabolic profiles, large number of overlapped peaks makes the 
assignment work a tough challenge. Thus, it is important to perform 2D NMR experiment 
that can provide extra information about NMR peaks connectivity. This helps in the 
identification of unknown metabolites in the biological samples. In 2D NMR experiment, 
the signal is recorded on two time variables, t1 and t2, and the resulting data Fourier 
Transformed twice to produce a spectrum with two frequency variables, F1 and F2 (Keeler, 
2002). Figure 2.3 presents the general scheme of 2D NMR spectroscopy.  
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Figure 2.3: General scheme for 2D NMR spectroscopy. (RD: relaxation delay, p1: first pulse 
width to reach 90o, t1: evolution time, p2: second pulse width to reach 90o, t2: acquisition 
time) 
 
In the first period, the spins are excited by several pulses. Then, the spin relaxation 
evolves for the first time period, t1. This follows by the second set of pulses during the 
mixing time. After this mixing period, the signal is recorded during the second time 
variable, t2. The signal is only recorded during the time t2 at the end of the sequence. The 
information present in the spectrum is determined by the nature and the time of pulse 
during the relaxation delay and mixing periods (Keeler, 2002). The example of 2D NMR 
experiments that normally used in metabonomics is the J-Resolved experiment (J-Res), the 
correlation spectroscopy (COSY), and the heteronuclear single quantum coherence (HSQC) 
experiments.  
 
2.3 Statistical analysis 
Metabolic profiling using NMR spectroscopy method produces high-density data 
sets. In order to analyse these huge data sets, the use of multivariate statistical analysis 
can be exploited. This statistical analysis method can be used to detect and visualise the 
main sources of variation as well as performing multivariate classification and discriminant 
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analysis. There are two types of pattern recognition methods that frequently being used, 
which are the unsupervised and supervised methods (Eriksson et al., 2004; 2006).  
 
2.3.1 Unsupervised method: Principal Component Analysis (PCA) 
PCA is one of the simplest techniques that has been used widely in metabonomics 
(Nicholson et al., 2007). It is a common unsupervised method used for which no `prior’ 
knowledge is required for the construction of the model. PCA is based on the 
representation of multivariate data comprising n rows (observation) and X columns (NMR 
variables).This method involves a mathematical procedure in which a number of variables 
(e.g. variables of NMR spectra), are transformed into a smaller number of components 
called principal components (PC). The first PC (PC1) accounts for the direction in the 
multidimensional space explaining the much of the variance in the data as possible. The 
second PC (PC2), which is orthogonal to the PC1 further improves the interpretation 
(Figure 2.4). PCs are constructed to give a low dimensionality representation of the data 
set. PCA is a common method in identifying outliers in large data sets (Trygg et al., 2007; 
2006). 
Geometrically, one can imagine that NMR spectrum corresponds to a point in K –
dimensional space, where K is the different variables. The scores plot (T) represents the 
point values of the observations in K-dimensional space, while loadings plot (P) describes 
the weight of variables in the model and identifies them (i.e. metabolites). Unexplained 
part of the matrix are referred to as residuals (E), that is defined by the distance between 
each observation and its projection on the PC space (Trygg et al., 2007). Information from 
the PCA can be interpreted by both the scores plot and the loadings plot (Figure 2.4).  
63 
 
 
Figure 2.4: Diagrammatic representation of PCA. PCA is used to define the data in a lower 
dimensional space. The first principal component (PC1) describes the largest variations within the 
samples, followed by PC2 etc. The s samples are projected onto a hyperspace with x dimensions. 
Thus, a plane with dimensions k is built from the principal components. The score (T) characterises 
the position of every observation in the plane and the loading (P) shows the positions in space of s. 
variation. Unexplained data is referred to as residual matrix (E). 
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2.3.2 Supervised methods 
Unlike unsupervised methods, supervised methods rely on prior knowledge of 
classes. In metabonomics, most of the researchers are focusing on group classification such 
as between treated and untreated groups, therefore the use of supervised method is 
desirable (2006). One of the most commonly used supervised methods is partial least 
squares (PLS) (Nicholson et al., 2007). 
Supervised PLS regression is a method that relates a matrix that contains variables 
from samples (e.g. spectral data, the X matrix), to a second matrix (Y) containing 
quantitative values such as time or concentration of the treatments by linear regression 
(Figure 2.5). PLS aims to construct a model that maximises the covariance between X, e.g., 
the spectral data, and the response variable (Y) (Bollard et al., 2005). It can be used to 
investigate the influence of time or the dose responses on a data set, which is useful for 
NMR profiling of biofluids. PLS can also be used in a discriminant analysis, termed (PLS-DA), 
in which Y matrix contains dummy variables to maximise discriminant between the two 
classes.  
However, X matrices often comprises a certain level of variation uncorrelated to 
the Y matrix which lowering the interpretability of the PLS model, typically when there is 
high within-group variance not directly associated with the between-group variance of 
interest. Therefore, orthogonal partial least square discriminant analysis (OPLS-DA) was 
developed as an extension of PLS-DA in which a built-in Orthogonal Signal Correlation (OSC) 
filter is added in the construction of the model (Cloarec et al., 2005a; Fonville et al., 2010; 
2006). This OSC filter is used to model the within-class variation independently as 
orthogonal component (Xortho) to the between-class variation (Xpred/Ypred), thus improve the 
interpretation of the model (Trygg and Wold, 2002). Analysis of the score plot and the 
loadings plot of the orthogonal component can provide extra information on subgroup 
structure within the data (Cloarec et al., 2005a; Trygg et al., 2007). Figure 2.6 illustrates 
comparison between PCA, PLS-DA, and OPLS-DA. 
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Figure 2.5: PLS schematic. (A) PLS regression tries to explain Y using X variables and PLS-DA models 
separation between classes. (B) Multidimensional X matrix (top left) represents the predictor and 
the multidimensional Y matrix (top right) represents the response to predict. In each multivariate 
space, the orientation of the first component must approximate as well as possible the shape of 
the point cloud and the scores T1 and U1 should be maximally correlated. The second component 
is orthogonal to the first component using the same principle. 
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Figure 2.6: Comparison between PCA, PLS-DA, and O-PLS-DA. (A) Unsupervised PCA shows that the 
two diet groups have very different variance structure, which overwhelms the genetic background. 
(B) PLS-DA discriminates the two strains resulting in good separation of the genetic background, 
but because of the strong diet-related within-group variance (i.e. orthogonal noise), the scores plot 
shows a significant dietary effect on T2, but a weak genetic discrimination on T1. (C) OPLS-DA shows 
a clear discrimination on Tpred, while Torth provides a strong within-group variance based on the 
effect of diet. Adapted from Fonville et al., (2010) with modification. 
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Additionally, in OPLS regression and OPLS-DA models, R2X and R2Y indicate the 
proportion of explained variance and so estimate the robustness of the model. However, 
in constructing multivariate models, it is easy to over-fit the models. Thus, in order to avoid 
over-fitting, a cross-validation (CV) step is applied to assess the real predictability of the 
model (Figure 2.7). In 7-fold cross-validation, 6/7th of the data are considered as training 
set, and 1/7th of the data as test set. A model is fitted on calibration set and then the test 
set is projected back into the models to test the performance of the model. This step is 
repeated until all data have been once kept out. This results in the determination of the 
cross-validation parameters (Q2Y), indicating the percentage of predicted variance from 
the Y vector in the tested model. Q2 value above 0.5 is regarded as a good value, thus the 
model is strong enough to be used for data interpretation (Eriksson et al., 2004). In 
addition, a permutation test can also be used for model validation which estimates the 
significance of the estimated predicted power (Q2Y). The significance of the model is 
determined by the p-value calculated from the permutation test (Eriksson et al., 2004). 
 
 
Figure 2.7: A 7-fold cross validation. Cross validation is a technique used to protect against over-
fitting in a predictive model. 
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 Using a back-scaling method, OPLS regression coefficients are displayed, producing 
a pseudo unit-variance scaled NMR spectrum, which is colour coded (from red to blue) 
according to correlation coefficient. This is represented by the squared regression 
coefficients (R2) (Cloarec et al., 2005a). While the hot colours are assigned to high 
correlated variables, the cold colours represent the non-significant correlation variables. 
This method has been shown to be a useful tool in helping the interpretation of the 
loadings plot by facilitating the identification of the most influential metabolites (Cloarec 
et al., 2005b). 
 
2.4 Cell culture 
2.4.1 HepG2 cell line 
HepG2 is an immortalised hepatocarcinoma cell line derived from liver tissue of 
patient with well-differentiated hepatocellular carcinoma. HepG2 cells are adherent, 
epithelial-like, and grow as monolayers. These cells synthesise and secrete a variety of 
major human plasma proteins including albumin and transferrin (Knowles et al., 1980). 
HepG2 cells can be used as a model system for liver cancer metabolism study as well as for 
studying the toxicity of xenobiotics (Knowles et al., 1980). The protocols used for 
maintaining and subculturing of this cell line are explained in chapter 3 (section 3.2.1). 
 
2.4.2 HepaRGTM cell line 
HepaRGTM are terminally differentiated hepatic cell line derived from a human 
hepatic progenitor cell. HepaRG cell line has been established from a liver tumour 
associated with chronic hepatitis C, and is capable to differentiate into two different cell 
phenotypes, which are billiary-like epithelial and hepatocyte-like cells when differentiation 
medium containing DMSO is introduced (Parent et al., 2004). HepaRG™ cells exhibit many 
features and characteristics of primary human hepatocytes, and has been used to 
investigate drugs metabolism and toxicity studies (Marion et al., 2010).  
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2.4.3 3T3-L1 cell line 
3T3-L1 cell line is derived from clonal expansion from murine fibroblast 3T3 cells 
(Green and Meuth, 1974). This cell line has been used extensively as an in vitro model of 
adipocyte because of its ability to differentiate from fibroblasts to adipocytes under 
appropriate conditions (Poulos et al., 2010). 3T3-L1 cells stop growing when they reach a 
confluent monolayer, and the addition of pro-differentiation agents such as insulin, 
dexamethasone, and 3-isobutyl-1-methylxantine (IBMX), at concentrations of usually 1 
µg/mL, 0.25 µM, and 0.5 mM, respectively,  induced the differentiation into adipocytes-
like cells (Green and Kehinde, 1975; Rubin et al., 1978; Russell and Ho, 1976). After 
hormonal induction, the 3T3-L1 preadipocytes begin to accumulate lipid and undergo 
terminal differentiation into mature adipocytes. Mature adipocytes are characterised by 
having high expression of adipogenic genes and high cytoplasmic storage of triglyceride 
(Student et al., 1980). The protocols for 3T3-L1 differentiation were elaborated in chapter 
6 (section 6.2.2). 
 
2.4.4 CHO-K1 cell line 
In chapter 5, the assays used in this chapter for the screening of the ligands were 
provided by DiscoveRx, USA. CHO-K1 cells overexpress human receptors, FFAR2, FFAR3, 
and GPR109A were used as the cell model for these kits. CHO-K1 cell line is derived from 
the original Chinese hamster ovary (CHO) cell line (Lewis et al., 2013). CHO-derived cell 
lines are the most preferred host expression system due to having manufacturing 
adaptability (Xu et al., 2011). The genes of these cells also can easily be manipulated and 
can be grown as adherent or in suspension. Moreover, the methods for cell transfection, 
gene amplification in CHO cells also have been well optimised. In addition, CHO cells have 
fast growth rate and high protein productivity, as well as stable gene expression (Lim et al., 
2010).  
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2.4.5 Justification of the cell line used for chapter 3 and chapter 4 
In chapter 3 and chapter 4, HepG2 cell line has been selected as the hepatocyte cell 
model to investigate the effect of SCFAs on the host’s metabolism. This cell line is a 
hepatocarcinoma cell line and has been previously used to study drugs metabolism and 
toxicity. Hence the findings generated from this study will therefore explain the effect of 
SCFAs on hepatic cancer metabolism and not the metabolism of normal hepatocytes. 
Another cell line has also been tested and considered which was HepaRGTM. However, a 
number of problems were encountered when dealing with this cell line, such as 
inconsistent growth rate, long differentiation time, and cost ineffective. Moreover, the cell 
line also is a terminally differentiated cell line and licence is needed in order to propagate 
the cell line. Due to these stated reasons, it is decided to not continue working with the 
HepaRG cell line and HepG2 is used as the hepatic cell model for the study carried out in 
chapter 3 and chapter 4. 
 
2.5 Biological assays 
2.5.1 Cell viability 
Measuring cell viability is important in cell culture experiments. A cell viability assay 
is often used to determine if the test compounds have effects on cell proliferation at 
certain concentration. It is very important to know the number of viable cells at the end of 
the experiment. In this thesis, two types of cell viability assays were used: PrestoBlue, a 
resazurin-based reagent measuring mitochondrial activity and crystal violet dye which 
stain the nucleus.  
 
2.5.1.1 PrestoBlue® (Invitrogen) reagent 
PrestoBlue, a resazurin-based reagent, contains a cell-permeant compound that is 
blue in colour and almost non-fluorescent in solution. This reagent is rapidly taken up by 
the cells when added to the culture media. Inside viable cells, resazurin is reduced by the 
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reducing environment in mitochondria, thus indicating mitochondrial metabolic activity. In 
this condition, resazurin is converted into it reduced form of resorufin, resulting in a red-
fluorescent dye which can be quantitatively measured to determine viability (Figure 2.8). 
This reagent can measure as low as 12 cells/well with a short incubation time (≥ 10 min) 
(Invitrogen, 2010). This method is used in chapter 3 and 4. 
 
Figure 2.8: Reduction of resazurin to resorufin in living cells.  
 
2.5.1.2 Crystal violet staining assay 
The crystal violet staining (CVS) method was developed by(Saotome et al., (1989) 
for evaluating the cytotoxicity of the chemicals. It is a triarylmethane used as a histological 
staining and also can be used to stain adherent cells. It is in blue-violet colour and can be 
measured at the maximum of 590 nm (Adams and Rosenstein, 1914). This dye stains nuclei, 
thus enhancing their visualision under the microscope, whilst providing a quantitative 
readout. This method is used in chapter 6. 
 
Figure 2.9: Chemical structure of crystal violet. 
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2.5.2 Lipid staining (Oil Red-O) 
When 3T3-L1 cells undergo differentiation, they change their fibroblastic shape 
cells to rounded cells with an increasing number of intracytoplasmic lipid droplets (Green 
and Meuth, 1974). The accumulation of intracytoplasmic lipid has been shown to be 
directly proportional to the differentiation of the cells (Kuri-Harcuch and Green, 1978). 
Based on this relationship, staining of the intracytoplasmic lipid droplets using Oil Red-O 
(ORO) staining method has been used to qualitatively measure the differentiation of this 
cell line from 3T3 pre-adipocytes to 3T3 adipocytes (Kuri-Harcuch and Green, 1978). ORO 
(C26H24N4O, Figure 2.10) is a fat soluble diazol dye that is suitable for the histochemical 
staining of neutral lipids and cholesteryl esters, but not biological membranes (Fowler and 
Greenspan, 1985). The principle of ORO staining is that this dye has a very low solubility in 
the solvent, and the solubility even lower when ORO is diluted in water prior to be used. 
Therefore, this dye will move from the solvent, and stain the lipid within the cytoplasm. 
ORO can be measured with a maximum absorption at 518 nm (Kuri-Harcuch, 1978; Kuri-
Harcuch and Green, 1978). This method is used in chapter 6. 
 
 
Figure 2.10: Chemical structure of Oil Red-O (1-(2,5-dimethyl-4-(2,5-dimethylphenyl) 
phenyldiazenyl) azonapthalen-2-ol).  
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2.5.3 Lipolysis assay 
In vitro, an increase in lipid accumulation can be observed in well-differentiated 
3T3-L1 adipocytes. The stored TGs in lipid droplets undergo continuous synthesis and 
breakdown. The hydrolysis of TGs produces free fatty acids (FFAs) and glycerol, which are 
subsequently released into the surrounding environment. In cells, lipolysis is triggered by 
the activation of β-adrenergic receptors by its ligand. These receptors are coupled with Gs 
protein family which activation leads to the stimulation of cAMP-dependent pathway by 
adenylate cyclase. This resulted in the increase of intracellular cAMP level which in turn 
activates protein kinase A (PKA), resulting in increased activity of the enzyme, hormone 
sensitive lipase (Kim, 2005). Lipolytic activity in the cells can be assessed by measuring the 
glycerol release into the medium as a consequence of TGs hydrolysis. In this study, Free 
Glycerol Determination Kit (FG0100, Sigma) was used to measure the glycerol in the 
medium. The kit measures free glycerol using several steps of enzymatic reactions. Glycerol 
released to the medium is first phosphorylated by adenosine triphosphate (ATP) forming 
glycerol-1-phosphate (G-1-P) and adenosine-5’-diphosphate (ADP) in the reaction 
catalysed by glycerol kinase (GK). Then the G-1-P is oxidized by glycerol phosphate oxidase 
(GPO) to dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H2O2). Peroxidase 
then catalyses the coupling of 4-aminoantipyrine (4-AAP) and sodium N-ethyl-N-(3-
sulfopropyl) m-anisidine (ESPA) with H2O2 to produce a quinoneimine dye. This dye shows 
an absorbance maximum at 540 nm. The absorbance at 540 nm is directly proportional 
with the glycerol concentration in the sample (Sigma-Aldrich, 2014). This method is used 
in chapter 6.
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CHAPTER 3 
 
3. METHODOLOGICAL OPTIMISATION OF 
NEGATIVE CONTROL GROUPS: THE EFFECT OF 
SODIUM CHLORIDE (NaCl) TREATMENT ON 
HEPG2 CELLS GROWTH AND METABOLISM. 
 
3.1 INTRODUCTION  
Inorganic ions are one of the essential compounds for living systems to maintain 
the system homeostasis. Ions such as sodium (Na+), potassium (K+), and chloride (Cl-), are 
not only involved in many enzymatic reactions, but they also contribute to other 
physiological role such as maintaining the osmotic pressure of body fluid and regulating 
the macromolecular behaviour (Northwestern University, 2011). Na+ is the main 
electrolyte that functions in regulating extracellular fluid in the body (Pohl et al., 2013). It 
is also essential in balancing the concentration gradient for the transmission of signal in 
nerve and muscle cells, as well as maintaining acid-base balance and plasma volume 
(Bouchard et al., 1993).  
Cell culture medium, also called growth medium, is a culture medium used to 
supply nutrients to support the growth of cells. Typically it is in the form of liquid or gel 
(Arora, 2013). Generally, culture media contain the complete nutrients for the growth of 
the cells such as amino acids, vitamins, glucose, and several other essential compounds. 
Culture media also contain a mixture of different concentration of inorganic salts, also 
called balanced salt solution. These inorganic salts are introduced to balance osmotic 
pressure and maintain optimum pH of the medium (Ham and McKeehan, 1979). Making 
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sure that the pH of the culture media is in an optimum range will ensure the survival of the 
cells in the culture. NaCl is the major inorganic salt in most of the culture media and the 
optimum growth for most of the cell line can be achieved at NaCl molarity between 100-
130 mM (Stubblefield and Mueller, 1960). The importance of NaCl in mammalian cell 
culture experiment has been studied extensively over the years. High NaCl concentration 
has been shown to cause DNA damage in both cell culture and in vivo experiments 
(Dmitrieva, 2004). Kidney cells, however, have been shown to be exposed to high NaCl 
levels which can be in excess of 500 mM. Although these cells appear to be healthy, DNA 
damage could be detected (Dmitrieva and Burg, 2005). In addition to high NaCl 
concentrations, a previous study has also shown that reducing sodium chloride 
concentration to 90 mM below the normal levels affects  proliferation of chicken 
fibroblasts (Balk and Polimeni, 1982).  
This current chapter aimed to assess the effect of NaCl on the growth and 
metabolism of HepG2 hepatocarcinoma cell line using cell biology and 1H NMR-based 
metabolomic approaches. This is particularly relevant as the ultimate aim is to assess the 
effect of short-chain fatty acids (propionate and butyrate) in regulating HepG2 cells 
metabolism, in the next chapter. SCFAs will be used in the form of sodium propionate and 
sodium butyrate, sodium being used as a counter-ion. So, the current chapter will serve as 
a preliminary methodological optimisation study deciphering the effect of sodium as a 
counter-ion from the effect of short-chain fatty acids (propionate and butyrate) and 
eliminate potential biases in later experiments.  
 
3.2 MATERIALS AND METHODS  
3.2.1 Cell culture  
In this study, HepG2 cell line, which is a perpetual cell line originated from the 15-
years-old Caucasian American male’s liver tissue with a well-differentiated hepatocellular 
carcinoma, was used as a hepatocyte model to assess the effects of sodium salt have on 
liver metabolism and signalling. The HepG2 cell line were obtained from American Type 
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Culture Collection (ATCC) and were maintained in complete growth medium containing 
Eagle’s Minimum Essential Media (MEM, Gibco®), 1% v/v of L-glutamine (Gibco®) and 10% 
v/v fetal bovine serum (FBS, Gibco®) as recommended by the manufacturer. The complete 
growth media was also supplemented with 1% v/v Penicillin-Streptomycin (100U/mL, 
100μg/mL respectively) (Gibco®) to prevent any contamination caused by gram-positive 
and gram-negative bacteria that might occur.  
Nutrients to support the cell growth are supplemented to the FBS. The FBS contains 
nutrients such as essential fatty acids, cholesterol, serum growth factors (insulin, insulin-
like growth factor (IGF) and epidermal growth factor (EGF)), endocrine growth factors 
(androgen, triidothyronine), as well as cell attachment proteins such as fetuin (Hedlund 
and Miller, 1994).  
 
3.2.2 Cell thawing and seeding 
To culture the cell line, a cell vial was removed from liquid nitrogen storage and was 
immediately place on dry ice in a covered container prior to thawing. The cell vial was left 
in the container for at least one minute before opening the vial in order to allow any liquid 
nitrogen inside the vial to evaporate. The cell vial was then allowed to reach room 
temperature for 1-2 minutes, and was warmed in a water bath (37oC) until partially 
thawed. Approximately 0.5 mL of pre-warmed complete growth media was added to the 
vial and the mixture was then centrifuged at 300 x g for 5 minutes to pellet the cells. The 
cell freezing media containing DMSO was removed and the cell pellet was resuspended in 
15 mL pre-warmed complete growth media. The cells were transferred to a T75 flask and 
were incubated for 24 hours at 37oC and 5% air in cell culture incubator. After 24 hours, 
the growth media was gently removed, and was replaced with 15 mL fresh complete 
growth media. Upon reaching confluency, the cells were transferred into T75 flasks for 
routine culturing.  
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3.2.3 Cell maintenance and passaging 
HepG2 cells were routinely maintained in T75 plastic flasks (Falcon, Merck Eurolab, 
Strasbourg, France) with 15 mL complete growth media with sub-cultivation ratio of 1:4 to 
1:6 and medium renewal twice a week. The cells were used between passage 4 and 30. 
After reaching ~80% confluency at day 4-5 in culture, the cell monolayer was first washed 
twice with sterile 1x Dulbecco's phosphate-buffered saline (DPBS, Gibco®) to remove all 
traces of serum. 1x dissociation reagent (Trypsin-EDTA (ethylenediaminetetraacetic acid), 
Gibco®), prepared by diluting the stock solution of 10x Trypsin-EDTA using sterile DPBS was 
used to detach the cells. Cells were gently pipetted up and down to minimise the 
trypsinisation time. Once the cells are detached, 1 volume of complete medium was added 
to the cells-trypsin mixture to deactivate the trypsin-EDTA. The mixture was then 
centrifuged at 1000 rpm for 5 minutes to pellet the cells. The supernatant was removed 
and the cell pellet was re-suspended in fresh complete growth medium and then seeded 
into new T75 flask.  
 
3.2.4 Cell count 
Cells were manually counted by using haemocytometer and Trypan Blue reagent 
was used to determine cell viability. Trypan Blue dye method of determining cell viability 
is based on the principle that live cells do not taken up certain dyes, but dead cells do, due 
to permeabilisation of their cell membrane, allowing differentiation between live and dead 
cells. Briefly, an aliquot of the cell suspension (10 μL) was added to an equal volume of 
0.4% Trypan Blue (dilution factor of two). The mixture of cells and Trypan Blue were gently 
mixed by pipetting up and down and incubated at room temperature for 1-2 minutes. 
Approximately 8 μL of the mixture was then loaded onto each side of the haemocytometer. 
Live cells (non-blue) were counted in 10 squares, averaged, and the total number of live 
cells was determined by: 
Cell number = cell count (per square) * 2(dilution factor) *104 
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3.2.5 Cell freezing 
To prepare stocks of cells, the early passage number of cells was frozen in liquid 
nitrogen. Cells were harvested, pelleted, and counted as described in previous section. The 
cell pellet was resuspended in freezing media containing 95% complete growth media and 
5% of the cryoprotectant dimethylsulphoxide (DMSO) at final concentration of 1.0 x 106 
cells/mL. The cells were frozen at -80°C in a foam cooler for 24 hours before finally 
transferred to liquid nitrogen dewar for long term storage.  
 
3.2.6 Cell proliferation assay- PrestoBlue® 
PrestoBlue® (Life Technologies) is a cell-permeable resazurin-based dye that use as 
cell viability indicator. This reagent uses the reducing power of living cells, and when added 
to cells, the reducing environment of the live cells modified the PrestoBlue® reagent and 
changes the colour to red, thus make it highly fluorescent. The fluorescent signal is directly 
proportional to the viable cells present in the sample and used to quantitatively measure 
the cell number. 
In this experiment, HepG2 cells were incubated with complete growth medium with 
the addition of different doses of sodium chloride (NaCl). The cells were incubated at three 
different time points, which are 24, 48, and 72 hours. Briefly, at the start of the experiment, 
60,000 cells/well were seeded in 96 well-plates and were culture in complete growth 
medium at 37oC. Twenty-four hours later, the growth media was changed and NaCl was 
added to the fresh complete growth media at final doses of 0.1 nM, 1.0 µM, and 1.0 mM. 
Complete growth medium without the addition of NaCl was used as control for this 
experiment. Upon reaching the time points described above, PrestoBlue® reagent was 
added directly to the cells in each well to obtain 1x final PrestoBlue® concentration in the 
well. The sample was then incubated at 37oC for 30 minutes and the plate was read on the 
FLUOStar microplate reader, at 535 nanometres (nm) excitation and 615 nm emission 
(ex/em) to measure cell viability. The reading of the well that contains only media and dye 
was used for background removal. 
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3.2.7 pH optimisation of the culture media  
Culture media pH plays an important role in maintaining the optimum growth of 
the cells. In order to maintain its pH level, the growth media contains a mixture of inorganic 
salts known as a balanced salt solution. This allows the medium to maintain the pH and the 
osmotic pressure. In this part, in order to assess the effect of salt addition on the pH of the 
growth media, the complete growth media was prepared with the addition of different 
types of salts (sodium chloride (NaCl), sodium bicarbonate (NaHCO3), sodium hydroxide 
(NaOH)) with varying final doses of 0.1 nM, 1.0 µM, and 1.0 mM. The sample was warmed 
in a water bath (37oC) and the pH of the media was then measured using bench top pH 
meter (Sigma). 
 
3.2.8 Cell culture preparation for 1H NMR study 
HepG2 cells from ~80% confluent T75 culture flask were harvested and seeded at a 
density of 6.0 x 104 cells/well in 24 well-plates using complete growth medium prior to the 
experiment. The cells were left to grow in cell culture incubator for 24 hours for adhesion. 
After 24 hours, growth medium was removed and a fresh growth medium with the addition 
of NaCl at different final doses as describe in previous section (section 3.2.7) was added. 
Experiment was performed for 24, 48, and 72 hours with sample number of six for each 
conditions (n=6). At each designed time points (24-, 48-, and 72-hr exposure of NaCl), the 
cells were harvested and the culture medium samples were collected for 1H-NMR analysis. 
Figure 3.1 summarises the design for this experiment. 
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Figure 3.1: Experimental design for the exposure of HepG2 cell to the NaCl treatment. 
 
3.2.9 Sample preparation for 1H-NMR cell supernatant analysis 
After reaching each incubation time point, cell media supernatant was collected 
and prepared for 1H-NMR analysis according to Ellis et al., (2011). Briefly, 1 mL of cell 
medium was transferred to Eppendorf tube and was centrifuged 5 minutes at 10 000 rpm 
to remove any remaining cell pellet. After centrifugation, 550 µL of cell media supernatant 
was carefully transferred to a new clean tube. A volume of 50 µL of D2O (mix with 0.2% TSP 
(w/v)) was then added into the tube and the mixture was vortex to mix. 550 µL of the 
mixture was transferred into 5 mm NMR tubes for analysis.  
 
3.2.10 Metabolic profiling by 1H-NMR spectroscopy 
The metabolic profiling of the HepG2 cell culture media was carried out on a Bruker 
spectrometer operating at 600-MHz 1H frequency. High-resolution, 1D, 1H NMR spectra of 
culture media were acquired at 14.1 T (600.13 MHz 1H frequency) using a Bruker AVANCE 
600 spectrometer (Bruker Biospin, Rheinstetten, Germany) by performing 128 scans and 
16 dummy transients. The temperature of NMR experiment was maintained at 300 K. The 
water signal was supressed at δ4.7 by a presaturation pulse during relaxation delay (RD, 3 
s). For each sample, free induction decays (FID) were multiplied by an exponential function 
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corresponding to a line broadening of 0.3 Hz before Fourier transformation. Data NMR 
spectra were phased automatically, baseline corrected, and normalised to TSP signal at 
δ0.00. The metabolites identification and assignment were carried out from 1D NMR data 
using Chenomx NMR suite 7.0 software, published assignments and The Human 
metabolome database (HMDB)(http://www.hmdb.ca/) (Wishart et al., 2007). 
 
3.2.11 Data processing and multivariate data analysis 
The spectral data were exported in Matlab software (R2012b version Mathwork Inc, 
Natwick MA) and signals were aligned using in-house software (Shintu et al., 2012). The 
spectra were discarded at the region of δ4.68-5.00 to remove the variation caused by the 
residual water resonance. The pre-processed spectra were then analysed by using 
multivariate data analysis such as Orthogonal Partial Least-Squares (OPLS) and 
Discriminant Analysis based on Orthogonal Partial Least-Squares (OPLS-DA). To identify 
relevant features in the metabolic profiles, OPLS regression coefficients were back-scaled 
using a back-scaling method which allows the estimation of the proportion of variance for 
each NMR variable.  
 
3.2.12 Metabolite-Set Enrichment Analysis (MSEA) 
In order to identify pattern of the significant metabolites (significant metabolic 
signature) in biologically meaningful context, Metabolite-Set Enrichment Analysis (MSEA) 
was carried out. The list of the significant metabolites obtained from OPLS-loadings plots 
was tested to see whether there is an enrichment of metabolites of a particular pathway 
within the significant metabolic signature. (http://www.msea.ca/) (Xia and Wishart, 2010). 
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3.3 RESULTS 
3.3.1 Complete growth media is able to maintain its pH after the addition 
of different types of sodium salts. 
In order to study the effect of the addition of different salts concentrations on the 
growth and metabolism of HepG2 cells, first the pH reading of the media after the addition 
of the salts were measured. This is to eliminate any effect that might be seen later on that 
caused by the extreme pH change of the media. Complete growth media was prepared as 
described in methodology section and was mixed individually with sodium chloride, sodium 
bicarbonate, and sodium hydroxide at different final doses of 0.1 nM, 1.0 µM, and 1.0 mM. 
The pH of the complete growth media-sodium mixture was then measured to see if the 
addition of sodium at any doses were able to change the pH of the media out of the 
optimum range for cell growth. The addition sodium chloride (NaCl), sodium hydroxide 
(NaOH), and sodium bicarbonate (NaHCO3) to the complete growth medium did not show 
any extreme variations on the pH of the growth media as shown in Figure 3.2. Under 
normal conditions, the pH of the complete growth media was measured at around pH 7.5. 
The addition of NaOH and NaHCO3 at the molarity of 0.1 nM, 1.0 µM, and 1.0 mM, but not 
for NaCl, slightly increased the pH of the growth media. However, these pH change are not 
extreme, and the net effect of the pH change compared to the control (complete growth 
media) is only a small reduction by about 0.02 and for the highest pH is by 0.03. The 
complete growth media was able to maintain its pH in optimum pH range due to the good 
buffering ability of the media. The initial molarity of NaCl and NaHCO3 in the cell medium 
(MEM medium) are 117.24 mM and 26.20 mM, respectively. In this study, the highest 
molarity added was 1.0 mM which was approximately 1/100 the initial molarity of NaCl in 
the medium. This dose is respectively low to have any effect on the pH of the media as the 
buffering capacity of the media was able to maintain its pH. This result shows that the 
addition of all tested sodium doses in this study were not able to bring the pH of the media 
out of the optimum pH range. It also suggests that any effects shown by growing HepG2 
cells with these doses are unlikely to be due to the modulation of the pH of the growth 
media.   
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Figure 3.2: pH of growth media. NaCl, NaOH, and NaHCO3 were individually added to the complete 
growth media at different final doses and the pH of the media was read using bench top pH reader 
to see any change in the pH. 
 
3.3.2 The effect of different sodium chloride (NaCl) doses on the growth of 
HepG2 cells. 
In the previous section, it has been shown that the growth media was able to 
maintain its pH even after the addition of the highest dose of sodium. In this study, NaCl 
was selected as sodium control due to the fact that it has been used widely in molecular 
biology applications and considered as an essential nutrient for living cell. The effect of 
NaCl on HepG2 cells viability was assessed by adding NaCl to the complete growth media 
to have the final NaCl doses of 0.1 nM, 1.0 µM, and 1.0 mM. Figure 3.3 presents the results 
obtained when HepG2 cells were cultured in the growth media containing different doses 
of NaCl at three different time points which are 24, 48, and 72 hours. At 24 hours 
incubation, the addition of NaCl increases the cell viability when compared to the control 
in a dose-dependent manner. The highest cell viability reading was measured at 1.0 µM of 
NaCl with approximately 10% more viable cells when compared to the control. This 
however, was not statistically significant (p>0.05) when compared to the control group. 
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The same trend was also observed for the samples at 48- and 72-hour time points with an 
increase in cell viability of ~3% and ~8% of the control’s level respectively. Despite showing 
an increasing trend in cell viability except for the highest tested dose, none of the 
conditions were significantly different when compared to their respective control (p>0.05). 
These cell viability results suggest that the addition of sodium in the form of NaCl to the 
complete growth media was not able to cause any significant changes in HepG2 cells 
growth and viability even at the highest tested dose. 
  
Figure 3.3: Proliferation of HepG2 cells in growth media containing various doses of NaCl. HepG2 
cells were seeded in 96-well plates at approximately 60,000 cells/cm2 using complete growth media 
and left to adhere to the surface of the well for 24 hours (37oC, 5% CO2). After 24 hours (post-
seeding), the growth media was changed to fresh complete growth media containing different 
doses of NaCl. Cell proliferation was assessed every 24 hours starting from this point using 
PrestoBlue®. Results are represented as percentage fluorescence of each conditions vs respective 
control for every time points with SEM errors bar (n=6). Mann-Whitney two-tailed test was 
performed. No significant difference across all the conditions were observed (p>0.05). 
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3.3.3 1H NMR cell media supernatant metabolic profiling of sodium chloride 
(NaCl) treatment on HepG2 cells.  
To investigate if a specific metabolic signature associated with the treatment of 
NaCl on HepG2 cells, cell culture media metabolic profiles were acquired from growth 
media supernatant collected at 24-hr, 48-hr, and 72-hr time points using 1H NMR 
spectroscopy. OPLS-DA models were constructed to compare the cell media metabolic 
profiles from four different experimental conditions at each time point. The OPLS-DA 
models were built by using three predictive components and several orthogonal 
components. The optimal number of the orthogonal component to be used for the models 
was determined by checking the good value of R2Y (goodness of fit) and Q2Y (goodness of 
prediction) (Table 3.1). OPLS-DA scores plots for all time points were able to separate 
control from treated group, as well as between doses within the treated groups (Figure 
3.4-A.i, B.i, C.i). There was a good discrimination between the groups along the predictive 
components (Tpred1, Tpred2, Tpred3). However, the validation of the models using 
permutation testing with 10,000 iterations were only able to significantly validate the 
model for 72-hr time point (p=0.0036) but not the models of 24- and 48-hr time point with 
high p value of p=0.0707 and p=0.1617 respectively (Figure 3.4-A.ii, B.ii, C.ii). 
To identify dose-dependent features in cell media metabolic profiles, an O-PLS 
regression analysis was then carried out for each time point. O-PLS regression is used to 
determine whether 1H NMR cell medium spectra could show the dose-related response of 
NaCl treatment on HepG2 cells (Figure 3.5). For each model, OPLS scores plots showed a 
good discrimination between the groups and also showed that there is a linear effect of 
NaCl treatment on HepG2 cells along the predictive score 1 (Tpred 1) (Figure 3.5-A.i, B.i, 
C.i). The OPLS-loadings plots allowed to identify the metabolites that positively or 
negatively correlated with the treatment of NaCl for each time point (Figure 3.6-A, B, C). 
For all models, the optimal number of component was determined by R2Y and Q2Y values 
(Table 3.2). The models were then validated by using permutation test with 10,000 
iterations, resulting in significant p values for the 48- and 72-hr models (p= 0.0122 and 
0.0001) but not for 24-hr model (p>0.05) (Figure 3.5-A.ii, B.ii, C.ii). The Q2Y value for the 
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24-hr model was also noticeably low (Q2Y=0.1884) while higher value obtained for the rest 
of the models (48-hr and 72-hr) (Q2Y>0.3). 
 
Table 3.1: Value of Q2Y, R2Y, and validation of OPLS-DA models. 
Abbreviations; PC- Number of Predictive components, OC- Number of Orthogonal 
components.   
Time points PC OC Q2Y R2Y Permutation 
p-value 
24-hr 3 2 0.2896 0.9891 0.0707 
48-hr 3 5 0.3243 0.9979 0.1617 
72-hr 3 3 0.3569 0.9319 0.0036 
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Figure 3.4: OPLS-DA score and validation plots separating the control group and the treatment 
groups (NaCl) as well as separating between the treatments groups themselves. Score plots of 
different doses of NaCl treatment on HepG2 cells at (A.i) 24-hr (B.i) 48-hr and (C.i) 72-hr. All the 
OPLS-DA models were validated with multiple permutations testing with 10,000 iterations and 
cross validations in figures A.ii, B.ii, and C.ii for the models of 24-hr, 48-hr, and 72-hr respectively. 
Only model for 72-hr time point shows significant p value when validated with permutation test 
(p<0.05). *Please note, the dose-related trajectory visualised by black arrow is not a regression line. 
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The loadings plot for 24-hr model could not be validated by permutation testing as 
revealed by high p value (p>0.05). As a result it did not show any strong correlation and no 
biomarker could be visualised. This might be due to the reason that the treatment of NaCl 
does not possess any detectable biological effect on HepG2 cells when compared to the 
control (Figure 3.6-A). The loadings plot for the model of 48-hr time point showed that 
leucine, isoleucine and valine were negatively correlated with the treatment, while lactate 
was positively correlated with the treatment of NaCl on HepG2 cells (Figure 3.6-B). 
Loadings plot for 72-hr time point showed that branched chain amino acids (BCAAs) valine, 
leucine, and isoleucine, as well as glutamine and phenylalanine, were negatively correlated 
with the treatment (Figure 3.6-C). The R values for all assigned metabolites were listed in 
Table 3.3. Moreover, a specific time-dependent markers in α-keto-β-methylvalerate and 
formate are observed, as these metabolites were strongly correlated with the treatment 
only at the 72-hr time point. Although the R values for some of the metabolites are high 
which makes them look highly correlated with the treatment of NaCl, they are however, 
not significantly difference when compared to the control group for all time points (p>0.05 
Table 3.3). Although the exposure of NaCl on HepG2 cells caused slight modulation on cell 
metabolism, the effect however, was not significant based on statistical test using 
http://vassarstats.net/ for Significance of a Correlation Coefficient. These results indicate 
that NaCl at all tested doses (0.1 nm, 1.0 µM, and 1.0 mM) does not have significant effect 
on HepG2 cells.  
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Table 3.2: Goodness of fit (R2Y), prediction (Q2Y) and validation values for OPLS regression models 
of NaCl-treated vs control. 
Abbreviations; PC- Number of Predictive components, OC- Number of Orthogonal 
components. 
  
Time points PC OC Q2Y R2Y p-value 
24-hr 1 2 0.1884 0.9883 0.216 
48-hr 1 2 0.3939 0.9594 0.0122 
72-hr 1 3 0.6650 0.9953 0.0001 
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Figure 3.5: OPLS- regression models predicting the dose-related response of NaCl treatment on 
HepG2 cells. For each model, the scores plots indicate a linear effect of NaCl treatment on HepG2 
cells at (A.i) 24-hr (B.i) 48-hr and (C.i) 72-hr exposure. Results of random permutation with 10,000 
iterations for models validation in figures A.ii, B.ii, and C.ii showing a good validation of models for 
48-hr and 72-hr time points (p<0.05) but not for 24-hr (p>0.05). 
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Figure 3.6: Loadings plots of OPLS-regression models showing the quantitative dose-response of 
NaCl on HepG2 cells culture media samples at (A) 24-hr, (B) 48-hr, and (C) 72-hr exposure. 
Horizontal axis corresponds to the NMR chemical shift scale; vertical axis corresponds to the O-PLS 
model coefficients (also referred to as loadings). The line variation corresponds to model 
covariance derived from the mean-centred model, whereas the colour map corresponds to model 
correlation derived from the unit-variance model. Metabolites that correlated significantly and 
associated with the NaCl dose response were assigned on the model coefficient plot. R2: square. 
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Table 3.3: List of metabolites assigned in the loadings plots of OPLS-regression models shown in  
Figure 3.6). The significant R values were identified by using http://vassarstats.net/ for Significance 
of a Correlation Coefficient. 
 Correlation with treatment (R values)  
Metabolite 
key 
Metabolites Chemical shift (1H 
ppm) 
24-hr 48-hr 72-hr 
M1 Leucine 0.93 (d), 0.94 (d), 
1.71 (m) 
- -0.5011 
(ns) 
-0.6003 
(p=0.039) 
M2 Isoleucine 0.94 (t), 1.02 (t) - -0.5412 
(ns) 
-0.4910 
(ns) 
M3 Valine 0.98 (d), 1.04 (d), 
3.62 (d) 
- -0.4841 
(ns) 
-0.5109 
(ns) 
M4 Lactate 1.32 (d), 4.11 (q) - 0.4606 
(ns) 
-0.1268 
(ns) 
M5 α-keto-β-
methylvalerate 
1.10 (d) - - 0.5572 
(ns) 
M6 Glutamine 
 
2.15 (m), 2.44 (m), 
3.77 (t) 
- -0.2853 
(ns) 
-0.5612 
(ns) 
M7 Pyruvate 2.37 (s) - 0.3662 
(ns) 
-0.4148 
(ns) 
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M8 
 
α-D-Glucose  5.24 (d) - -0.2920 
(ns) 
-0.4153 
(ns) 
M9 Phenylalanine 7.31 (m), 7.36 (m), 
7.4 (m) 
- -0.2711 
(ns) 
-0.5716 
(ns) 
M10 Formate 8.45 (s) - 0.1439 
(ns) 
0.7519 
(p=0.005) 
***Notes: (+) values correlate with NaCl doses, (-) values correlate with control. ns= non-
significant R value. 
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3.3.4 Metabolite-Set Enrichment Analysis of the list of significant 
metabolites revealed a significant enrichment in the BCAA 
degradation pathway. 
Metabolites that strongly correlated with both control and treatment groups were 
analysed using Over Representative Analysis in MSEA web server to identify the pathway 
involved (Xia and Wishart, 2010). MSEA analysis revealed a significant enrichment in 
“protein biosynthesis” and “BCAA degradation” pathways (p<0.01) (Table 3.4). However, 
the fact that the list of the signature metabolites consists of an essential amino acid such 
as phenylalanine, valine, leucine, and isoleucine, no amino acids synthesis occurred. MSEA 
revealed that branched-chain amino acids in valine, leucine, and isoleucine belong to BCAA 
degradation pathway. As for the other metabolites such as lactate and formate, the 
analysis was not able to identify the enrichment of these metabolites in their respective 
pathways. 
 
Table 3.4: Result from Over Representation Analysis (ORA) of MSEA based on the set of significant 
metabolites. 
Metabolite set Number of related metabolite 
(metabolite hits) 
p value 
Protein biosynthesis 5 7.54e-8 
Valine, leucine and isoleucine 
degradation 
3 0.00237 
Phenylalanine and tyrosine 
metabolism 
1 0.106 
Pyruvate metabolism 1 0.158 
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3.4 DISCUSSION 
This study assessed the effect of NaCl treatment on HepG2 cells growth and 
proliferation as well as using 1H NMR based metabonomics approach to assess the effect 
of sodium as a SCFA counter ion on hepatocyte metabotypes. 
 
3.4.1 The addition of sodium salt did not alter the pH of the growth media. 
Eagle’s Minimum Essential Media (MEM) was used as the growth medium in this 
study and it uses sodium bicarbonate as the buffering system (life technologies). 
(Supplementary data Table S1). The pH of the complete growth media (prepared as 
describe in section 3.2.1) should be kept in a range of pH 7.0-7.6 as this range is the 
optimum pH range for most of the mammalian cell culture works (Ceccarini and Eagle, 
1971). The pH of the complete growth media after the addition of different types of sodium 
salt (NaCl, bicarbonate, and NaOH) at three different final doses; 0.1 nM, 1.0 µM, and 1.0 
mM is determined in this experiment. The addition of the salt to the growth media was not 
able to alter the pH of the media outside the optimum range that serves best for cell culture 
purpose. The buffering system of the media functioned in maintaining the pH so that the 
pH of the media is well balanced when there is an exogenous compound added. The 
highest molarity of salt used in this study was 1.0 mM for all tested sodium types, and even 
at this dose the pH change was very small. MEM media already contains a mixture of 
inorganic salts such as NaCl and NaHCO3 in its composition. The final molarity of these 
inorganic salts (before experiment) was 117.24 mM for NaCl and 26.20 mM for NaHCO3. 
As mentioned earlier, the highest dose used in the experiment was only 1.0 mM, which 
was approximately 1/100 of the initial NaCl concentration and 1/26 for NaHCO3. This 
concentration when compared to the initial concentration in the media was very small and 
it was unlikely to cause any modulation in pH.  
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3.4.2 Exposure to NaCl at different doses and time points did not affect 
HepG2 cell viability. 
The previous section has demonstrated that the addition of salt even at the highest 
dose tested does not change to pH of the culture media. Based on this, the effect of 
different doses of sodium on HepG2 cell viability is then assessed. The doses used in this 
experiment are similar to the previous section. NaCl has been selected as the test 
compound in this chapter. This is due to the fact that NaCl has been used widely in 
molecular biology and cell biology applications and considered as an essential 
micronutrient for living cell and a classical negative control for osmolarity and pH (Pohl et 
al., 2013). The effect of NaCl on cell viability was assessed at different doses; 0.1 nM, 1.0 
µM, and 1.0 mM after 24, 48, and 72 hours exposure. HepG2 cell viability, measured using 
Prestoblue reagent, shows an increase of viable cells when NaCl dose increases from 0.1 
nM to 1.0 µM, and decreases when the highest dose was introduced. However, there was 
no significant difference across all the conditions that were observed. The highest dose 
used in this experiment was not enough to modulate the cell growth as revealed by 
previous studies that only at high ~ 220 mM of NaCl, cell growth was affected and DNA 
damage was observed (Dmitrieva et al., 2003; Kultz and Chakravarty, 2001). High 
concentration of NaCl prevents DNA damage response from taking place by preventing the 
Mre11 exonuclease to localise on DNA damage sites, as well as inhibits the phosphorylation 
of histone H2AX protein (Dmitrieva, 2004).  
More recently, study has shown that increasing the culture media NaCl 
concentration from 270 to 295-380 mosmol/kg (145-188 mmol/L) for HUVEC cells resulted 
in increase in the expression of genes that play role in the inflammation and 
pathophysiological of cardiovascular disease (CVD) (Dmitrieva and Burg, 2015). However, 
in the present study, the doses of NaCl used were not as high as those studies to cause any 
of these effects, thus no significant effect on cell viability was observed at all tested time 
points. 
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3.4.3 NaCl does not possess significant effect on HepG2 cells metabolism at. 
To investigate the signature metabolites related to the exposure of HepG2 cells to 
NaCl, OPLS models were constructed, and loadings plots of OPLS-regression were assigned. 
In order to identify the metabolic marker related to the NaCl dose-response, the HepG2 
cell media was analysed. The HepG2 cells response to NaCl doses lead to an increase in 
extracellular accumulation of lactate, α-keto-β-methylvalerate, and formate and a 
decrease in branched chain amino acids (BCAA) valine, leucine, and isoleucine, as well as 
glutamine and phenylalanine. Interestingly, all of the metabolites only found when the cells 
were incubated with NaCl for 48 and 72 hours, but not during early time point, which was 
24-hr. One possible explanation for this is that, in the treated-group, more amino acids 
being consumed by the cells for energy production or higher rate of protein synthesis 
occurred. Based on this observation, these particular metabolites could be a markers of 
the dose- and time-response of NaCl exposure on HepG2 cells. However, further analysis 
testing the significant of the correlation coefficient of the signature metabolites was not 
able to observe any significant effect of the NaCl on HepG2 cells (p>0.05). Thus nullifies all 
the initial observation made by observing the degree of the correlation alone.  
BCAA (valine, leucine, and isoleucine), glutamine, and phenylalanine that decreased 
or negatively correlated with the NaCl dose corresponding to the following KEGG pathways 
in the MSEA: “protein biosynthesis” and “valine, leucine and isoleucine degradation”. In 
addition, from the analysis, α-keto-β-methylvalerate was detected and assigned. This 
metabolite is an intermediate product of isoleucine degradation, suggesting that the 
extracellular accumulation of this metabolite is caused by the higher rate of isoleucine 
degradation in the NaCl-treated group compare to the control group.  
The other metabolites that positively correlated with NaCl treatment on HepG2 
cells were lactate and formate. Lactate is involved in pyruvate metabolism. Lactate 
dehydrogenase (LDH) catalyses the interconversion of pyruvate and lactate with the 
interconversion of NADH and NAD+ (Gray et al., 2014). Surprisingly, only at the 72-hr time 
point does formate shows a strong correlation with the NaCl treatment, but not at the 
other time points, 24- and 48-hr. The accumulation of formate can be explained by the 
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hepatic cells as well as cancer cells that can produce large amounts of formate by the folate 
cycle (Nijhout et al., 2006; Tedeschi et al., 2013).  
In this study, a number of significant metabolites that can be considered as 
metabolic markers of NaCl treatment on HepG2 cell have been initially identified by 
observing the R values of the metabolites when compared to the control. However, when 
calculating the level of significance of these R values using the ‘Significance of Correlation 
Coefficient’ test, none of the identified metabolites are significantly different when 
compared to their respective control (time point). Thus, these findings show that NaCl at 
all tested doses does not able to significantly modulate HepG2 cell metabolism. 
 
3.5 CONCLUSION 
In conclusion, experiments carried out in this chapter demonstrated that the 
addition of sodium in the form of sodium chloride (NaCl) has no effect on pH nor does it 
affect the growth of HepG2 cells in all tested conditions. In addition to this result, 
metabolomic experiments were carried out to investigate if the exposure of HepG2 cells 
with NaCl can reveal a specific biomarker related to dose- and/or time-dependent 
response. It has been demonstrated in this chapter that NaCl treatment on HepG2 cells has 
no significant effect on the cell metabolism even at the highest tested dose (1.0 mM). 
These results highlighted that there are no dose-dependent and time-dependent effects of 
NaCl on HepG2 cells when incubating the cells with this compound for 24, 48, and 72 hours. 
Thus, any effects that might be observed in the next chapter when treating the HepG2 cell 
with sodium propionate and sodium butyrate will be solely caused by the SCFAs 
themselves but not their sodium counter ion. 
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CHAPTER 4 
 
4. THE EFFECT OF SHORT-CHAIN FATTY ACIDS; 
PROPIONATE AND BUTYRATE ON HEPG2 CELL 
METABOLISM. 
 
4.1 INTRODUCTION  
The occurrence of obesity and the related disorders such as metabolic syndromes 
have increased drastically over the past decades. Data from World Health Organisation stated 
that there are more than 1 billion overweight adults, with 300 million classified as clinically 
obese (Hotamisligil, 2006). Obesity is associated with an array of additional health problems, 
including increased risk of insulin resistance, type 2 diabetes, fatty liver disease, 
atherosclerosis, and some cancers (Tilg and Kaser, 2011). It is a result of a long-term 
imbalance between energy intake and expenditure, which is regulated by a number of 
pathways involving metabolites and hormones (Greenwood et al., 2011).  
Recent research has suggested that the gut microbiota is involved in the development 
of obesity and metabolic disorders (Greiner and Bäckhed, 2011; Kau et al., 2011). Enzyme 
cellulase which cannot be synthesised by human body is needed to break down cellulose, the 
main component of plant cell wall. Thus gut microbiota plays an important role in fermenting 
dietary fibres that cannot be fully hydrolysed by the host enzymes during digestion processes 
(Topping and Clifton, 2001). The main metabolites produced during this fermentation process 
are short-chain fatty acids (mainly acetate, propionate, and butyrate) and other intermediate 
metabolites such as lactate, succinate, formate, ethanol, and gases (CO2, CH4, and H2) (Flint 
et al., 2007). Short-chain fatty acids (SCFAs) formed were then absorbed into the colonocytes 
which act as substrate for energy production.  
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Many studies have been focusing on the role of SCFAs acetate (C2), propionate (C3), 
and butyrate (C4) in the host. The majority of butyrate produced in the GI tract is in fact 
metabolised by colonocytes – as it is their preferred energy source, accounting for up to 80% 
of their CO2 production (Roediger, 1982). Moreover, it is also involved in regulating 
differentiation and proliferation of cells (Scheppach et al., 1992; Topping and Clifton, 2001). 
SCFA that is not consumed by the colonocytes gets transported across the basolateral 
membrane of the gut (Harig et al., 1996; Tyagi et al., 2002) and enters portal circulation 
towards the liver where they may be metabolised (e.g. propionate), or distributed to 
peripheral tissues (e.g. acetate) (Cummings and Macfarlane, 1997; Roediger, 1982).  While 
acetate has been demonstrated as the primary substrate for cholesterol synthesis, and may 
interfere directly in lipid metabolism (Day and Fidge, 1964), propionate is metabolised 
primarily in liver. This metabolite is a recognised gluconeogenic substrate that enters the TCA 
cycle via the succinyl-coenzyme A (succinyl-CoA) entry point and is then converted into 
oxaloacetate (den Besten et al., 2015; Jin et al., 2015; Wolever et al., 1991). Propionate also 
has been demonstrated to inhibit de novo biosynthesis of both cholesterol and fatty acids in 
rat hepatocytes and human models (Wolever et al., 1991; Wright et al., 1990).  
SCFAs also act as ligands for G protein-coupled receptors (GPCRs), thus activating 
subsequent signalling pathways (Brown et al., 2003). Free fatty acid receptor 2 and 3 (FFAR2 
and FFAR3) are GPCRs, the activation of which results in the inhibition of cAMP production 
via interaction with Gαi protein (Le Poul et al., 2003; Stoddart et al., 2008). Several studies 
have shown that SCFA receptors, FFAR2 and FFAR3 play roles in modulating host energy 
metabolism. Propionate directly regulates FFAR3-mediated sympathetic nervous system 
(SNS) activity, thus resulting in the increase of oxygen consumption in WT mice, but not in 
Ffar3-KO mice (Kimura et al., 2011). Moreover, a study conducted by De Vadder et al., 
suggests that propionate induces intestinal gluconeogenesis via gut-brain neural circuit 
involving the FFAR3 (De Vadder et al., 2014). Similarly, another study reported that SCFAs 
including acetate, propionate, and butyrate regulate energy uptake in adipose tissue and also 
regulate energy expenditure in other tissues, including liver and muscle (Kimura et al., 2013).  
In this chapter, the effect of SCFAs; propionate and butyrate on hepatic cancer 
metabolic network was assessed and investigated. As the liver is a known metabolism hub in 
human body here, using HepG2 hepatocarcinoma cell line, the dose-dependent effects of 
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propionate and butyrate on hepatic metabolism was investigated. To approach this, a 1H 
NMR-based metabonomics approach is used to profile the HepG2 cell culture medium in 
identifying the metabolic markers associated with SCFAs (propionate and butyrate) treatment 
on the cells. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Preliminary cell viability test (toxicity test). 
A cell toxicity assay was conducted to observe the effect of different SCFAs 
concentrations on HepG2 cell growth and to determine the non-toxic range for further 
experiments. This experiment was carried out at three different time points (24-hr, 48-hr, and 
72-hr). Briefly, 60,000 cells/well were seeded in 96 well-plates and were grown in complete 
growth medium (as described previously) at 37oC in a humidified atmosphere comprised of 
5% CO2 and 95% air. The cells were left for 24 hour to form a monolayer. After 24 hours, the 
growth medium was changed and SCFAs (propionate or butyrate) were added to the final 
doses ranging from 0.01 nM to 100 mM. Upon reaching the time points described above, 
PrestoBlue® (Invitrogen) reagent, an oxidation-reduction indicator based on Resazurin dye 
was added to each well. The sample was then incubated at 37oC for 30 minutes before read 
with a plate reader for fluorescence measurement at 535 nm (excitation) and 615 nm 
(emission) observing the cell viability. 
 
4.2.2 Detection of FFAR2 and FFAR3 expression in HepG2 cell line using 
Western blot analysis. 
In order to decipher between the metabolism and the signalling properties of SCFA 
(propionate and butyrate), the expression of free fatty acid receptors (FFAR2 and FFAR3) in 
HepG2 cells was first investigated. These receptors have been shown previously to be 
activated by SCFA (mainly acetate, propionate, and butyrate) (Brown et al., 2003; Nilsson et 
al., 2003). Briefly, HepG2 cells from ~80% confluence flasks were washed twice with ice-cold 
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PBS, scraped off, and suspended in RIPA Buffer (Sigma) and incubated for 5 minutes on ice. 
The lysates were then centrifuged for 10 minutes at 8,000 g at 4oC to pellet the cell debris. 
The supernatant containing the soluble proteins was separated using sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE 10% gel). Proteins were then 
transferred from the gel to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad Japan, 
Tokyo, Japan) by electroblotting. The membranes were blocked using 5% skim milk in Tris-
buffered saline containing 0.1% Tween-20 (TBST) at room temperature for 1 hour after which 
the membranes were incubated with each primary antibody at 4oC overnight. On the next 
day, the membranes were washed 3 times with TBST and were incubated with the secondary 
antibody for 1 hour at room temperature. Finally, the membranes were washed before 
visualised using ECL on Kodak Image Station 2000MM or onto photographic film (Amersham 
GE) to reveal the proteins band. The antibodies used were Anti- GPR41 antibody (ab103718, 
abcam®), Anti-GPR43 antibody (ab131003, abcam®), and Goat anti-Rabbit (1721019, Biorad). 
 
4.2.3 Cell culture preparation for 1H NMR analysis. 
For NMR metabolomics analysis, HepG2 cells were plated in six well-plates using 
complete medium prior to the experiment at the seeding density of 60,000 cells/well. After 
24 hours, new medium was added with the additional of SCFAs (propionate or butyrate) 
according to the non-toxic concentration range selected based on results from the toxicity 
study. Propionate and butyrate were used in the form of sodium salt in this chapter. The 
selected doses were 0.1 nM, 1.0 µM, and 1.0 mM. Medium without propionate or butyrate 
supplementation serves as control for this experiment. The experiment was performed for 
24, 48, and 72 hours. After reaching each incubation time point, cell media supernatant was 
collected for 1H-NMR analysis and at the same time the cells were counted by using Moxi ZTM 
mini automated cell counter (ORFLO Technologies) for the normalisation of the rate of 
metabolite production and consumption later on. In order to assess sole effect of propionate 
and butyrate on HepG2 cells metabolism, the identified metabolic signatures in this chapter 
will be compared with the results obtained from the experiment on the effect of NaCl on 
HepG2 cells in previous chapter (Chapter 3), thus eliminating the effect of sodium. 
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Figure 4.1: Experimental design for the exposure of HepG2 cells to the SCFAs treatment. 
 
4.2.4 Sample preparation and 1H NMR spectroscopy. 
The method for this part is as described previously in Chapter 3, section 3.2.9 (for 
sample preparation of cell media NMR analysis), and in Chapter 3, section 3.2.10 (for 1H NMR 
spectroscopy). 
 
4.2.5 1H NMR spectra pre-processing, 1H NMR data processing, and 
multivariate data analysis. 
See Chapter 3, section 3.2.10 for 1H NMR spectra pre-processing and Chapter 3, 
section 3.2.11 for 1H NMR data processing and multivariate data analysis. 
 
4.2.6 Pathways-specific analysis using univariate analysis. 
The concentration of highly correlated metabolites related to TCA cycle, BCAA 
catabolism and gluconeogenesis detected in cell media 1H NMR spectra were quantified using 
Chenomx NMR suite 7.0 software. In order to calculate the consumption or production rate 
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per-cell for each metabolite, the concentration of the respective metabolite at each final time 
point was normalised to the initial concentration of that particular metabolite in fresh 
medium from the day 0 sample. Finally, to get the consumption or production rate per-cell 
for each metabolite, the net metabolite concentration after being normalised was divided by 
the number of cell from its respective time point. The number of cell was obtained by using 
Moxi ZTM mini automated cell counter (ORFLO Technologies) according to the manufacturer 
protocol. The net consumption or production rate per-cell obtained was then compared 
between SCFA-treated and control group at each time point using non-parametric Mann-
Whitney tests. 
 
4.3 RESULTS 
4.3.1 Optimisation of the pharmacological concentrations of SCFA; 
propionate and butyrate on HepG2 cell viability. 
In order to assess the effects of propionate and butyrate on HepG2 hepatocarcinoma 
cell line, a toxicity study was carried out. This chapter aims at preliminary screening of the 
SCFA concentrations that could have an effect on the growth of HepG2 cell line. A wide range 
of SCFA concentrations were initially assessed ranging from 0.01 nM to 100 mM. Figure 4.2-
B shows that there were no significant changes observed on cell viability when propionate is 
added to growth medium of HepG2 cells at final doses from 0.01 nM to 1.0 mM for all tested 
time points. Microscopic observation of cell morphology further indicates that the cells grew 
healthy by having normal morphology at this range of concentration without any apparent 
changes observed (Figure 4.2-A). However, as seen in Figure 4.2-B, propionate significantly 
(p<0.01) decreased cell viability in dose-dependent and time-dependent manners when used 
at 0.1 mM and 1.0 mM doses. When compared with the control condition, 10 and 100 mM 
propionate reduce the HepG2 cell viability by ~50% and ~90%, respectively. Propionate seems 
to exert its toxic effect when using at high dose starting from 10 mM and above. 
Incubation of HepG2 cells with 4-carbon SCFA butyrate with the same range of 
concentration did not affect the proliferation rate of HepG2 cells. There was no significant 
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difference observed in cell viability from 0.01 nM to 1.0 mM (Figure 4.3-B). The same pattern 
of toxicity also observed when increasing the dose of butyrate to 10 mM and above. HepG2 
cell viability dropped drastically up to 70% off from the control after 24 hours exposure to 
butyrate at this concentration, and even worse at 48 and 72 hours incubation where almost 
none survived. Butyrate concentrations at 10 mM and higher appear to be extreme for the 
cells to grow and observation on the cells morphologies under light microscope revealed that 
almost all cells died at this conditions (Figure 4.3-A). The results of this chapter indicate that 
low dose of SCFA; propionate and butyrate does not have an effect on the cell growth and 
viability, while exert their toxic effect when using at higher doses. 
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Figure 4.2: The effect of propionate on HepG2 cell viability. (A) Microscopic images (10x magnification) 
of HepG2 at different dose and time point were shown. (B) Viability was assessed by PrestoBlue® 
reagent (Invitrogen), and fluorescence measurement was measured at 535 nm (excitation) and 615 
nm (emission). Results are represented as means ± SEM of two independent experiments (n=6 
replicates per condition, **p <0.01). Mann-Whitney two-tail test was performed. 
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Figure 4.3: The effect of butyrate on HepG2 cell viability. (A) Microscopic images (10x magnification) 
of HepG2 at different dose and time point were shown. (B) Viability was assessed by PrestoBlue® 
reagent (Invitrogen), and fluorescence measurement was measured at 535 nm (excitation) and 615 
nm (emission). Results are represented as means ± SEM of two independent experiments (n=6 
replicates per condition, **p <0.01). Mann-Whitney two-tail test was performed. 
 
 
0.01 nM 10 µM 100 mM 
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4.3.2 Investigating the expression of free fatty acids receptor 2 (FFAR2) and 
free fatty acid receptor 3 (FFAR3) in HepG2 cells. 
In this experiment, the protein expression of free fatty acid receptor 2 (FFAR2) and 
free fatty acid receptor 3 (FFAR3) in treated and non-treated HepG2 cells is first investigated. 
The Western blot analysis of HepG2 cell lysates was not able to detect protein expression of 
these two receptors, FFAR2 and FFAR3 in this cell line at all tested conditions (Figure 4.4). 
FFAR3 was found to be expressed in adipose tissue, gut, and the peripheral nervous system 
(Hong, 2005; Inoue et al., 2014), while the expression of FFAR2 was reported in the adipose 
tissue, intestines, and immune tissues (Hong, 2005; Maslowski et al., 2009). These results 
indicate that the effect that might be observed further in this chapter when dosing the HepG2 
cells with propionate and butyrate might be mainly from the metabolism properties of SCFA 
and not via signalling through FFAR2 and FFAR3.  
 
 
Figure 4.4: Examining the expression of free fatty acid receptor (FFAR2 and FFAR3) in HepG2 cell. In 
all conditions including the control (except for the positive control, using Jurkat cell lysate), the 
expression of both (A) FFAR3 and (B) FFAR2 in HepG2 cells were not detected. HepG2 cells were 
cultured with or without the addition SCFA until reaching ~80% confluence prior to harvest for western 
blotting analysis. 
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4.3.3 Characterisation of 1H NMR metabolic profiles of HepG2 cell media.  
To investigate the potential of metabolic profiling in characterizing the responses of 
HepG2 hepatocarcinoma cell line to SCFA, culture media obtained directly from 24, 48, and 
72 hours incubation were profiled using 1D 600 MHz 1H NMR spectroscopy. Based on the 
results from the preliminary study on pharmacological range of propionate and butyrate, 
certain SCFA concentrations that are not toxic to the HepG2 cell were selected for metabolic 
profiling of HepG2 cell medium. The chosen doses for the subsequent NMR study are 
therefore 0.1 nM, 1.0 µM, and 1.0 mM. Complete growth media without any addition of SCFA 
served as control for this experiment.  
Mean 1H NMR spectrum of HepG2 cell media was assigned with the help of 
appropriate database such “The Human metabolome database” (HMDB), published 
assignments, and Chenomx NMR suite 7.0 software. Representative 1H NMR spectra of cell 
media samples metabolic profiles with metabolites assignment was shown in Figure 4.5. In 
total 30 metabolites were identified and assigned. Most of the identified metabolites, mainly 
amino acids are commonly found in Minimal Essential Media (MEM) culture media 
composition as this type of media being used in this experiment.  
Numerous common signals from organic acids (acetate, butyrate, propionate, citrate, 
etc.), amino acids (leucine, isoleucine, valine, alanine, arginine, and many other) and sugar 
(D-glucose) were observed in HepG2 cell culture media. Table 4.1 lists all the identified 
metabolites. Interestingly, large signals form a metabolite appears at ~1.17 and 3.65 ppm, 
which were identified as ethanol. This metabolite consistently produced high intensity 
resonance in all spectra from both propionate and butyrate study samples. This is suggestive 
of ethanol contamination during the experiment as the result of excessive use of ethanol 
spray as surface decontamination during routine cell culture work to prevent any biological 
contamination.   
      
 
110 
 
 
Figure 4.5: Mean of 1H NMR spectra of cell media from SCFA-treated HepG2 cells at 24 hours exposure 
measured by 600-MHz 1H NMR spectroscopy. 
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Table 4.1: 1H NMR chemical shifts from metabolites assigned of cell media obtained from SCFA-treated 
HepG2 cells measured by 600-MHz 1H NMR spectroscopy. The concentration of each metabolites was 
calculated based on the average of 6 samples from 2 separate experiments (n=6). 
Metabolite Chemical shift (1H ppm) Status: 
Y (appear in media 
composition) 
N (not appear in 
media composition) 
Concentration 
(mM) 
2-Hydroxybutyrate 0.9 (t), 1.7 (m), 4.0 (dd) N 0.2070 
2-Hydroxyisobutyrate 1.36 (s) N 0.0103 
2-Oxoglutarate 2.44 (t), 3.01 (t) N 1.0370 
α-keto-β-methylvalerate  1.10 (d) N 0.0550 
4-Aminobutyrate 1.89 (m), 2.28 (t) N 0.0794 
Acetate 1.91 (s) N 0.1726 
Alanine 1.46 (d), 3.77 (q) N 2.6011 
Butyrate 0.88 (t), 1.55 (m), 2.15 (m) N 1.1450 
Choline 3.22 (s), 3.51 (dd), 4.06 (ddd) Y 0.0171 
Citrate 2.53 (d), 2.70 (d) N 0.0505 
Ethanol 1.17 (t), 3.65 (q) N 2.6893 
Formate 8.44 (s) N 0.2531 
α-D-Glucose 5.22 (d) Y 5.1095 
Glutamate 2.04 (m), 2.34 (m) N 0.6751 
Glutamine 2.12 (m), 2.44 (m), 3.76 (t) Y 1.6429 
Glycine 3.55 (s) N 0.2054 
Isoleucine 0.93 (t), 1.02 (d) Y 0.3328 
Lactate 1.32 (d), 4.11 (q) N 5.1436 
Leucine 9.94 (d), 9.95 (d), 1.70 (m) Y 0.4084 
Lysine 1.71 (m), 1.86 (m), 3.02 (t) Y 0.4427 
Methionine 2.12 (s), 2.13 (m), 3.01(t) Y 0.1454 
Phenylalanine 3.12 (dd), 3.26 (dd), 7.31 
(m), 7.36 (m), 7.40 (m) 
Y 0.1856 
Propionate 1.06 (t), 2.18 (q) N 1.1626 
Pyruvate 2.36 (s) Y 1.6698 
Succinate 2.39 (s) Y 0.1734 
Threonine 1.31 (d), 3.60 (d), 4.24 (m) Y 0.5102 
Tryptophan 7.53 (d) Y 0.0554 
Tyrosine 6.89 (d), 7.10 (d) Y 0.1750 
Valine 0.98 (d), 1.03 (d), 2.26 (m), 
3.59 (d) 
Y 0.4348 
3-methylhistidine 7.01 (s) Y 0.2546 
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4.3.4 1H NMR cell media metabolic profiling of propionate-treated HepG2 
cells identifies constant metabolic signature associated to isoleucine 
metabolism.  
To investigate the specific metabolite signature associated with propionate treatment 
on HepG2 cell line, supervised multivariate statistics using orthogonal partial least-squares 
discriminant analysis (OPLS-DA) and orthogonal partial least-squares regression (OPLS-
regression) were carried out. First, metabolic profiles from media of HepG2 cells treated with 
propionate were compared at each time point by using OPLS-DA models. Each OPLS-DA model 
was constructed by using three predictive components and several orthogonal components. 
To select the optimum number of orthogonal components, the value of R2Y (goodness of fit) 
and Q2Y (goodness-of-prediction) statistics were observed. OPLS-DA score plots present a 
clear discrimination between the control and the treated group as well as between doses 
within the treated groups with goodness-of-prediction parameters Q2Y equal to 0.3660, 
0.5745, and 0.4950, for model of 24, 48, and 72-hr, respectively (Table 4.2). As shown in 
Figure 4.6, OPLS-DA score plots separate the doses within the treated group along predictive 
score-1 (Tpred 1), and between control and the treated group along predictive score-2 
(Tpred2). The robustness of the models was then validated by multiple permutation tests with 
10,000 iterations resulting in significant p value (p<0.05) for all three time points (Figure 4.6-
A.ii, B.ii, and C.ii). 
 
Table 4.2: Value of Q2Y, R2Y, and validation of OPLS-DA models for propionate experiment. 
Time points PC OC Q2Y R2Y p-value 
24-hr 3 5 0.3660 0.9669 0.0107 
48-hr 3 3 0.5745 0.9991 0.0021 
72-hr 3 4 0.4950 0.9995 0.0106 
Abbreviations; PC- Number of Predictive components, OC- Number of Orthogonal 
components. 
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Figure 4.6: OPLS-DA score and validation plots separating the control group and the treatment groups 
(propionate) as well as separating between the treatment groups themselves. Score plots of different 
doses of propionate treatment on HepG2 cells at (Ai) 24-hr (Bi) 48-hr and (Ci) 72-hr. All the OPLS-DA 
models were validated with multiple permutations testing with 10,000 iterations and cross validations 
in figures A.ii, B.ii, and C.ii for the models of 24-, 48-, and 72-hr respectively. (p<0.05). *Please note, 
the dose-related trajectory visualised by black arrow is not a regression line. 
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In order to test whether there is a dose-response related to the treatment of 
propionate on HepG2 cells, supervised multivariate analysis was carried out using orthogonal 
partial least-squares regression (OPLS-regression). OPLS-regression was able to show the 
dose response of propionate (0.1 nM, 1.0 µM, and 1.0 mM) in HepG2 cells (Figure 4.7-A.i, B.i, 
and C.i). The models were constructed with satisfactory values for goodness-of-fit and 
goodness-of-prediction parameters (Table 4.3). This is used as an indicator of how well the Y 
matrix is explained by the corresponding NMR X matrix (Fonville et al., 2010). Permutation 
tests were carried out in order to validate the dose-response models for each time points (24, 
48, and 72-hr).  
 
Table 4.3: Goodness of fit (R2Y), prediction (Q2Y) and validation values for OPLS regression models of 
propionate -treated vs control. 
Time points PC OC Q2Y R2Y p-value 
24-hr 1 3 0.4408 0.9977 0.0184 
48-hr 1 4 0.4935 0.9997 0.0205 
72-hr 1 3 0.4524 0.9981 0.0102 
Abbreviations; PC- Number of Predictive components, OC- Number of Orthogonal 
components. 
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Figure 4.7: OPLS- regression models predicting the dose-related response of propionate treatment on 
HepG2 cells. For each model, the scores plots indicate a linear effect of propionate treatment on 
HepG2 cells at (A) 24, (B) 48, and (C) 72 hours of exposure. Results of random permutation with 10,000 
iterations for models validation (A.ii), (B.ii), and (C.ii) showing a good validation of models (p<0.05). 
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Figure 4.8: Loadings plots of OPLS-regression models showing the quantitative dose-response of 
propionate on HepG2 cells culture media samples at (A) 24, (B) 48, and (C) 72 hours of exposure. 
Horizontal axis corresponds to the NMR chemical shift scale; vertical axis corresponds to the O-PLS 
model coefficients (also referred to as loadings). The line variation corresponds to model covariance 
derived from the mean-centred model, whereas the colour map corresponds to model correlation 
derived from the unit-variance model. Metabolites that correlated significantly and associated with 
the propionate dose response were assigned on the model coefficient plot. 
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Table 4.4: List of metabolites assigned in the loadings plots of OPLS-regression models for propionate 
experiment (shown in Figure 4.8). R values and p-values were calculated by comparing the SCFA-
treated group with control group for each time point. (n=12). The significant R values were identified 
by using http://vassarstats.net/ for Significance of a Correlation Coefficient.  
 Correlation with treatment values 
(R values) and the p-value for the significance 
metabolite 
Metabolite 
key 
Metabolites Chemical shift 
(1H ppm) 
24-hr 48-hr 72-hr 
M1 Leucine 0.93 (d), 0.94 
(d), 1.71 (m) 
-0.2354       
(ns) 
-0.1247        
(ns) 
-0.3427         
(ns) 
M2 Isoleucine 0.94 (t), 1.02 
(t) 
-0.3140       
(ns) 
-0.1887        
(ns) 
-0.4341         
(ns) 
M3 Valine 0.98 (d), 1.04 
(d), 3.62 (d) 
-0.2557      
(ns) 
-0.1733         
(ns) 
-0.4397          
(ns) 
M4 Propionate 1,06 (t), 2.183 
(q) 
0.7948 
(p=0.004) 
0.8511 
(p=0.002) 
0.8277 
(p=0.0004) 
M5 α-keto-β-
methylvalerate 
1.10 (d) 0.6660 
(p=0.0180) 
0.7058 
(p=0.0104) 
0.7944 
(p=0.0020) 
M6 Threonine 1.32 (d), 3.6 
(d), 4.25 (m) 
-0.1561      
(ns) 
-0.1680        
(ns) 
-0.1938         
(ns) 
M7 Lactate 1.32 (d), 4.11 
(q) 
0.6901 
(p=0.0130) 
0.3913         
(ns) 
0.4279          
(ns) 
M8 Alanine 1.46 (d) 0.6982 
(p=0.0116) 
0.8161 
(p=0.0012) 
-0.4608         
(ns) 
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M9 Acetate 1.92 (s) 0.6281 
(0.0287) 
0.5040         
(ns) 
0.7214 
(p=0.0081) 
M10 Pyruvate 2.37 (s) 0.8113 
(p=0.0014) 
0.8661 
(p=0.0003) 
0.4411          
(ns) 
M11 
 
α-D-Glucose  
 
5.24 (d) 
 
-0.6557 
(p=0.0210) 
 
 
-0.1317        
(ns) 
 
-0.2840         
(ns) 
M12 
 
Tyrosine 6.89 (d), 7.18 
(d) 
-0.3362      
(ns) 
-0.2240        
(ns) 
-0.3907         
(ns) 
M13 
 
Phenylalanine 
 
7.31 (m), 7.36 
(m), 7.4 (m) 
 
-0.3252      
(ns) 
 
 
0.3316         
(ns) 
 
0.2960          
(ns) 
M14 
 
Formate 8.45 (s) 0.2210         
(ns) 
0.0051         
(ns) 
0.4536          
(ns) 
Note: *** (-) values mean the metabolites negatively correlated with the treatment; ns, non-
significance metabolite. 
 
For OPLS-regression models, the metabolites with the highest correlation coefficients 
were identified and summarised in order to investigate the metabolic signature related to 
dose- and/or time-response of propionate on HepG2 cells. The OPLS-regression loadings plots 
of each model are presented in Figure 4.8-A, B, and C, while Table 4.4 summarises the 
metabolite assignments with R values for each metabolites. The hot colours on the loadings 
plots show the high correlated variables whereas the cold colours represent the weak 
correlation. Specifically, α-keto-β-methylvalerate and acetate were the markers of the dose- 
and time-response as these two metabolites consistently positively correlated with the 
propionate treatment at all time points. When compared to the sodium control experiment, 
for α-keto-β-methylvalerate, 80% of the variance has been shown to be caused by the 
treatment of propionate, while 50% is caused by the sodium. Thus highlighting the major role 
of propionate in driving this effect. On the other hand, acetate is not a signature metabolite 
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in our sodium control experiment, therefore the effect that is observed here is solely caused 
by the propionate treatment on the cells. Moreover, lactate, alanine, and pyruvate were 
positively correlated, while glucose was negatively correlated in propionate-treated group at 
24-hr time point.  
In order to summarise the results, a synthetic metabolic pathways were constructed 
using a univariate analysis comparing the final concentration of these metabolites between 
the propionate and the control group at each time point. Based on the results from the 
univariate analysis however, only glucose and alanine were significantly modulated when the 
cells were treated with propionate at 24-hr time point with the p–values of p=0.0021 and 
p=0.0474, respectively (Figure 4.9, Table S.1 in Appendix for detailed p values). At 48-hr time 
point, only alanine was significantly modulated by the treatment of propionate (p=0.0010). 
The relative quantifications for 48-hr and 72-hr time points showed that all of the quantified 
metabolites, amino acids, lactate, pyruvate, as well as intermediate of BCAA catabolism α-
keto-β-methylvalerate in particularly were increased in the propionate treated group (p>0.05, 
Figure 4.9, Table S.1 in Appendix for detailed p valuse). However, univariate data analysis 
using Wilcoxon-Mann-Whitney tests was not able to show any significant difference in these 
metabolites when compared to the control group. Pyruvate is involved in many important 
pathways and reactions. Alanine transaminase is a transaminase enzyme that catalyses a 
reversible reaction between pyruvate and alanine. Moreover, pyruvate also can be generated 
from phosphoenolpyruvate (PEP) in glycolysis pathway, and in certain conditions, such as 
when oxygen supply is limited, it is reduced to generate lactate.  
Interestingly, both the multivariate and univariate analysis showed that propionate 
was significantly and consistently difference in all time points (Table 4.4, Figure 4.9). Although 
the metabolites that is expected to be significantly modulated as the result of the 
consumption of propionate by the cells for energy metabolism (e.g., high level of glucose, 
amino acids, pyruvate, lactate, and succinyl-CoA) are not observed, based on the patterns of 
propionate consumption by the cell at all time point, it suggests the potential use of 
propionate by cells as substitute to glucose for energy production.  
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Figure 4.9: Mapping of HepG2 cells medium metabolites accumulation and consumption pattern 
involved in BCAAs metabolism, amino acids metabolism, TCA cycle, and gluconeogenesis for 
propionate experiment. The bar plots are expressed as the mean ± SEM over control values (n=6). For 
each time point, metabolites concentration measured from cell medium were normalised by cell 
numbers. Significance difference between propionate-treated group and control group were 
calculated with non-parametric Wilcoxon-Mann Whitney test: * p<0.05. (p values in Table S.1 in 
Appendix). 
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Next, in order to identify patterns of these metabolic markers in a biologically 
perspective, Metabolite-Set Enrichment Analysis (MSEA) was carried out on the set of 
metabolites that have been identified as the markers of propionate treatment on HepG2 cells. 
Table 4.5 shows the result of Over Representative Analysis in MSEA.  
 
Table 4.5: Result from Over Representation Analysis (ORA) of MSEA based on the set of significant 
metabolites. 
Metabolite set Hit p-value 
Pyruvate metabolism 3 2.33E-4 
Alanine metabolism 2 0.00155 
Glucose-alanine cycle 2 0.0066 
Propionate metabolism 2 0.0148 
Gluconeogenesis 2 0.0332 
BCAA degradation 2 0.0339 
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4.3.5 HepG2 cells treated with butyrate have an increase rate in nutrient 
consumption and nutrient uptake related to energy metabolism 
pathways.  
Similar to previous section (section 4.3.4), supervised multivariate statistics were used 
in this chapter to investigate the specific metabolic signature associated with the treatment 
of butyrate (0.1 nM, 1.0 µM, and 1.0 mM) on HepG2 cells. As a complementary analysis, the 
signature metabolites observed from the multivariate analysis were then quantified and 
compared between the butyrate-treated and the control group at each time point using non 
parametric Wilcoxon-Mann Whitney test. OPLS-DA models were constructed to compare cell 
media metabolic profiles at each time point. Three predictive components and several 
number of orthogonal components have been used to construct the OPLS-DA models. The 
optimal number of orthogonal components was determined by goodness-of-fit (R2Y) and 
goodness-of-prediction (Q2Y) statistics (Table 4.6). All OPLS-DA models (24, 48, and 72-hr time 
point), were able to separate between the control and the treated group. 3D OPLS-DA models 
also showed a good separation between the control and the treated group along the 
predictive component 1 (Tpred 1) and the Tpred 2 shows variations related to dose-response 
(Figure 4.10-A.i, B.i, and C.i). All models were validated by using permutation tests that show 
the significance of the models (p<0.05) (Figure 4.10-A.ii, B.ii, and C.ii). 
 
Table 4.6 : Value of Q2Y, R2Y, and validation of OPLS-DA models for butyrate experiment. 
Time points PC OC Q2Y R2Y p-value 
24-hr 3 3 0.5072 0.9689 0.0001 
48-hr 3 4 0.5028 0.9938 0.0036 
72-hr 3 3 0.54529 0.9971 0.0001 
Abbreviations; PC- Number of Predictive components, OC- Number of Orthogonal 
components. 
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Figure 4.10: OPLS-DA score and validation plots separating the control group and the treatment 
groups (butyrate) as well as separating between the treatments groups themselves. Score plots of 
different doses of butyrate treatment on HepG2 cells at (Ai) 24 (Bi) 48 and (Ci) 72 hours exposure. All 
the OPLS-DA models were validated with multiple permutations testing with 10,000 iterations and 
cross validations in figures A.ii, B.ii, and C.ii for models of 24-hr, 48-hr, and 72-hr respectively. (p<0.05). 
*Please note the dose-related trajectory visualised by black arrow is not a regression line. 
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In addition to discriminant analysis, OPLS-regression was able to significantly model 
the dose response of butyrate (0.1 nM, 1.0 µM, and 1.0 mM) treatment on HepG2 cells at 
each time point. The numbers of predictive and orthogonal components for this analysis were 
listed in Table 4.7. OPLS-regression score plots showed a good linear dose response of 
butyrate treatment for all models (Figure 4.11-A.i, B.i, and C.i). Finally, model validations 
were performed which resulted in significant p value for all time points (p<0.05).  
 
Table 4.7: Goodness of fit (R2Y), prediction (Q2Y) and validation values for OPLS regression models of 
butyrate -treated vs control. 
Time points PC OC Q2Y R2Y p-value 
24-hr 1 2 0.7585 0.9821 0.0001 
48-hr 1 2 0.5360 0.9995 0.0392 
72-hr 1 2 0.8121 0.9771 0.0001 
Abbreviations; PC- Number of Predictive components, OC- Number of Orthogonal 
components. 
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Figure 4.11: OPLS regression models predicting the dose-related response of butyrate treatment on 
HepG2 cells. For each model, the scores plots indicate a linear effect of butyrate treatment on HepG2 
cells at (A) 24, (B) 48, and (C) 72 hours of exposure. Results of random permutation with 10,000 
iterations for models validation (A.ii), (B.ii), and (C.ii) showing a good validation of models (p<0.05). 
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In order to visualise the biomarkers that explain the variations in the models, 
metabolites with a strong degree of correlation were identified and assigned. OPLS-regression 
loadings plots of each models are presented in Figure 4.12 and metabolite assignments along 
with their R values are summarised in Table 4.8.  
At 24-hr time point, metabolites mainly amino acids were found negatively correlated 
with the treatment. In particular, a specific metabolic signature involving isoleucine 
degradation, pyruvate metabolism, and alanine metabolism has been found to be associated 
with butyrate treatment. Indeed, α-keto-β-methylvalerate, pyruvate, and alanine, as well as 
glucose were positively correlated with the treatment with high R values (0.7572, 0.7736, and 
0.5985) (Figure 4.12) (Table 4.8). Univariate data analysis of the concentration of these 
metabolites at 24-hr time point confirms that these metabolites were significantly modulated 
in butyrate-treated group compared to control group (Figure 4.13, Table S.2 in Appendix for 
detailed p values).   
Loadings plot for 48-hr model also show the same pattern of metabolites modulation 
as in 24-hr model (Figure 4.12). Amino acids, such as valine, leucine, isoleucine, threonine, 
and tyrosine were consistently high in control group compared to butyrate-treated group 
throughout the experiment, thus considered as markers of butyrate dose- response. 
Surprisingly, univariate data analysis using nonparametic Wilcoxon-Mann Whitney test on the 
final concentration of these signature metabolites at 48-hr time point, was not able to show 
any significant difference when comparing between the butyrate-treated and the control 
group (p>0.05) (Figure 4.13).  
Interestingly, loadings plot of 72-hr model again revealed that α-keto-β-
methylvalerate and alanine were positively correlated with the treatment of butyrate on 
HepG2 cell. As these metabolites were consistently up-regulated in the butyrate-treated 
group in all models, they constitute stable candidate markers of butyrate dose-response 
phenotype. However, despite showing strong correlation with the treatment of butyrate on 
HepG2 cells (Table 4.8), only alanine, glucose, and butyrate were significantly modulated in 
butyrate-treated group when compared to the control group at 72-hr time point, based on 
the nonparametric test using Mann Whitney test (Figure 4.13, see Table S.2 for detailed p 
values). While alanine can be generated from the transamination reaction with pyruvate that 
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catalyse by the alanine transaminase enzyme, α-keto-β-methylvalerate is produced during 
the BCAA isoleucine degradation by cytosolic branched chain aminotransferase 1 (EC: 
2.6.1.42). The appearance of α-keto-β-methylvalerate in butyrate-treated group suggests that 
there is possibly less incorporation of this metabolite into TCA cycle in butyrate-treated 
condition as the cells might preferred butyrate as their energy source. 
Combining multivariate data analysis and univariate data analysis using Wilcoxon-
Mann-Whitney tests enabled us to better understand the link between β-oxidation, BCAA 
catabolism, and TCA cycle in the context of SCFA treatment on HepG2 cells. As butyrate has 
been established as the main energy substrate for colonocytes, the results of this study point 
out that there is a possibility that butyrate might also be the preferred source of energy as 
substitute to glucose in this hepatic cell model if this SCFA is available. 
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Figure 4.12: Loadings plots of OPLS-regression models showing the quantitative dose-response of 
butyrate on HepG2 cells culture media samples at (A) 24, (B) 48, and (C) 72 hours exposure. Horizontal 
axis corresponds to the NMR chemical shift scale; vertical axis corresponds to the O-PLS model 
coefficients (also referred to as loadings). The line variation corresponds to model covariance derived 
from the mean-centred model, whereas the colour map corresponds to model correlation derived 
from the unit-variance model. Metabolites that correlated significantly and associated with the 
butyrate dose response were assigned on the model coefficient plot. 
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Table 4.8: List of metabolites assigned in the loadings plots of OPLS-regression models for butyrate 
experiment (shown in Figure 4.11). R values and p-values were calculated by comparing the SCFA-
treated group with control group for each time point. (n=12). The significant R values were identified 
by using http://vassarstats.net/ for Significance of a Correlation Coefficient.  
 Correlation with treatment values 
(R values) and the p-value for the 
significance metabolite 
Metabolite 
key 
Metabolites Chemical shift (1H 
ppm) 
24-hr 48-hr 72-hr 
M1 
 
Butyrate 
 
0.88 (s), 1.55 (m), 2.14 
(m)  
 
 
0.8816 
(0.0015) 
 
0.8030 
(0.0016) 
 
0.8001 
(0.0017) 
M2 Leucine 0.93 (d), 0.94 (d), 1.71 
(m) 
-0.5020    
(ns) 
-0.2687         
(ns) 
-0.5516    
(ns) 
M3 Isoleucine 0.94 (t), 1.02 (t) -0.4245     
(ns) 
-0.3359     (ns) -0.5340    
(ns) 
M4  Valine 0.98 (d), 1.04 (d), 3.62 
(d) 
-0.4544    
(ns) 
-0.4859    (ns) -0.4970    
(ns) 
M5 α-keto-β-
methylvalerate 
 
1.10 (d) 
 
0.7392 
(p=0.0060) 
 
0.7869 
(p=0.0027) 
 
0.7572 
(p=0.0043) 
M6  Threonine 
 
1.32 (d), 3.6 (d), 4.25 
(m)  
 
-0.5259    
(ns) 
 
-0.4446    (ns) 
 
-0.5125   (ns) 
M7 Lactate 
 
1.32 (d), 4.11 (q) 
 
0.3952     
(ns) 
 
0.4340     (ns) 
 
-0.5117   (ns) 
M8 Alanine 1.46 (d) 0.7736 
(p=0.0032) 
0.7129 
(p=0.0092) 
0.6901 
(p=0.0130) 
M9 Glutamine 
 
2.15 (m), 2.44 (m), 3.77 
(t) 
 
 
-0.4828     
(ns) 
 
-0.6281 
(p=0.0290) 
 
-0.6788 
(p=0.0154) 
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M10 Pyruvate 2.37 (s) 0.57455    
(ns) 
0.6557 
(p=0.0207) 
-0.2073    
(ns) 
M11 
 
α-D-Glucose  
 
5.24 (d) 
 
-0.5421       
(ns) 
 
-0.5107      (ns) 
 
-0.4011   (ns) 
M12 
 
β-D-Glucose  
 
 
3.25 (m), 3.49 (m), 3.49 
(m), 3.5 (m), 3.91 (d), 
4.66 (d) 
 
-0.4202    
(ns) 
 
-0.3008    (ns) 
 
-0.7709 
(p=0.0034) 
M13 
 
Tyrosine 
 
6.89 (d), 7.18 (d) 
 
-0.5062     
(ns) 
 
-0.4413      (ns) 
 
-0.5506     
(ns) 
M14 
 
3-methylhistidine 
 
7.05 (s), 7.70 (s) 
 
-0.5355         
(ns) 
 
-0.3896           
(ns) 
 
-0.3004       
(ns) 
M15 Phenylalanine 
 
7.31 (m), 7.36 (m), 7.4 
(m) 
 
-0.4849         
(ns) 
 
-0.2637        
(ns) 
 
-0.4666        
(ns) 
M16 Formate 
 
8.45 (s) 
 
0.2591       
(ns) 
 
0.3204       (ns) 
 
0.6127 
(p=0.034) 
Note: *** (-) values mean the metabolites negatively correlated with the treatment; ns, non-
significance metabolite. 
      
 
131 
 
 
Figure 4.13: Mapping of HepG2 cells medium metabolites accumulation and consumption pattern 
involved in BCAAs metabolism, amino acids metabolism, TCA cycle, and gluconeogenesis for 
propionate experiment. The bar plots are expressed as the mean ± SEM over control values (n=6). For 
each time point, metabolites concentration measured from cell medium were normalised by cell 
numbers. Significance difference between butyrate-treated group and control group were calculated 
with non-parametric Wilcoxon-Mann Whitney test: * p<0.05. (p values in Table S.2 in Appendix).  
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In order to put these results into biological perspective, the metabolites that show 
strong correlation were analysed using MSEA analysis. Over Representative Analysis in MSEA 
further revealed an enrichment of metabolites in a number of KEGG pathways within the 
signature metabolites. Table 4.9 lists the results of the MSEA analysis.  
 
Table 4.9: Metabolic pathway enrichment analysis of the set of metabolites that positively correlate 
with the treatment of butyrate in HepG2 cells. Enriched pathways were identified using Metabolite-
Set Enrichment Analysis. 
Description Metabolites hit p-value 
BCAAs degradation 4 3.31E-4 
Pyruvate metabolism 2 0.0182 
Alanine metabolism 2 0.00155 
Glucose-alanine cycle 2 0.0066 
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4.5 DISCUSSION 
A growing body of evidence suggests microbiota-derived metabolites; SCFAs play a 
vital role in regulating host energy metabolism (den Besten et al., 2015; Gao et al., 2009; Lin 
et al., 2012). In this chapter, HepG2 hepatocarcinoma cell line was used to investigate the 
effect of SCFAs: propionate and butyrate on hepatic cancer metabolism by using a cell 
metabonomics approach. Cell media obtained from different time of incubation was assessed 
and profiled by using 1H NMR spectroscopy. 
It has been demonstrated that there is a dose-response relationship of propionate and 
butyrate treatment on HepG2 cells. Dosing the cells with increasing doses of propionate and 
butyrate at each time point increased the accumulation of α-keto-β-methylvalerate, 
pyruvate, and alanine. These suggest that there was a modulation in a number of metabolic 
pathways including BCAA metabolism, pyruvate metabolism, as well as alanine metabolism, 
which link to host energy metabolism. 
 
4.5.1 SCFA: propionate and butyrate demonstrate growth inhibition in HepG2 
cells at dose above 10 mM. 
In this chapter, a wide range of SCFA concentrations was first screened to assess their 
pharmacological range. This is a preliminary optimisation step to determine the concentration 
that is toxic to the cells. This is to make sure that this concentration is avoided in subsequent 
metabonomics analyses and keeping them in the pharmacological range. The screening 
experiment was based on the HepG2 cell viability after the exposure with SCFA: propionate 
and butyrate. Based on the results for both propionate and butyrate experiments, it has been 
demonstrated that 0.01 nM to 1.0 mM of these two compounds did not affect cell viability at 
all tested time points (24-, 48-, and 72-hr). This range of concentration further considered as 
the pharmacological concentration. A previous study has shown that butyrate and other 
SCFAs decreased cell proliferation in intestinal HT29-MTX cells when use at concentration 
higher than 0.5 mM (Giromini et al., 2015). Based on our results, both propionate and 
butyrate at 10 mM and higher have been shown to drastically decreased cell viability. 
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Propionate has been reported to inhibit the growth of rat basophilic leukaemia cell lines, RBL-
2H3, as well as demonstrated the inhibitory role in rat and human lymphocytes at the dose 
of 2 mM and higher (Curi et al., 1993; Vecchia et al., 1997). In human neutrophil model, 4 mM 
butyrate and propionate were able to induce the apoptosis and growth arrest via histone 
deacetylase inhibitor (HDAC) activities that lead to caspase-dependent apoptotic pathways 
and not GPR41/GPR43-dependent pathways (Aoyama et al., 2010).  
The effect of butyrate in inhibiting proliferation and stimulating differentiation of a 
number of colorectal cancer cell lines has been well studied (Gamet et al., 1992; Siavoshian 
et al., 1997, 2000; Whitehead et al., 1986). A previous study by Hinnebusch et al., indicated 
that slightly higher concentrations of butyrate and propionate at 5 mM but not at 1 mM 
caused growth arrest and differentiation of HT-29 cell line (Hinnebusch et al., 2002). The 
effect of butyrate and propionate on growth arrest was said to be associated with the increase 
of p21, cell cycle regulator gene expression and down-regulation of cyclin B1 (CB1) 
(Hinnebusch et al., 2002). Our results highlight that high doses used in our study, which were 
10 mM and 100 mM might also inhibit HepG2 cells proliferation and viability via pathways 
discussed above, thus signifies the role of propionate and butyrate in regulating cell growth. 
To summarise, based on our experiment, HepG2 cells undergo normal proliferation 
when exposed to different doses of propionate and butyrate ranging from 0.01 nM to 1.0 mM 
for 72 hours. This range of concentration is considered as a safe pharmacological range for 
both SCFAs. Both propionate and butyrate exert their toxic effect when using at 10 mM and 
higher. 
 
4.5.2 Accumulation of α-keto-β-methylvalerate associated to modulation of 
BCAA isoleucine metabolism in propionate-treated HepG2 cells. 
In this chapter, HepG2 cells treated with propionate showed an increase in 
extracellular lactate, α-keto-β-methylvalerate, acetate, pyruvate, and alanine metabolite. 
Propionate is a substrate for hepatic gluconeogenesis (Anderson and Bridges, 1984). 
Propionate is one of the major SCFAs produced during the fermentation of dietary fibres in 
gut. This metabolite is metabolised primarily in liver where it enters the TCA cycle via the 
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succinyl-CoA entry point. Besides being used as fuel, propionate also has been reported to 
play significant role in maintaining metabolic homeostasis. Recently, a study has shown that 
this metabolite increased the rate of intestinal gluconeogenesis by acting as free fatty acid 
receptor 3 (FFAR3) agonist to induce intestinal gluconeogenesis gene expression via a gut-
brain neural circuit (De Vadder et al., 2014).  Den Besten et al., demonstrated that propionate 
and other SCFAs were able to protect against diet-induced obesity via a PPARy-dependent 
pathway in in vivo and in vitro models with HepG2 as one of their cellular model. In addition, 
a study conducted by Lin et al., using Ffar3 knockout mice showed that the ability of 
propionate and butyrate in stimulating gut hormone release, suppressing food intake, and 
protect against diet-induced obesity is via FFAR3-independent pathway (Lin et al., 2012). 
To summarise the results, a synthetic metabolic pathways consisting of all the 
signature metabolites identified in this analysis is constructed (Figure 4.9). Higher production 
of lactate by the HepG2 cells was observed in the propionate-treated condition as compared 
to the control. The possible explanation for this is that, in the presence of propionate, this 
metabolite might involve in the gluconeogenesis producing glucose. More glucose will then 
be available to be metabolised to produce pyruvate in glycolysis. As pyruvate can be reduced 
to lactate by lactate dehydrogenase (LDH) in cytosol, more lactate can be generated in this 
condition. Under certain conditions, such as when there is a limited oxygen supply, 
mammalian cells undergo anaerobic glycolysis, producing large amount of lactate (Mulukutla 
et al., 2010). However, in cancer cells or fast proliferating cells, the consumption of glucose is 
high even under normal oxygen condition, resulting in the end product lactate. Lactate 
produced is then excreted to the extracellular environment (Mulukutla et al., 2010; Vazquez 
et al., 2010; Warburg, 1956). This phenomenon is known as Warburg effect or also called an 
aerobic glycolysis (Warburg, 1956). In cells, the levels of lactate and pyruvate are always kept 
in balance by a reversible reaction catalysed by lactate dehydrogenase enzyme as it converts 
NADH to NAD+ and back (Latham et al., 2012). A previous study demonstrated that the level 
of lactate was found to increase significantly in muscle during intense exercise as glycolysis 
exceeded the ability of mitochondria to metabolised the pyruvate produced (Putman et al., 
1995). In this chapter, the excreted level of lactate and pyruvate were observed when 
assessing the extracellular environment (cell media). Moreover, both lactate and pyruvate 
were found to be positively correlated with the treatment of propionate on HepG2 cells.  
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Alanine is another metabolite that can be produced from pyruvate. Like lactate, 
alanine is the other signature metabolite in this study, as revealed by the strong correlation 
of this metabolite in propionate-treated group. Alanine, a non-essential amino acids can be 
produced from pyruvate by the glucose-alanine cycle. This primarily happens in skeletal 
muscle to eliminate nitrogen and at the same time replenishing the energy supply. Pyruvate 
produced from glucose oxidation is then converted to alanine by alanine transaminase 
enzyme. The synthetic metabolic pathway illustrates that the accumulation of alanine is 
concurrently with the accumulation of lactate in HepG2 cells media for propionate-treated 
group (Figure 4.9). 
α-keto-β-methylvalerate is one of the dose- and time-response metabolic markers of 
propionate treatment on HepG2 cells. This metabolite is produced during the degradation of 
amino acid isoleucine by cytosolic branched chain aminotransferase 1 (BCAT). This keto-acid 
is then further degraded by branched chain keto acid dehydrogenase E1 (BCKHD) to 2-Methyl-
1-hydroxybutyl-ThPP and eventually to acetyl-CoA which enters TCA cycle for ATP production 
(Rennie et al., 2006). In addition, higher accumulation of α-keto-β-methylvalerate in 
propionate-treated group compared to the control group suggests that propionate 
preferentially enters TCA cycle at the level of succinyl-CoA, thus caused an accumulation of 
α-keto-β-methylvalerate in the growth media (Figure 4.9). However, α-ketoisocaproate and 
α-ketoisovalerate, the intermediate metabolites from the degradation of BCAAs leucine and 
valine, respectively were not able to be detected. BCAAs catabolism, occurs in most tissues 
such as kidney, liver, heart, and brain, but was found to be at the highest rates in skeletal 
muscle (Harris et al., 2005; Rennie et al., 2006). 
 
4.5.3 Butyrate changes HepG2 cells energy metabolism by modulating BCAA 
metabolism. 
Butyrate, alongside with acetate and propionate is the major product of intestinal 
fermentation (Roediger, 1982). It has been well documented that colonocytes metabolised 
majority of the butyrate produced as substrate for fuel, however, some portion can reach the 
liver via portal vein (Beauvieux et al., 2001). In this chapter, the cell specific-markers of 
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butyrate dose responses were investigated when HepG2 cells were treated with sodium 
butyrate. Butyrate, unlike propionate does not enter the TCA cycle via succinyl-CoA but 
undergoes β-oxidation in mitochondria to produce acetyl-CoA, which then enters the TCA 
cycle (Donohoe et al., 2011). Based on the metabonomics analysis, a number of amino acids, 
including phenylalanine, tyrosine, and BCAAs (valine, leucine, and isoleucine) have been 
found to be consistently down-regulated in butyrate-treated group. Moreover, when 
analysing the rate of metabolites consumed by the cells, it is confirmed that there were higher 
consumptions rate per cell for these amino acids in butyrate-treated groups when compared 
to the control group (Figure 4.13). These results suggest that more amino acids consumption 
occurred to generate intermediates for TCA cycle for energy production when HepG2 cell 
were treated with butyrate. It has been shown that there was an increase levels of amino 
acids including BCAAs in germ-free mice colonocytes compared to conventionally-raised mice, 
where autophagy is used to generate amino acids for energy production (Donohoe et al., 
2011). Autophagy is a mechanism that involves the breakdown of cellular components to 
maintain cellular energy levels during starvation. However, in our study it is not possible that 
the cells were in substrate-starved condition as glucose and other essential growth 
components were supplied at a normal level in the growth media during the experiment.  
As butyrate is the preferred energy substrate for colonocytes, most of the studies 
carried out in this area focusing on the role of butyrate in colonocytes. As mentioned earlier, 
butyrate has to be converted into acetyl-CoA before it can enter the TCA cycle. It is then 
converted to citrate in the first step of TCA cycle before being transported out of 
mitochondria. In present study, HepG2 cells have been found to produce more citrate in 
butyrate-treated group compared to control. The mode of transportation for citrate to be 
transported across mitochondrial membrane into the cytoplasm is via the citrate channel 
(Donohoe et al., 2012; Sun et al., 2015). However, the mechanism of its release outside of the 
cell is still not well understood and it was suggested via K+ ion transporter based on previous 
study carried out on prostatic epithelial cells (Mycielska and Djamgoz, 2004). 
In this study, the treatment of butyrate has been shown to consistently increase the 
levels of extracellular lactate. As previously discussed (section 4.5.2), production of lactate 
came from the reversible reaction between lactate and pyruvate by the action of enzyme 
lactate dehydrogenase. As the cell might switch to use butyrate as substitute to glucose, 
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acetyl-CoA is synthesised and incorporating into the TCA cycle for energy production. When 
there is enough acetyl-CoA generated from the oxidation of butyrate, pyruvate may not be 
used, thus reversible reaction between pyruvate and lactate might occur resulting in the 
increase level of lactate. Moreover, cancer cells as in HepG2 cells produce high amount of 
lactate from pyruvate even in the presence of oxygen, described as “Warburg effect” (Cairns 
et al., 2011; Feron, 2009). Lactate transport across plasma membrane is of fundamental 
importance in mammalian cells. In order to maintain the high rate of glycolysis, glycolytic cells 
must transport lactate out of the cell and this is mediated by a family of monocarboxylate 
transporters (MCTs) (Juel and Halestrap, 1999; Ullah et al., 2006). In contrast, other tissues 
that require lactate to fuel respiration (red muscle and heart) or gluconeogenesis (liver and 
kidney) needed to transport lactate into the cell (Halestrap and Meredith, 2004; Halestrap 
and Price, 1999).  
Additionally, there was also a marked increase of alanine in butyrate-treated group. 
Univariate analysis of the individual metabolite per cells also revealed that HepG2 cells 
accumulated more alanine in the butyrate-treated group compared to the control (Figure 
4.13). Alanine can be produced and excreted during the catabolism of glutamine to lactate. 
In cells, glutamine is used to replenish TCA cycle intermediates, and the secretion of nitrogen 
as ammonia and alanine accompanies this process. Glutamine was converted to glutamate, 
producing α-ketoglutarate by transamination reaction. Alanine aminotransferase removes an 
α-amino group from glutamate and transfers it to non-essential amino acids. The decrease in 
glutamine levels and at the same time an increase in glutamate production was also observed 
in this experiment. The accumulation of alanine in the cell medium was significantly higher in 
butyrate-treated group when compared to the control (p<0.05). This suggests that less 
alanine is being taken up and converted into pyruvate by the cells, as the cells may possibly 
prefer to utilise butyrate for their energy source instead. 
Catabolism of BCAA valine, leucine, and isoleucine produced α-keto-isovalerate, α-
keto-isocaproate, and α-keto-β-methylvalerate, respectively, as intermediate metabolites by 
transamination reactions. These metabolites either can serve as a source of acetyl-CoA for 
the TCA cycle, or enter via the succinyl-CoA entry point. However, only α-keto-β-
methylvalerate was able to be detected and measured in this study. The increase in α-keto-
β-methylvalerate suggests that the activity of branched chain aminotransferase (BCAT) and 
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branched-chain keto acid dehydrogenase (BCKDH) during early steps of BCAA catabolism 
outstrips the capacity of the downstream enzymes in metabolising α-keto-β-methylvalerate 
and incorporating acetyl-CoA in TCA cycle. In this study, higher level of α-keto-β-
methylvalerate was observed in HepG2 cells treated with butyrate compared to the control 
group. This may suggest that the treatment of butyrate may up-regulate the expression of 
enzymes that play role in regulating the BCAA catabolism. It has been shown previously that 
fatty acids oxidation and the activation of peroxisome proliferator-activated receptor-α 
(PPARα) activate rat hepatic BCKDH complex by decreasing BCKDH kinase, thus promote 
BCAA catabolism (Shimomura et al., 2004). To summarise, in the presence of butyrate, instead 
of using glucose, HepG2 cells might possibly use butyrate to generate acetyl-CoA for TCA 
cycle. The influx of acetyl-CoA appears to exceed the capacity for incorporating in TCA cycle, 
thus potentially cause an accumulation of β-oxidation and BCAA intermediates (i.e., α-keto-
β-methylvalerate) which can be exported out of the mitochondria.  
 
4.6 CONCLUSION 
This study provides an explanation on the mechanisms related to the treatment of 
propionate and butyrate on hepatic cancer cell line (HepG2) as well as highlighting the 
signature metabolites related to the dose-response of these SCFAs. Firstly, SCFAs; propionate 
and butyrate from 0.01 nM to 1.0 mM have been demonstrated to not able to alter the HepG2 
cell viability, while the concentrations of 10 mM and above are toxic to the cells. Subsequent 
experiments using several doses selected from pharmacological range of propionate and 
butyrate further demonstrate an up-regulation of a number of metabolites related to several 
pathways including BCAAs metabolism, pyruvate metabolism, alanine metabolism, and 
gluconeogenesis. Dosing HepG2 cells with propionate and butyrate also displayed an increase 
in isoleucine catabolism product, α-keto-β-methylvalerate as revealed by the accumulation 
of this metabolite in the cell media. To summarise, in response to SCFA (propionate and 
butyrate) treatment, HepG2 cells might switch from glucose to SCFA as substrate for acetyl-
CoA synthesis and incorporation into TCA cycle for energy production. Thus, this in vitro study 
further highlights the role of SCFA in regulating host’s energy metabolism in a view of hepatic 
cancer metabolism in HepG2 cell line.  
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CHAPTER 5 
 
5. PHARMACOLOGICAL EFFECT OF SHORT-CHAIN 
FATTY ACIDS IN RECEPTOR ACTIVATION: 
GPR109A (HYDROXYCARBOXYLIC ACID 
RECEPTOR 2 OR HCAR2), FREE FATTY ACID 
RECEPTOR 2 (FFAR2/GPR43), AND FREE FATTY 
ACID RECEPTOR 3 (FFAR3/GPR41). 
 
5.1 INTRODUCTION 
Short-chain fatty acids (SCFAs), mainly acetate, propionate, butyrate, and valerate are 
produced by gut microbiota through the fermentation of complex carbohydrates such as 
dietary fibres (Cummings, 1981). SCFA concentrations can reach up to 100 mM in the lumen 
of the colon and provide 6-9% of our daily energy requirement (Stevens and Hume, 1998). 
However, SCFAs not only serve as energy source, but also act as signalling molecules by 
activating G-protein coupled receptors, therefore activating subsequent signalling pathways. 
G-protein coupled receptors (GPCRs), also known as 7TM receptors, are the largest 
protein family of receptors in mammals (Trzaskowski et al., 2012). This receptor family is 
involved in the regulation of almost all physiological processes in the body. G-protein coupled 
receptors sense molecules outside the cell and activates intracellular signal transduction 
pathways thus regulating cellular responses. GPCRs have been shown to be activated by a 
number of endogenous ligands, such as hormones, neurotransmitters, peptides, proteins, 
and fatty acids(Howard et al., 2001; Kirkham et al., 1992). Upon ligand binding, GPCRs can 
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activate four different families of heterotrimeric G proteins (Gs, Gi/o, Gq/11, and G12/13) inside 
the cell, which in turn activate cellular responses through a variety of second messenger 
cascades (Lefkowitz, 2007; Oldham and Hamm, 2007; Wettschureck and Offermanns, 2005). 
Recently, several groups identified that fatty acids act as ligands for GPCRs and play a 
significant role in the body’s function. Three independent groups simultaneously 
deorphanised G-protein coupled receptor 41 (GPR41) and 43 (GPR43), and that short-chain 
fatty acids as a ligand for these receptors, hence the name of FFAR3 and FFAR2 for GPR41 and 
GPR43, respectively (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003). FFAR2 
belongs to the same family as FFAR3 which shares 42% amino acid identity (Brown et al., 
2003). These receptors are activated by SCFAs, particularly acetate, propionate, and butyrate 
at high micromolar or millimolar concentrations. 
Recently, another type of GPCR, GPR109A (also known as hydroxycarboxylic acid 
receptor 2 or HCA2) was identified to be activated by nicotinic acid or niacin. Niacin, also 
known as nicotinamide or nicotinic acid, is one of the essential human nutrients and must be 
obtained either from the diet or the gut microbiota (Rucker, 2007). Humans are able to 
synthesise niacin in the liver from the essential amino acid tryptophan and distribute it to 
non-hepatic tissues (Fukuwatari and Shibata, 2013). The pathway in which tryptophan is 
converted to niacin is called tryptophan-nicotinamide pathway and requires 9 steps of 
reaction. Although niacin can be produced from tryptophan, it is considered as the byproduct 
of the kynurenine pathway; the first part of the tryptophan-nicotinamide pathway 
(Fukuwatari and Shibata, 2013). Figure 5.1 summarises the tryptophan-nicotinamide 
pathway.  
Recently, genomic assessment of 256 common human gut microbiota revealed that 
niacin is one of the most commonly synthesised vitamins of the human gut microbiota 
genomes with 162 predicted producers. This study revealed that the phyla Actinobacteria, 
Firmicutes, Fusobacteria, Bacilli, and Proteobacteria are the main niacin producers 
(Magnúsdóttir et al., 2015). 
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Figure 5.1: Biosynthesis of niacin from essential amino acid tryptophan. Information taken from 
Fukuwatari and Shibata, (2013). 
 
Niacin has been used for treating dyslipidaemia for years (Knopp, 1999).  It has been 
shown that niacin significantly reduces cardiovascular events and atherosclerosis based on 
meta-analysis of seven trials of secondary prevention (Duggal et al., 2010). In addition, study 
conducted on statin-treated and statin-intolerant patients has shown that niacin increases 
HDL-C plasma concentration by 20% while decreases plasma concentrations of LDL 
cholesterol and lipoprotein-(a) (Bruckert et al., 2010). Using mice lacking the gene coding for 
this receptor, the lipid-lowering effects of niacin was demonstrated to be via receptor 
activation (Tunaru et al., 2003; Wise et al., 2003). GPR109A in humans corresponds to PUMA-
G in rodents. This receptor also can be activated by butyrate as demonstrated by Blad et al., 
(2012) and Taggart et al., (2005), and has been shown to suppress colonic inflammation and 
carcinogenesis in GPR109A-dependent manner (Singh et al., 2014b).  
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Due to the fact that butyrate activates GPR109A and exhibits the same effect as niacin, 
it is hypothesised that the other SCFAs may also have the same properties in activating this 
receptor. To test this hypothesis, the role of SCFAs (1 to 5 carbons) in GPR109A activation is 
investigated by using a cAMP accumulation assay. In addition to this, a harmonised 
pharmacological assessment of a comprehensive SCFA panel, as well as niacin on FFAR2 and 
FFAR3 are also implemented.  
 
5.2 MATERIALS AND METHODS 
5.2.1 GPR109A activation assay. 
The pharmacological effect of short-chain fatty acids in GPR109A activation was 
carried out using cAMP HunterTM eXpress GPCR Assays kit (DiscoveRx, USA) according to the 
manufacturer’s protocol. The functional status of GPR109A activation is monitored by 
measuring the accumulation of cellular cAMP using a homogeneous, gain-of-signal 
competitive immunoassay based on Enzyme Fragment Complementation (EFC). The cAMP 
Hunter eXpress cells expressing stably GPR109A (DiscoveRx, USA), and stimulated with 
forskolin were used in this experiment. The experiment was carried out in two days. Briefly, 
on day 1, the frozen cAMP Hunter eXpress CHO-K1 cells expressing GPR109A were thawed 
and plated on a 96-well microplate at the seeding density of 30,000 cells/well. The microplate 
was then placed in a humidified incubator with an atmosphere of 5% CO2 at 37ºC for 18-24 
hours prior to testing. On day 2, the media was carefully aspirated and 45 µL of diluted cAMP 
Antibody was added. Then, the test compounds (formate, acetate, propionate, butyrate, 
valerate, isobutyrate, isovalerate, and niacin) were prepared in 8-point dose curve serial 
dilution in Cell Assay Buffer containing 15 µM forskolin. The agonist-forskolin mixture was 
added to the well and then was incubated for 30 minutes at 37oC. Following agonist 
incubation, 60 µL of working cAMP detection reagents/cAMP Solution D mixture was added 
to the wells, and the microplate was incubated for 1 hour at room temperature, protected 
from light. Then 60 µL of cAMP solution A was gently added to the wells and the plate was 
incubated for another 3 hours at room temperature, protected from light. Finally, the 
microplate was read for luminescence using spectrophotometer plate reader.  
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5.2.2 Free fatty acid receptor 3 (FFAR3) activation assay. 
The effect of short-chain fatty acids and related compounds on free fatty acid receptor 
3 (FFAR3) was carried out using cAMP HunterTM eXpress GPCR Assays kit (DiscoveRx, USA). 
This assay was carried out according to the manufacturer’s protocol with slight modifications 
to suit the experimental design. This kit is highly sensitive to measure G-protein coupled 
receptor (GPCR) activation based on 3’-5’-cyclic adenosine monophosphate (cAMP) 
production in cells. This kit was used in line with cAMP HunterTM eXpress FFAR3 CHO-K1 cell 
line (DiscoveRx, USA).  
In brief, CHO-K1 cells expressing FFAR3 were mixed with cell plating reagent and 
plated in 96-well plate at the seeding density of 30,000 cells/well. Cells were incubated at 5% 
CO2 at 37oC overnight prior to the assay. The next day, designed as day 2, the cell-plating 
reagent was gently removed, and the cells were treated with several concentrations of 
agonist with 15 µM forskolin. The cells were then incubated for 30 minutes at 37ºC. Following 
agonist incubation, 15 µL of cAMP antibody reagent and 60 µL of cAMP detection solution 
were added to the wells and the plate was incubated for another 1 hour at room temperature 
in the dark to allow the immunocompetition reaction to occur. Then, 60 µL of cAMP Solution 
A was added and the plate was incubated at room temperature in the dark for another 3 
hours. Finally the samples were read on a standard luminescence plate reader. 
 
5.2.3 Free fatty acid receptor 2 (FFAR2) activation assay. 
In this experiment, the pharmacological effect of short-chain fatty acids and niacin in 
activating FFAR2 are investigated. Similar with FFAR3 activation experiment, activation of the 
FFAR2 by the agonist was carried out by measuring the accumulation of cAMP in the cells. 
cAMP accumulation was measured by HitHunter®cAMP XS+ Assay kit (DiscoveRx, USA). CHO-
K1 cells expressing stably FFAR2, and stimulated with forskolin was used as a reporter cells. 
The same protocol as FFAR3 activation assay was applied for this assay with slight 
modification on the volume of the reagents to suit the experimental design (section 5.2.2). 
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5.3 RESULTS 
5.3.1 SCFAs: C4 and C5 SCFAs as well as niacin, induced activation of GPR109A. 
The pharmacology of GPR109A was investigated by assaying several short-chain 
carboxylic acids and related molecules using cAMP HunterTM eXpress GPCR Assays kit 
(DiscoveRx, USA). The compounds tested in this experiment were carboxylic acids with 1 to 6 
carbons, either linear or branched, with niacin as a positive control. Table 5.1 lists the 
compounds tested together with their EC50 value.  
Being the classical agonist for GPR109A, niacin shows the highest affinity for the 
receptor with EC50 of 0.02 µM (Figure 5.2). This indicates that our assay worked and allowed 
us to progress with analysis of the test compounds which were short-chain fatty acids. Based 
on the analysis, butyrate, valerate, isobutyrate, and isovalerate were found to display an 
agonist activity on GPR109A (Figure 5.2). These compounds were characterized by similar 
micromolar potency in activating the receptor, except for butyrate where we were not able 
to calculate the EC50 for this metabolite (Figure 5.2). Butyrate is an agonist of this receptor 
based on the study carried out by Taggart et al., (2005) with EC50 of 1590 µM. Out of the other 
three agonists metabolites, only valerate displayed a full cAMP inhibition curve and showed 
the highest affinity for GPR109A with calculated EC50 of ~280 µM. Isobutyrate and isovalerate 
(C4 and C5), only displayed a partial agonist for this receptor with low affinity for GPR109A for 
both compounds (EC50= ~ 0.1 mM) (Figure 5.2). Shorter carbon chain of carboxylic acids, in 
formate (C1), acetate, (C2), and propionate (C3) however, are found to be a non-agonist for 
this receptor (Figure 5.2) (Table 5.1).  
These screening results indicate that i) GPR109A is activated by longer chain length 
SCFAs with valerate being the strongest agonist for the receptor, ii) BCFAs being partial 
agonists and finally  iii) shorter chain length SCFAs below 3 carbons (formate, acetate, and 
propionate) could not activate GPR109A.  
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Figure 5.2: Pharmacology of GPR109A in a cAMP accumulation assay. cAMP Hunter eXpress cells 
expressing GPR109A (DiscoveRx, USA) were incubated with various concentrations of SCFA and niacin, 
together with 15 µM forskolin. The data represent the mean ± S.E. for triplicate data points (n=3). 
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5.3.2 SCFAs and niacin –induced activation of FFAR3. 
Next, the pharmacology of free fatty acid receptor 3 (FFAR3), or also called G-protein 
coupled receptor 41 (GPR41), was extended by assaying the same compounds as previous 
section (5.2.1) in a cAMP accumulation assay using cAMP HunterTM eXpress CHO-K1 cells 
(DiscoveRx, USA), expressing stably FFAR3, and stimulated with forskolin. As expected, FFAR3 
was found to be activated by all tested compounds with different affinity for each compounds 
(Figure 5.3). Propionate, a known ligand for FFAR3 was used as control in this assay and was 
found to be the strongest agonist for this receptor. The order of potency for FFAR3 was 
propionate > valerate > isobutyrate > butyrate > isovalerate > acetate > niacin > formate. The 
shortest carbon chain fatty acid tested which was carbon 1, formate shows the lowest affinity 
for FFAR3 with EC50 value of 7017 µM. Surprisingly, niacin, a classical agonist for GPR109A, 
also was found to activate FFAR3 (EC50=1465 µM), which has not been reported before. 
However, the potency of niacin in activating FFAR3 is relatively low and only considered as 
partial agonist based on the result generated using this cell model (Figure 5.3). Table 5.2 lists 
the complete EC50 values for each of the tested compound. 
 The results of this screening experiment was in agreement with previous studies that 
demonstrated FFAR3 has affinity for slightly longer chain length SCFAs with formate and 
acetate as the weakest agonist for this receptor compared to longer chain SCFAs with 3-5 
carbons.  
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Figure 5.3: Pharmacology of FFAR3 in a cAMP accumulation assay. CHO-K1 cell lines expressing FFAR3 
(DiscoveRx, USA) were incubated with various concentrations of SCFA and niacin, together with 15 
µM forskolin. The data represent the mean ± S.E. for triplicate data points (n=3). 
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5.3.3 SCFAs and niacin –induced activation of FFAR2. 
In this study, the ability of SCFA and niacin have been screened in activating free fatty 
acid receptor 2 (FFAR2), another member of the GPR40-43 receptor subfamily. This receptor 
is also known as GPR43.  
The results of this experiment show that all tested compounds were able to activate 
the receptor with different potency. Propionate served as the positive control for this assay 
as it was the most potent agonist for FFAR2 with EC50 of 0.443 µM. Among the compounds 
displaying an agonist activity on this receptor, acetate, propionate, and butyrate activated 
FFAR2 with similar micromolar potency (Figure 5.4). Isobutyrate also showed an agonist 
activity but was slightly less potent compared to acetate, propionate, and butyrate. The linear 
and the branched chain of carbon 5, valerate and isovalerate, were also able to activate the 
receptor and decreased the level of forskolin-induced cAMP levels in the cells. However, these 
compounds were lower efficacy agonists of FFAR2 relative to propionate with millimolar 
range of potency. Carbon 1 short-chain fatty acid, formate, and the other test compound, 
niacin were also able to activate the receptor but to a lesser extent. Although these 
compounds were able to activate FFAR2, the EC50 values were relatively high when compared 
to propionate. Using the reporter cells, approximate EC50 value of formate was determined 
to be 1920 µM. The agonist activity of SCFAs and niacin on FFAR2 can be ranked as follows: 
propionate > butyrate > acetate > isobutyrate > isovalerate > valerate > formate > niacin.  
Table 5.3 lists the complete EC50 value for all tested compounds. Based on the results 
of this experiment, the same pattern of receptor activation by SCFAs as previously shown by 
Le Poul et al., (2003) were generated. Interestingly, this study is the first study to report on 
the activation of FFAR2 by niacin (EC50 >10 mM), which is a known GPR109A classical ligand. 
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Figure 5.4: Short-chain fatty acids (SCFA) activate FFAR2. SCFA, from 1 to 5 carbons, and niacin were 
screened on FFAR2 activation using cAMP accumulation assay. CHO-K1 cell lines expressing FFAR2 
(DiscoveRx, USA) were incubated with various concentrations of SCFA and niacin, together with 15 
µM forskolin. The data represent the mean ± S.E. for triplicate data points (n=3). 
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Table 5.1: EC50 values of SCFAs and related molecule for GPR109A. The functional parameter of 
GPR109A activation by SCFAs and related molecule were determined using a cAMP accumulation 
assay (in the presence of forskolin). 
*Butyrate has an EC50 of 1590 µM based on previous study (Taggart et al., 2005). *NA-non agonist
 
Table 5.2: EC50 values of SCFAs and related molecule for FFAR3. The functional parameter of FFAR3 
activation by SCFAs and related molecule were determined using a cAMP accumulation assay (in the 
presence of forskolin). 
 
 
 
Compounds 
 
Carbon 
 
EC50 (µM) 
 
Formate  1 NA 
Acetate  2 NA 
Propionate  3 NA 
Butyrate 4 > 1000*  
Isobutyrate  4 Partial agonist  100 
Valerate  5 279.9 
Isovalerate  5 Partial agonist  100 
Niacin 6 0.02 
Compounds Carbon EC50 (µM) 
Formate  1 7017 
Acetate  2 1007 
Propionate  3 7.41 
Butyrate 4 26.63 
Isobutyrate  4 24.90 
Valerate  5 9.45 
Isovalerate  5 36.08 
Niacin 6 1465 
      
 
152 
 
Table 5.3: EC50 values of SCFAs and related molecule for FFAR2. The functional parameter of FFAR2 
activation by SCFAs and related molecule were determined using a cAMP accumulation assay (in the 
presence of forskolin). 
 
Compounds 
 
 
Carbon 
 
EC50 (µM) 
Formate  1 1920 
Acetate  2 0.866 
Propionate  3 0.443 
Butyrate 4 0.523 
Isobutyrate  4 31.8 
Valerate  5 1624 
Isovalerate  5 1195 
Niacin 6 >10 mM 
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5.4 DISCUSSION 
SCFAs have been shown to activate several GPCRs (FFAR2, FFAR3, and GPR109A), 
thus activating intracellular cascades that regulate many intracellular processes. The 
development of new agonist for these receptors is important as it could potentially be used 
in treating disorders. In this chapter, the agonist activity of SCFAs and niacin in activating 
FFAR2, FFAR3, and GPR109A were investigated. This was carried out by measuring the 
accumulation of intracellular cAMP in CHO-K1 cells overexpressing these receptors. 
Interestingly, this study is the first to demonstrate the agonist activity of niacin on FFAR2 
and FFAR3. Moreover, it has also been demonstrated that isobutyrate and isovalerate as 
the partial agonists for GPR109A, which is to our knowledge is a novel finding. 
 
5.4.1 Butyrate and valerate are full agonists of G-protein coupled receptor 
109A (GPR109A) whereas isobutyrate and isovalerate are partial 
agonists. 
SCFAs have been identified as endogenous ligands for the GPCRs; FFAR3 (GPR41) 
and FFAR2 (GPR43) (Brown et al., 2003; Le Poul et al., 2003). These receptors have been 
shown to be expressed in adipocytes, which also happen to express another G-protein-
coupled receptor, GPR109A (Tunaru et al., 2003; Xiong et al., 2004). Given their similarity 
in butyrate-induced activation of these receptors, this study investigated whether other 
short-chain fatty acids are able to activate GPR109A. The activation of GPR109A by SCFAs 
was investigated by measuring the levels of cellular cAMP after agonist incubation. 
Stronger agonist activity by longer chain length SCFAs has been observed, with valerate as 
the strongest agonist for GPR109A. This result is in agreement with previous studies that 
demonstrated valeric acid (C5) and caproic acid (C6) were the most active on this receptor, 
in both human and mouse models (Taggart et al., 2005). Though, the latter compound was 
not screened in our work. The reason for us to not incorporate caproate in our study is 
because this metabolite is produced in low amounts in the colon compared to others 
(Cummings, 1981). GPR109A has affinity for slightly longer chain length SCFAs with the 
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minimum of 4 carbons needed to activate this receptor. Butyrate is an agonist for this 
receptor with EC50 of 1590 µM. It has been shown in this screening experiment that 
butyrate was also able to activate GPR109A. 
The concentration of SCFAs was found to be around 0.1 to 1.5 µM in blood based 
on the data from Human Metabolome Database (HMDB). The physiological levels of SCFAs 
in blood are not sufficient to activate GPR109A, suggesting that, even though some of these 
SCFA able to activate this receptor, these are not physiological ligands of the receptor. In 
addition, the concentrations of butyrate in both portal and hepatic venous are around 30.1 
and 12 µmol/L respectively, which are not enough to act as endogenous ligand for 
GPR109A in this tissues (Bloemen et al., 2009). The first endogenous ligand of this receptor 
is ketone body 3-hydroxybutyrate, with an EC50 of 767 µM (Taggart et al., 2005).  
GPR109A is expressed in various tissues including white and brown adipose tissue 
(Soga et al., 2003; Tunaru et al., 2003; Wise et al., 2003), as well as in many immune cells 
including monocytes, neutrophils, and macrophages (Benyó et al., 2005; Kostylina et al., 
2008; Schaub et al., 2001). Recently GPR109A also has been shown to be expressed in colon 
(Thangaraju et al., 2009b). Since butyrate is an agonist of this receptor and present in high 
millimolar concentrations in colon, this metabolite is a biologically-relevant agonist for 
GPR109A in this tissue (Thangaraju et al., 2009b). The presence of butyrate and niacin 
induces death of colon cancer cells, suggesting the involvement of GPR109A (Ganapathy et 
al., 2013).  
It has been demonstrated in this study that branched chain fatty acids of 
isobutyrate and isovalerate are partial agonists (EC50 around 0.1 mM) for GPR109A. The 
concentration of these compounds in blood is around 0.7-4.4 µM for isobutyrate and 0.3-
2.7 µM for isovalerate. It is therefore unlikely that these compounds reach appropriate 
concentrations in plasma to activate this receptor. So, their low affinity for GPR109A is not 
physiologically relevant. The shorter carbon chain length of SCFA tested in this study, which 
were formate (C1), acetate (C2), and propionate (C3), were not agonists of GPR109A. This 
present study is the first to identify isobutyrate and isovalerate as partial agonists for 
GPR109A and also further confirmed the previously reported activation of GPR109A by 
SCFAs butyrate and valerate.   
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5.4.2 SCFAs 3 to 5 carbons are stronger FFAR3 agonists. 
Free fatty acid receptor 3 (FFAR3) is a G-protein coupled receptor which is also 
known as GPR41, belonging to a group of four GPCRs together with GPR43 (FFAR2), GPR40, 
and GPR42 (Le Poul et al., 2003). In this chapter, several SCFAs have been screened in 
activating FFAR3 using cAMP accumulation assay. Short-chain carboxylic acids, including 
acetate, propionate, butyrate, isobutyrate, valerate, and isovalerate have been shown to 
have agonist activity on FFAR3 with different potency. Propionate (C3), being the positive 
control for this experiment, is the most potent and effective ligand for FFAR3. This receptor 
has been previously deorphanised by several groups, and has been identified to be 
activated by SCFA. In the present chapter, a similar activation pattern of FFAR3 by SCFAs 
as demonstrated by others was obtained. In general, it has also been shown that the 
ranked agonists and dose-dependent responses to SCFAs were consistent between 
research groups, and assay formats, with propionate being the most potent agonist while 
acetate (C2) and formate (C1) displaying lower potencies. Based on this study, valerate (C5) 
has been found to be more potent than butyrate (C4) in activating FFAR3, which was 
different with what has been reported by others. When comparing the EC50 of both 
compounds however, the EC50 values between valerate and butyrate is very close. The 
values are 9.45 µM and 26.6 µM, respectively.  
FFAR3 has been shown to couple exclusively to Gi/o proteins family (Covington et 
al., 2006). FFAR3 activation following ligand binding triggers a series of second messenger 
cascades that result in an intracellular response. Gαi activation inhibits cAMP-dependent 
pathway by inhibiting adenylate cyclase, thus decreasing the production of intracellular 
cAMP from ATP (Birnbaumer, 2007; Le Poul et al., 2003). In this study, it has been 
demonstrated that the optimal length of carbon atoms for FFAR3 activation is from three 
to five carbons. Interestingly, it has also been demonstrated in this study that niacin, a 
known GPR109A agonist are able to activate FFAR3, but in much lower potency compared 
to propionate, butyrate, isobutyrate, and valerate, but higher when compared to formate. 
The EC50 of niacin for FFAR3 is determined to be around 1500 µM. Straight chain of 5 
carbons SCFA in valerate is more potent agonist that the branched-chain isovalerate which 
contains methyl group chain.  
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FFAR3 appears to be expressed in kidney, colon, spleen, lymph node, and bone 
marrow (Brown et al., 2003; Hong, 2005; Le Poul et al., 2003). However the expression of 
FFAR3 in adipose tissue is rather controversial where some investigators were able to 
detect the expression of the receptor in human and mouse adipose tissue (Brown et al., 
2003; Le Poul et al., 2003; Nilsson et al., 2003; Xiong et al., 2004), other groups were not 
(Frost et al., 2014a; Hong, 2005; Kimura et al., 2011; Zaibi et al., 2010). Despite the fact 
that SCFAs are able to activate FFAR3, the concentration of these metabolites in blood is 
low and very unlikely to reach the desired concentration to activate the receptor. The 
concentration of these metabolites in portal blood is around 258 µM for acetate, ~88 µM 
for propionate, and ~29 µM for butyrate (Cummings et al., 1987). Moreover, acetate 
concentration in plasma can increase up to 10-fold in the event of alcohol administration, 
resulting in the conversion of around 75% of alcohol to acetate (Siler et al., 1999). 
Accumulation of propionate, butyrate, and isobutyrate are characteristic features in some 
inherited diseases (Thompson et al., 1990; Trauner et al., 1975). The accumulation of 
propionate in the blood can be caused by the disease called propionic acidemia (PA). This 
rare inherited disorder is caused by the inability of the body to convert propionyl-CoA to 
methylmalonyl-CoA. Propionyl-CoA, the product of the catabolism of essential amino acids 
and odd numbers fatty acids cannot be metabolised due to the deficiency of the enzyme 
propionyl-CoA carboxylase (Brown et al., 2003). 
The physiologically relevant site of FFAR3 activation is in the gut where the 
concentrations of SCFAs in this tissue are known to be much higher than in the blood. SCFAs 
levels in this tissue can be found up to 500 mM through the gut microbiota fermentation 
of dietary fibres (Cummings, 1981). 
 
5.4.3 SCFAs with 2 to 4 carbons are stronger FFAR2 agonists. 
In this part of the chapter, SCFA, ranging from 1 to 5 carbons, linear and branched, 
as well as niacin were used to screen on the activation of free fatty acid receptor 2 (FFAR2), 
or GPR43. Free fatty acid receptor 2 (FFAR2) is structurally related to FFAR3, where FFAR3 
shares 42% amino acid identity with FFAR2 (Brown et al., 2003; Le Poul et al., 2003). As 
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expected, FFAR2 was activated by the same carboxylate ligands as FFAR3, whereas all 
SCFAs tested in this study displaying an agonist activity on FFAR2. For this receptor 
however, the rank order of potency was found to be slightly difference when compared to 
FFAR3. For the instance, acetate was demonstrated to be less potent on FFAR3 compared 
to valerate, but was more potent in activating FFAR2. In fact, acetate activates FFAR2 with 
similar potency as propionate and butyrate. This observation was in line with what has 
been reported by previous studies conducted by Brown et al., (2003) and Le Poul et al., 
(2003), the first two groups to demonstrate that SCFA as ligands for FFAR2 and FFAR3. 
 In the present study, another compound has also been screened, which was niacin. 
As mentioned earlier in previous section (5.3.1), niacin is a known agonist of other type of 
G-protein coupled receptor, GPR109A. moreover, butyrate, a ligand for FFAR2 and FFAR3 
also has been shown to activate GPR109A (Taggart et al., 2005). To standardise these three 
assays, therefore it has been decided for this experiment to test whether niacin could also 
activate FFAR2 and FFAR3. Interestingly, niacin was found to decrease the intracellular 
cAMP level in a dose-dependent manner and displayed an agonist activity on this receptor 
at least based on the screening assay used in this study. However, the EC50 value was 
relatively higher (EC50 >10 mM) when compared to acetate, propionate, and butyrate. The 
concentration of niacin in plasma is around 0.1–0.4 μM (Gille et al., 2008), and is unlikely 
to be the endogenous ligand of FFAR2.  
FFAR2 has been shown to be coupled through Gq and Gi/o proteins family. Activation 
of this receptor results in the activation of intracellular pathways including inositol 1,4,5-
triphosphate production, intracellular Ca2+ release, activation of ERK1/2, and inhibition of 
cAMP production (Le Poul et al., 2003). This receptor is highly expressed in adipose tissue 
(Hong, 2005), and in various immune cells (Karaki et al., 2006; Le Poul et al., 2003; 
Maslowski et al., 2009; Nilsson et al., 2003). As discussed in the previous section (5.4.2), 
the average concentrations of propionate and butyrate in blood are very low and not likely 
to trigger an activation of FFAR2. The relevant SCFAs in vivo are acetate, propionate, and 
butyrate, as these metabolites are produced in significant amounts from the fermentation 
of dietary fibres by gut microbiota in the hindgut. Moreover, SCFAs also can be produced 
as metabolic by-products of pathogenic bacteria metabolism at sites of anaerobic infection 
in periodontal disease (Niederman et al., 1997). More recently, a study has shown that 
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SCFAs have an anti-inflammatory properties and that SCFA-FFAR2 interactions greatly 
affect inflammatory responses (Maslowski et al., 2009). 
In addition to the previous studies, this present study further confirms SCFA as a 
ligand for free fatty acid receptor 2 (FFAR2). FFAR2 activation by SCFAs inhibits intracellular 
cAMP production by inhibiting adenylate cyclase activity through Gi protein pathway. The 
optimal length is from two to four carbon atoms of SCFA for FFAR2 activation.  
 
5.5 CONCLUSION 
In this chapter, the pharmacological effects of a comprehensive SCFA panel on their 
GPCRs, i.e., GPR109A, FFAR3, and FFAR3 have successfully been characterised using a 
cAMP accumulation assay. This study further confirms previously reported studies on the 
receptors’ activation by SCFAs and extended the knowledge on niacin activation of FFAR3 
and FFAR2. Although niacin is not a strong agonist for these receptors, to our knowledge, 
this is the first study to report on the activation of the receptors by this compound at least 
based on the cAMP accumulation assay used in this study. The overlapping pattern of 
expression for FFAR2 and FFAR3, and their somewhat common ligand suggests that both 
receptors might function similarly. Since many studies have demonstrated that these three 
receptors play an important role in various body functions, it became clear that these 
receptors are important targets for the development of high affinity agonist and 
antagonist. Thus, this study provides a new knowledge on the novel agonists for these 
receptors that could potentially be used for treating disorders such as cardiovascular and 
metabolic diseases as well as inflammatory diseases and some cancers. 
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CHAPTER 6 
 
6. EFFECTS OF SHORT-CHAIN FATTY ACIDS ON 
3T3-L1 DIFFERENTIATION AND 3T3-L1 
ADIPOCYTE LIPOLYSIS. 
 
6.1 INTRODUCTION 
Mature adipocytes are spherical cells with the majority of its cellular component 
being a lipid droplet. These cells are metabolically active and dynamic in response to 
different hormones stimulation. Adipocytes plays a vital role in maintaining lipid and 
energy homeostasis in vertebrate organisms (Klaus, 1997). In the event of food intake, 
which causes nutritional abundance, the ratio of insulin/glucagon is increased, causing a 
net influx of free fatty acids and glucose into adipocytes by up-regulating lipoprotein lipase 
and GLUT4. Acetyl-CoA generated from glycolytic pathway then serves as a precursor for 
de novo fatty acid synthesis which is then subsequently esterified with glycerol and stored 
in forms of triacylglycerol (TG). This process occurs mainly in adipose tissue and liver 
(Pearce, 1983). During fasting, TG is mobilised and then hydrolysed by desnutrin, hormone-
sensitive lipase and monoacylglycerol lipase to generate free fatty acids, which are 
subsequently exported from adipose tissue into the blood stream to undergo 
mitochondrial β-oxidation in energy-demanding tissues such as muscle and liver (Duncan 
et al., 2007a). 
Excess adipose tissue and its dysregulation have a major role in the development 
of obesity and type 2 diabetes. During adipose tissue expansion, there is an accumulation 
of fat mass attributed to both hypertrophy and hyperplasia. In general, hypertrophy 
without hyperplasia generates adipocytes that are metabolically unhealthy (Stephens, 
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2012). Moreover, during the development of obesity,  there is an increase in angiogenesis 
and macrophage infiltration into adipose tissue, as well as alterations in its secretory profile 
(Bourlier et al., 2008). For years, we thought that less fat mass is healthy. However, it has 
been shown that this is not necessarily true as revealed by studies conducted in human 
and mouse (Stephens, 2012). Ectopic lipid, a condition in which lipid accumulates in other 
tissues due to not being stored in adipocytes, has been linked with insulin resistance and 
the development of type 2 diabetes (Gastaldelli, 2011). In addition, obesity is also 
associated with an increase in basal lipolysis (Reynisdottir et al., 1995). Due to its vital role 
in regulating lipid and whole body energy homeostasis, the dysregulation of adipocyte 
function can contribute to metabolic disorders. Hence, a great understanding of these 
processes is important for maintaining metabolic health.  
High dietary fibres cannot be hydrolysed in the small intestine and are fermented 
in the colon, producing short-chain fatty acids (SCFAs). These gut microbial fermentation 
products have previously been shown to decrease obesity (Pawlak et al., 2004; So et al., 
2007). The increase in plasma SCFAs concentration has been demonstrated to affect 
adipocyte size and function (Frost et al., 1998; Pawlak et al., 2004). Furthermore, Hong et 
al., showed that SCFAs increase 3T3-L1 differentiation, and this effect is mediated via its 
receptor, FFAR2 (Hong, 2005). In another study, adipocytes treated with SCFAs show a 
reduction in lipolytic activity, and further revealed the involvement of FFAR2 activation as 
this effect is abolished in adipocytes isolated from FFAR2 knockout mice (Ge et al., 2008). 
In this chapter, the role of a comprehensive SCFA panel on adipocytes 
differentiation and lipolysis was investigated using 3T3-L1 cell line as adipocyte cell model. 
In order to address their role, a combination of cell-based assays and molecular approaches 
was used. 
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6.2 MATERIALS AND METHODS 
6.2.1 Cell culture 
3T3-L1 mouse embryo fibroblast was obtained from Sigma Aldrich. In brief, 
preadipocytes were cultured in Dulbecco’s Minimal Eagle Medium (DMEM, Gibco®) 
containing high glucose (4500 mg/L), supplemented with 10% of fetal bovine serum (FBS), 
1% of penicillin-streptomycin and 1% of glutamine, in an atmosphere of 5% CO2 at 37oC. 
When reaching 70-80% confluent, cells were sub-cultured at the ratio of 1:2 to 1:6, equal 
to seeding density of 2-5x104 cells/cm2 twice a week in order to prevent the culture to 
become fully confluent. Cells were maintained in T75 flask during routine subculturing. 
Cells with passage number between 3 and 10 were used for experiment. 
 
6.2.2 Differentiation to adipocytes. 
3T3-L1 preadipocytes were plated in 24-well plates, at a density of 2000 cells/cm2. 
Two days after confluence (designated as day 0), differentiation into adipocytes was 
induced by adding 0.25 μM dexamethasone, 500 μM isobutylmethylxanthine (IBMX), and 
0.4 μM insulin into basic culture medium (DMEM, 10% FBS, 1% penicillin-streptomycin, 1% 
glutamine) with or without the addition of SCFAs for 2 days. This medium is called induction 
medium. On day 2, the medium was replaced with differentiation medium (DMEM 
containing 10% FBS, 1% penicillin-streptomycin, 1% glutamine, 0.4 μM insulin) with or 
without the addition of SCFAs for another 2 days and maintained in basic culture medium 
thereafter. This medium was repleted every two days until end of experiment. 
Preadipocyte and adipocyte were treated with vehicle or several concentrations of test 
compounds from the induction of differentiation until end of differentiation (day 0 until 
day 10). The short-chain fatty acids used were formate, acetate, propionate, butyrate, and 
valerate, while for the branched short-chain fatty acids were isobutyrate, and isovalerate. 
These compounds were tested at different final doses of 1.0 µM, 10 µM, and 100 µM. Cells 
were considered fully differentiated 10 days after the induction of differentiation (noted 
as day 10). 
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6.2.3 Cell viability assay 
At day 10 post differentiation (differentiation process described above - see section 
6.2.2), 3T3-L1 adipocytes were fixed with 3.7% of paraformaldehyde for 20 min, stained 
during 30 minutes with 0.05% (w/v) Crystal Violet, and washed twice with tap water. A 
third of the total volume of methanol was then added to solubilise the dye. Cell viability 
was measured by reading the absorbance in a spectrophotometer plate reader at 540 nm. 
 
6.2.4 Adipogenesis assay 
At day 10 post-differentiation, adipogenesis was assessed in 3T3-L1 adipocyte by 
lipid staining with freshly made Oil Red-O (Sigma Aldrich Co, LCC). Cell monolayers were 
gently rinsed with phosphate-buffered saline (PBS) and fixed with 3.7% paraformaldehyde 
for 20 min. The cells were then stained with filtered Oil Red-O solution (0.5% (w/v) in 
isopropanol) and incubated for 1 hour at room temperature. After washing four times with 
water, the stained lipids were observed under microscope and picture was taken. Oil Red-
O dye retained in the cell was quantified by elution into isopropanol (100%) and the 
absorbance was measured at 500 nm using spectrophotometer plate reader. 
 
6.2.5 Lipolysis assay 
On day 10 of differentiation, mature 3T3-L1 adipocytes were washed twice with 
PBS and starved with minimal volume of serum-free medium (DMEM with 1% P/S, 1% L-
Glutamine and 0.1% free fatty acids-BSA (Sigma)) for 2 hours at 37oC prior to treatment. 
Cells were then treated with minimal volume of serum-free medium containing either 
vehicle (0.1% Dimethyl sulfoxide, (DMSO)) or selected doses (1.0 µM, 10 µM, and 100 µM) 
of test compounds (see section 6.2.2). After 3 hours of incubation, samples of the media 
were collected, transferred into clean Eppendorf tubes, and centrifuged at 8000 rpm for 5 
minutes to remove cell debris. Supernatant was transferred to fresh Eppendorf tubes for 
glycerol release assay. 
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Glycerol release from lipolysis during treatment of 3T3 adipocyte with test 
compounds was measured by Free Glycerol Reagent kit (Sigma F6248) according to the 
manufacturer’s protocol with slight modification to suit the design of the experiment. 
Briefly, the glycerol reagent was added with 40 mL of distilled water and was left at room 
temperature prior to the assay. Cell medium was mixed with the glycerol reagent in a 1:1 
volume ratio and the cell medium-reagent mixture was then incubated at room 
temperature for 30 minutes. Absorbance was measured with spectrophotometer plate 
reader at 540 nm.  
 
6.2.6 RNA extraction and quantification. 
RNA extraction was performed using RNA extraction kit according to the 
manufacturer’s instruction. Adhered cells in the 24-well plates were directly lysed with lysis 
buffer provided by the extraction kit supplemented with 1% 2-mecapethonol. Lysates were 
transferred to Eppendorf tubes, reduced viscosity and homogenised manually by repeated 
pipetting, vortex, and centrifuging. Homogenised lysate was mixed with 70% ethanol in a 
1:1 volume ratio to adjust column binding condition. The mixtures were then transferred 
to the RNA binding column and centrifuged at 11000 rpm for 30s. After one wash with RW1 
buffer and two washes with RW2 buffer provided by the extraction kit, the RNA binding 
column was dry spun at 11000 rpm for 1 minutes followed by RNA elution with 40uL RNase-
free water. RNA concentration in each sample was quantified using nanodrop and stored 
at -80oC until used. 
 
6.2.7 Reverse transcription. 
300ng RNA was reversed transcribed into cDNA using a SuperScript® II Reverse 
Transcriptase kit and random hexamers. A calculated volume of RNA was topped up to a 
total volume of 13 uL with RNase-free water then mixed with random primers and heated 
at 65oC for 5 minutes (calculation is stated in Table 6.1). The master-mix consisting of 
transcriptase, DTT and first strand buffer were then added to the mixture. The volume of 
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each component in the master-mix is stated in Table 6.2. Samples were then run on Peltier 
Thermal Cycler PTC-200 (MJ Research) with following program: 10 minutes at 25oC, 90 
minutes at 42oC and 15 minutes at 70oC. 
 
Table 6.1: Calculation of sample preparation for reverse transcription. [RNA]=RNA concentration 
in each sample (ng/uL). 
 Volume (µL) 
RNA  300/[RNA] 
RNase-free water 13- (300/[RNA]) 
Random Hexamer 3 
Total volume 16 
 
Table 6.2: Preparation of MasterMix. (#samples=number of samples) 
 Volume per sample (µL) Volume in MasterMix 
dNTP (10 mM) 1.5  
X #samples + 10% excess 
5X First Strand Buffer 5 
DTT (0.1 mM) 2 
Superscript II enzyme 0.5 
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6.2.8 Quantitative polymerase chain reaction (q-PCR). 
Expression of Pparg, Fasn, Adipoq, Hcar2, Ffar2, and Ffar3 were determined by 
qPCR with StepOne Plus Instrument (Applied Biosystems) using TaqMan® Array 96-Well 
Fast Plates (Applied Biosystem, USA) according to the manufacturer protocols. Briefly, 10uL 
of cDNA in a total volume of 20uL reaction mix per well in a 96-well PCR plate was used to 
carry out the reaction. The reaction mix containing the enzymes and pre-designed Taqman 
Gene Expression primers for the targeted genes was customised from Thermo Fisher 
Scientific webpage. Quantification was carried out with the comparative Ct method. 
δCt= Ct(target gene) – Ct(reference gene) 
δδCt= δCt(condition2) – δCt(condition1) 
Fold change= 2^ (- δδCt) 
 
6.2.9 Statistical analysis. 
Comparisons between groups (compounds-treated vs vehicle-treated) were 
performed using two-tailed, Mann-Whitney test for all experiments. All data are presented 
as mean ± SEM from 2 separate experiment with the total of 6 samples (n=6) and the 
critical p value for statistical significance was <0.05.  
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6.3 RESULTS 
6.3.1 Validation of GPR41/Ffar3, GPR43/Ffar2, and GPR109A/Hcar2 
expression in 3T3-L1. 
In order to investigate the role of SCFA and niacin on 3T3-L1 cells differentiation, 
the expression of the genes encoding the receptors for free fatty acids and niacin, which 
are Ffar3, Ffar2, and Hcar2 in this cell model was first investigated. The expression of the 
genes encoding for the receptors were determined by analysing their mRNA levels using 
RT-qPCR analysis. The mRNA was extracted on day 2, 5, 7 and 10 post differentiation 
induction.  
To investigate the involvement of GPR109A, FFAR2, and FFAR3 in adipocyte 
differentiation in vitro, the mRNA levels of Ffar2, Ffar3, and Hcar2 were analysed during 
several differentiation stages of 3T3-L1 cells. The levels of Hcar2 and Ffar2 mRNAs in our 
3T3-L1 cells increased significantly as the cells differentiated (p<0.01). We also found that 
the mRNA expression level of these genes were significantly increased when compared 
among the differentiation days (p<0.01) (Figure 6.1-A, B). However, Ffar3 mRNA was not 
detected during any stage of adipocyte differentiation as shown by the high Ct value 
obtained for all samples (Ct value≥35).  
The expression levels of Pparg mRNA during 3T3-L1 differentiation to adipocyte 
were also investigated. Pparg is an adipocyte differentiation marker, and has been used 
widely as marker of preadipocyte differentiation. Indeed, the expression of this gene was 
significantly increased as the 3T3-L1 preadipocytes differentiated into adipocytes (p<0.01) 
(Figure 6.1-C). This indicates that our 3T3-L1 differentiation protocol worked and can be 
used for subsequent experiments. 
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Figure 6.1: The levels of Hcar2, Ffar2, and Pparg mRNA during differentiation of 3T3-L1 adipocytes. 
RT-qPCR analysis was performed on post confluent preadipocytes (Day 0) and adipocytes that had 
differentiated for 2, 5, 7, and 10 days. (A) Hcar2, (B) Ffar2, and (C) Pparg genes expression. Data 
were normalized using the Nono gene (Arsenijevic et al., 2012) and expressed as fold change 
relative to day 2. Results are expressed as mean ± SEM of two separate experiments with the same 
protocol (n=6). A Mann-Whitney two-tailed test was performed; * p<0.05, **p<0.01, ***p<0.001. 
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6.3.2 The effect of SCFA on 3T3-L1 differentiation and functions. 
6.3.2.1 The effect of SCFA on 3T3-L1 adipocytes cell viability. 
To provide initial evidence of the effect SCFA has on the differentiation of 3T3-L1 
cells, first the effect of these compounds on cell viability was studied. The 3T3-L1 cells were 
allowed to proliferate to confluence and then to differentiate to adipocytes in induction 
and differentiation medium with or without SCFA (1 to 5 carbons) (1.0 µM, 10 µM, 100 µM) 
for up to 10 days. On day 10 post induction of differentiation, cells were fixed and nuclei 
stained with crystal violet. Among compounds tested, only isobutyrate has been shown to 
increase the cell viability when used at the highest concentration when compared to 
control (Figure 6.2). In this condition, 3T3-L1 adipocyte cell viability was significantly 
increased by approximately 10% (p<0.05). However, no significant difference was observed 
when comparing among the treated conditions themselves. Moreover, no increasing or 
decreasing trend from this cell viability assay was observed for all tested compounds. This 
suggests that the selected concentrations were still within the pharmacological range that 
allows the cells to undergo normal proliferation.  
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Figure 6.2: Isobutyrate, but not other tested SCFAs, increases 3T3-L1 adipocytes cell viability at 100 
µM dose. After 10 days incubation with different types of SCFA (1.0 µM, 10 µM, 100 µM), cells were 
fixed and nuclei stained with crystal violet and O.D. 540 nm was measured on a microplate reader. 
Results are expressed as mean ± SEM of two separate experiments with the same protocol (n=6). 
A Mann-Whitney two-tailed test was performed; * p<0.05, **p<0.01, ***p<0.001. 
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6.3.2.2 SCFA; valerate, isobutyrate, and isovalerate promote de novo 
lipogenesis in 3T3-L1 adipocytes. 
In order to assess the effect of SCFAs on 3T3-L1 cells adipogenesis, Oil Red-O 
staining was performed and cellular morphology was assessed. The Oil Red-O staining 
allows us to assess the intracellular triglyceride content and provides a qualitative analysis 
of cellular morphology. Oil Red-O staining of cellular lipid in Figure 6.3 displays that 3T3-L1 
was able to differentiate to adipocytes at all tested conditions. In order to determine the 
rate of lipogenesis for each condition, the triglyceride contents were extracted and were 
normalised to the cell viability. The treatment of 3T3-L1 cells with 100 µM dose of valerate, 
isobutyrate, and isovalerate during differentiation, promotes a significant increase 
(p=0.047, p=0.037, and p=0.029, respectively) in the rate of lipogenesis (normalised to cell 
viability) of respectively, 16%, 16.6%, and 15% when compared to vehicle-treated cells 
(Figure 6.4-E, F, G). Treatment of shorter chain-length of SCFA of formate, acetate, 
propionate, and butyrate, however did not have any significant effect on the rate of lipid 
production per cells in 3T3-L1 adipocyte (p>0.05) (Figure 6.4). 
Based on this results, there was a carbon length preference effect on lipogenesis of 
3T3-L1. Higher rate of lipogenesis was found in C4 and C5 branched-chain fatty acids, i.e. 
isobutyrate and isovalerate, as well as in straight-chain C4 and C5 SCFAs. In addition to this, 
there was also a dose-response effect of the treatment as the rate of lipogenesis is 
significantly higher when the cells were treated with 100 µM dose compared to the control. 
However, no significant effect was observed among the treated conditions themselves 
(p>0.05).  
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Figure 6.3: Functional role of selected compounds on differentiation of 3T3-L1 cells. The 3T3-L1 
preadipocytes were allowed to grow to confluence and then to differentiate to adipocytes in 
differentiation medium with SCFAs (1.0 µM, 10 µM, 100 µM) for 10 days. Oil Red-O staining was 
carried out on day 10. Results are from two different experiments (n=6). 
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Figure 6.4: Isobutyrate, valerate, and isovalerate stimulate de novo lipogenesis in 3T3-L1 
adipocytes. 3T3-L1 adipocytes were treated with different doses of SCFAs (1.0 µM, 10 µM, 100 µM) 
or vehicle (DMSO) during differentiation. At day 10, triglycerides contents stained with Oil Red-O 
was extracted and was measured at 520 nm and then was normalised to cell viability to get the 
rate of lipogenesis. Results are expressed as mean ± SEM of two different experiments (n=6). A 
Mann-Whitney two-tailed test was performed; * p<0.05, **p<0.01, ***p<0.001. 
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6.3.2.3 Adipogenic genes expression in 3T3-L1 cells during differentiation 
into adipocytes. 
Based on the results from previous section, 100 µM dose of valerate, isobutyrate, 
and isovalerate significantly increase the 3T3-L1 cells lipogenesis. Here in this experiment, 
the involvement of single dose (100 µM) of SCFAs on the expression of genes that are 
correlated with adiposity and represent markers of adipogenesis and lipid formation was 
investigated. This is a complement method to check the adipogenesis and to relate with 
our lipogenesis results. Cells were treated with single dose of SCFAs throughout the 
differentiation process and mRNA was extracted on day 2, 5, 7, and 10 to determine the 
level of adipogenesis markers with RT-qPCR. The qPCR results are expressed as fold change 
relative to control-treated group from day 2 samples, and slope analysis was then used to 
compare the nonlinear fit of the curve between SCFAs-treated and control group, which 
results in p values (Figure 6.5-Aii) (Table S.1 in Appendix). These p values were then used 
in constructing a heatmap to simplify the observations (Figure 6.5-Ai). The expression 
levels of all tested genes are increased during 3T3-L1 differentiation, and peaked at day 10 
in both SCFAs-treated and control group (Figure S.2 in appendix). Slope analysis for the 
induction of the gene expression however, was not able to show any significant different 
when comparing the level of marker genes for adipocytes differentiation, Pparg, Adipoq, 
and Fasn, between SCFAs-treated and control group.  
SCFAs have been shown earlier to activate both FFAR2 and GPR109A. Indeed, a 
significant increase (p<0.05) in the expression level of Ffar2 was observed when the cells 
were treated with acetate, propionate, butyrate, isobutyrate, and valerate (Figure 6.5). 
These SCFAs are known strong agonist of this receptor. Butyrate, a known agonist of 
GPR109A also significantly increases the expression of this gene during 3T3-L1 
differentiation when compared to control group (Figure 6.5). However, none of these 
observations correlates with the adipogenesis result measured by using Oil Red-O staining 
method. In this study, due to the time constraint, the qPCR experiment was only able to be 
carried out once with only three samples from one biological replicate (n=3). Thus, our 
qPCR data lacked power of test which did not yield any significant conclusion. As for Ffar3 
expression, high CT values were obtained from our RT-qPCR analysis. This might suggest 
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the low expression level of this gene or possibly it is not express in this adipocyte cell 
model. 
 
 
 
Figure 6.5: RT-qPCR analysis of the gene expression during 3T3-L1 cell differentiation. (Ai) The RT-
qPCR results are expressed as fold change relative to control-treated group from day 2 samples, 
and slope analysis was then used to compare the nonlinear fit of the curve between SCFAs-treated 
and control-treated group, which results in p values. These p values were then used to construct a 
heatmap to summarise the results. Red colour represents the significant up-regulation of the gene 
(p<0.05), while the non-significant (p>0.05) is represented by the no colour. (Aii) Slop analysis 
comparing the effect between propionate-treated with control group on Ffar2 expression. (B) The 
non-linear fit curve of the genes that significantly (p<0.05) up-regulated by the treatment of SCFAs. 
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6.3.2.4 The anti-lipolysis activity of SCFAs in 3T3-L1 adipocytes. 
Finally, the effect of SCFAs on 3T3-L1 adipocytes lipolysis rate was investigated. In 
this experiment, fully differentiated 3T3-L1 adipocytes were treated with different SCFAs 
from 1 to 5 carbons at 100 µM dose for 3 hours. Niacin was used as positive control in this 
experiment since it has been shown to inhibit adipocytes triglyceride lipolysis previously 
(Carlson, 1963). The rate of lipolysis was assessed by measuring the release of glycerol in 
the culture media. As shown in Figure 6.6, propionate, butyrate, and valerate show an anti-
lipolytic effect by significantly reducing (p<0.05) the basal rates of lipolysis of respectively, 
9.63% (p=0.0274), 9.55% (p=0.0161), and 11.5% (p=0.0171) when compared to the vehicle-
treated condition. As for the niacin-treated cells, the lipolysis was significantly reduced 
(p<0.01) by 23.5% (p=0.0011) relative to control. However, no significant effect (p>0.05) 
on 3T3-L1 adipocytes lipolysis was observed when the cells were treated with formate, 
acetate, isobutyrate, and isovalerate. The rank for anti-lipolytic activity of SCFA is 
valerate>butyrate=propionate. These results suggest that longer chain of SCFAs with 
minimal of carbon 3 inhibits basal adipocytes lipolysis. Strikingly, the anti-lipolytic activity 
of C4 and C5 SCFAs, i.e., butyrate and isovalerate, disappear when the compounds have 
another branched chain methyl group chain (i.e., isobutyrate and isovalerate).  
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Figure 6.6: Propionate, butyrate, and valerate inhibit lipolysis in 3T3-L1 adipocytes. Differentiated 
3T3-L1 cells were treated with a numbers of SCFAs from carbon 1 to carbon 5 at 100 µM dose for 
3 hours. Lipolysis was assessed by measuring the release of glycerol in the culture medium. Results 
are expressed as percentages of the basal rate of 100% in the control group without SCFAs. The 
data represent the mean ± SEM of two different experiments (n=6). A Mann-Whitney two-tailed 
test was performed; * p<0.05, **p<0.01, ***p<0.001. 
 
6.4 DISCUSSION 
Adipocytes are highly specialised cells which are important in regulating lipid and 
energy homeostasis in mammals (Klaus, 1997). In the event of excess in nutrition, these 
cells store energy in the form of TG, and release it in the form of free fatty acids in response 
to energy needs. A dysregulation in adipocytes is associated with many metabolic 
abnormalities (Frayn et al., 2007). Previous studies have demonstrated the role of acetate 
and propionate in adipogenesis and lipolysis (Ge et al., 2008; Hong, 2005). In this study, 
the role of a comprehensive SCFA panel on 3T3-L1 adipocytes differentiation and mature 
adipocytes function i.e., adipogenesis and lipolysis was assessed.  
In this chapter SCFAs in valerate, isobutyrate, and isovalerate have been shown to 
promote 3T3-L1 cells lipogenesis by having an increase in total lipid accumulation after 10 
days of differentiation process. Furthermore, valerate, along with propionate and butyrate 
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at 100 µM dose exhibit anti-lipolytic effect in 3T3-L1 adipocytes by reducing the glycerol 
release into the culture medium after 3 hours exposure. These results suggest that SCFAs, 
valerate in particularly could plays an important role in regulating adipocytes development 
differentiation and function. 
 
6.4.1 Valerate, isobutyrate, and isovalerate (100 µM) stimulate 3T3-L1 
differentiation. 
In this chapter, the effect of several doses of SCFAs on 3T3-L1 cells differentiation 
was first investigated. Since the maximum concentration of these compounds in blood can 
be found in a range of 1-5 µM, it is decided to test a number of doses which were 1.0 µM, 
10 µM, and 100 µM to increase chance of observing any effects. First, viability test was 
carried out. Only the highest dose of isobutyrate shows an increase in cell viability. The 
increase in the 3T3-L1 adipocytes viability is slightly but statistically significant when 
compared to the vehicle-treated group (p<0.05). No effect for other tested SCFAs was 
observed. In order to investigate the effect of SCFAs on 3T3-L1 differentiation, cells were 
differentiated in the presence of SCFAs (1.0 µM, 10 µM, and 100 µM). At day 10 after the 
induction of differentiation, cellular lipid accumulation was qualitatively and quantitatively 
measured by Oil Red-O staining. Indeed, 3T3-L1 cells were able to differentiate into 
adipocytes at the end of the experiment (Day 10). However, no significant changes in Oil 
Red-O staining or gross cellular morphology between SCFAs-treated and vehicle-treated 
group were able to detect.  
Recently, study has revealed that acetate and propionate were able to reduce the 
free fatty acids release from adipocyte via the stimulation of FFAR2 activation, and this 
effect was abolished in adipose tissue from Ffar2 knockout mouse (Ge et al., 2008). 
Moreover, previous in vitro study using 3T3-L1 cell model has demonstrated that low dose 
of acetate and propionate (0.1 µM) increases the 3T3-L1 differentiation as revealed by the 
increase in intracellular lipid content based on Oil Red-O staining. In present study, the rate 
of lipogenesis was calculated by normalising the Oil Red-O value with its respective viability 
value. Only valerate, isobutyrate, and isovalerate were demonstrated to significantly 
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increase de novo lipogenesis in 3T3-L1 cells when these compounds were used at the 
highest tested dose which was 100 µM. Treatment of acetate and propionate, as well as 
other SCFAs, even at the highest dose during the 3T3-L1 differentiation were unable to 
significantly effecting the rate of lipogenesis even though the doses that is used were 
higher than what has been reported previously. In addition, Frost et al., also unable to 
observe any changes in 3T3-L1 lipogenesis when treating the cells with 0.1-10 µM of 
acetate and propionate throughout the differentiation process (Frost et al., 2014a). In 
general, SCFAs levels in blood can be found in micromolar concentration.  
In present study, the low doses (1.0 and 10 µM) of all tested SCFAs except for 
valerate did not have significant effect in term of modulating cell viability and 
differentiation of the cells. Valerate has been shown previously to increase insulin-
stimulated glucose uptake in 3T3-L1 adipocytes (Han et al., 2014). Our finding that valerate 
increases lipogenesis might be linked with the reason that it increases the glucose uptake 
by the cells via the action of insulin. The most common tissue where insulin-stimulated 
glucose uptake occurred is in skeletal muscle, where it stores glucose as glycogen (Kraegen 
et al., 1985). However, an approximately 10% of this process also occurs in adipose tissue, 
where glucose is stored as TG (Leto and Saltiel, 2012). 
 
6.4.2 Adipogenic genes expression was not affected by the treatment of 
SCFAs on 3T3-L1 cells. 
Adipocyte differentiation is regulated by a set of gene-expression events (Rosen 
and MacDougald, 2006). In order to test whether SCFAs influence the expression of related 
genes during the differentiation of 3T3-L1 cells, the expression level of adipocyte 
differentiation marker, Pparg, Fasn, and Adipoq were measured. Pparg belongs to the 
nuclear receptor superfamily of ligand-activated transcription factors and is essential for 
both white and brown adipocytes differentiation (Kajimura et al., 2008). It has been shown 
previously that the expression level of Pparg is high in adipose tissue and adipocyte cell 
line, while low expression level or even absent in other tissues and cell lines (Braissant et 
al., 1996; Forman et al., 1995; Schoonjans et al., 1996). The expression level of this gene is 
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low in in vitro model of 3T3-L1 preadipocytes, but dramatically induced during the 
differentiation into adipocytes in the presence of differentiation medium (Chawla et al., 
1994). In agreement with this study, our qPCR analysis demonstrates that Pparg expression 
is greatly increased during the differentiation of 3T3-L1 into adipocytes and was peaked at 
day 10 (end of differentiation).  
The mRNA levels of one of the Pparg target genes, fatty acid synthase (Fasn) were 
then investigated. Fatty acid synthase is one of the markers of the final stage of adipocyte 
differentiation and the key enzyme in the de novo lipogenesis (Liu et al., 2004). During 
adipogenesis, de novo fatty acid synthesis is an important step as it provides precursor to 
be incorporated into triglyceride. In 3T3-L1 adipocytes culture model, the major 
component in its growth medium is glucose, therefore the degree of adipogenesis may be 
highly dependent on expression and activity of enzymes involved in glucose metabolism, 
fatty acid synthesis, and esterification (Sul et al., 2000). Previously, it has been 
demonstrated that Pparg expression was highly up-regulated when the cells differentiated 
into adipocytes. Based on this, it is speculated that the expression of Pparg target gene, 
Fasn might also be up-regulated. Indeed, Fasn expression was significantly (p<0.001) up-
regulated when the cells differentiated into adipocytes at day 10 as compared to its 
expression at day 2 after induction of differentiation. Consistent with our finding, a 
previous study reported that both increase in Fasn gene transcription and the stabilisation 
of Fasn mRNA caused a dramatic increase in Fasn mRNA levels during 3T3-L1 cells 
differentiation (Moustaïd and Sul, 1991). However, no SCFAs treatment was found to 
significantly up-regulate the expression of this gene when compared to the control during 
the differentiation of 3T3-L1 to adipocytes. 
Adipose tissue secretes hormones and cytokines that regulate many biological 
processes such as food intake, energy expenditure, and carbohydrate and lipid metabolism 
(Havel, 2002). Adiponectin,  one of the adipocyte-specific genes, plays an important role in 
modulating differentiation of preadipocytes into mature adipocyte by acting as endocrine 
factor, regulating many biological processes by effecting target organs (Lara-Castro et al., 
2007). The expression of adiponectin gene, Adipoq has been shown to increase during 
adipocyte differentiation in both 3T3-L1 and 3T3-F442A cells, and that the expression was 
first observe at day 4 after induction of differentiation (Hu et al., 1996). This result is 
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consistent with what have been demonstrated in this study that the expression of this gene 
is significantly increased at day 5 after induction of differentiation and reaching the highest 
level at day 10. When a single dose of SCFAs (100 µM) was introduced in the culture 
medium throughout the differentiation process, no significant increase in Adipoq gene 
expression between SCFAs-treated and control group was observed. Low circulating level 
of adiponectin was suggested to have a role in the pathogenesis of diseases linked to 
obesity and metabolic syndrome (Funahashi et al., 1999; Matsuzawa et al., 1999). A 
previous study has demonstrated that overexpression of adiponectin protected ob/ob 
mice from diabetes and ApoE-deficient mice from atherosclerosis (Yamauchi et al., 2003). 
Moreover, in adipose tissues, insulin sensitivity was improved when adiponectin circulating 
levels are increased as a result of overexpression of this gene (Combs et al., 2004).  
In a previous chapter (Chapter 5), it has been demonstrated that some of the SCFAs 
used in this study showed an agonist activity for free fatty acid receptors, FFAR2, and FFAR3 
as well as for GPR109A. In order to assess if any of these SCFAs able to affect the expression 
of the genes encoding for these receptors, the expression levels of Hcar2, Ffar2, and Ffar3 
genes during the differentiation of 3T3-L1 cells were measured. The expression levels of 
Ffar2 and Hcar2 genes increase dramatically when 3T3-L1 cells differentiated into 
adipocytes and peaked at day 10 after induction of differentiation. These result is in line 
with study conducted by Hong, (2005), that showed an increase of Ffar2 mRNA level in 
3T3-L1 cells during differentiation from pre-adipocytes to adipocytes. As for GPR109A, 
previous study has shown that low expression level of this receptor in their native 3T3-L1 
adipocytes when compared to primary adipocytes (Plaisance et al., 2008). In this study, 
using RT-qPCR analysis, an increase on the expression of Hcar2 during 3T3-L1 
differentiation was observed. This study however, was not measuring the expression of the 
receptor, GPR109A itself. Despite showing that there was a significant (p<0.05) effect of 
time on expression of GPR109A, only butyrate but not other SCFAs has been found to 
significantly up-regulate this gene. A previous study has demonstrated that acetate and 
propionate (0.1 µM) stimulate Ffar2 expression in 3T3-L1 adipocytes, with an increase in 
the accumulation of fat as revealed by Oil Red-O staining (Hong, 2005). Despite showing 
an up-regulation in the Ffar2 gene expression, no effect on Oil Red-O staining was observed 
when the cells were treated with acetate, propionate, and butyrate during the 
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differentiation process. On the other hand, consistent with previously published data, a 
very low expression level of Ffar3 was found with high cycle threshold value (Ct), thus can 
be considered as not express (Frost et al., 2014a; Hong, 2005).  
 
6.4.3 Single dose (100 µM) of propionate, butyrate, and valerate decrease 
basal level of lipolysis in 3T3-L1 adipocytes. 
Fat accumulation within the cell in the form of triacylglycerol (TG) is determined by 
the equilibrium between lipogenesis (fat synthesis) and lipolysis (fat breakdown/fatty acid 
oxidation) (Kersten, 2001). In the event of food intake, the excess of non-esterified fatty 
acids (NEFA) in the diet are esterified to TG, which are then stored in the form of lipid 
droplets in the cytosol (Lass et al., 2011). During times of energy deprivation, adipose tissue 
undergoes higher rate of lipolysis to generate fatty acids and glycerol, which are 
subsequently used as energy substrates. Lipolysis is as great importance as lipogenesis in 
regulating lipid and energy homeostasis.  
In the present study, effort has been made to investigate the effects of SCFAs in the 
rate of adipocyte lipolysis using a fully differentiated 3T3-L1 adipocytes. A single dose (100 
µM) of propionate, butyrate, and valerate has been shown to significantly (p<0.05) inhibit 
basal lipolysis rate in differentiated 3T3-L1 adipocytes by measuring the release of glycerol 
in the medium. The inhibition of lipolysis in 3T3-L1 adipocytes has been shown previously 
by other group when the cells were incubated with acetate and propionate for 4 hours (Ge 
et al., 2008). More recently, a study has demonstrated that butyrate reduces lipolysis and 
inflammatory signalling generated by interaction of macrophages and adipocytes (Ohira et 
al., 2013). Lipolysis process begins with the hydrolysis of TG to form diacylglycerol (DAG), 
which is then followed by monoacylglycerol (MAG) formation, with the release of fatty 
acids at each step. Final step of this process is when MAG is hydrolysed to release fatty 
acids and glycerol (Duncan et al., 2007a). In this study, niacin is used as a positive control 
due to its well-documented anti-lipolytic effect in both in vivo and in vitro (Plaisance et al., 
2008). Indeed, an inhibition in the basal lipolysis rate is observed, with significant (p<0.001) 
reduction (15%) of glycerol release in the medium. Niacin has been used for over fifty years 
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for treating dyslipidaemia, the risk factor for atherosclerosis, by altering plasma lipid profile 
(Carlson, 2005). Furthermore, niacin reduces the levels of athrogenic VLDL and LDL-
lipoprotein, as well as Lp(a). In addition, it also raises the level of HDL lipoprotein which is 
known as good lipid (Carlson, 2005).  
Even though the inhibition of basal lipolysis by propionate, butyrate and valerate is 
less potent than niacin, the reduction of glycerol release in the medium is significant 
(p<0.05) when compared to the vehicle-treated cells. Out of the SCFAs that significantly 
inhibit basal lipolysis in mature 3T3-L1 adipocyte, valerate shows the most interesting 
findings. Earlier in this chapter (section 6.3.2.2), it has been demonstrated that 100 µM 
valerate promotes de novo 3T3-L1 lipogenesis. As the adipogenesis rate is controlled by 
the balance of TG formation and TG hydrolysis, it is possible that the effect of valerate in 
promoting lipogenesis in 3T3-L1 adipocyte is based on its ability in inhibiting lipolysis, thus 
allowing more fat accumulation in the cells. In striking contrast, isobutyrate and isovalerate 
did not show a significant effect on lipolysis. Thus, these results suggest the anti-lipolytic 
effect of short-chain fatty acids (propionate, butyrate and valerate) is lost when another 
methyl group is added (i.e., isobutyrate and isovalerate).  
 
6.5 CONCLUSION 
This chapter aimed at investigating the role of a comprehensive SCFA panel on 
adipocytes differentiation and function. It has been shown that the selected SCFAs doses 
were not able to reduce or inhibit the 3T3-L1 cell viability. Thus, the selected SCFAs doses 
were not toxic to this cell line. Moreover, Oil Red-O lipid staining revealed that 100 µM of 
valerate, isobutyrate, and isovalerate increased adipogenesis in 3T3-L1 cells. Despite 
showing a significant role in promoting adipogenesis for isobutyrate, valerate, and 
isovalerate, no significant different (p>0.05) was observed in adipogenic genes expression 
in Pparg, Fasn, and Adipoq between SCFAs-treated and control group. While it has been 
suggested that SCFAs promote adipogenesis in 3T3-L1 cell via GPCR-mediated pathways, 
however as mentioned previously, with low sample number for the qPCR analysis, no 
significant conclusion on the relationship between the effect of SCFAs treatment on 3T3-
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L1 adipogenesis and gene expression was able to yield. Furthermore, this present study 
also demonstrated that propionate, butyrate, and valerate significantly decrease basal 
lipolysis in this cell model but with less potent than niacin. Valerate in particularly, has been 
shown to promote 3T3-L1 adipogenesis by inhibiting basal lipolysis rate in 3T3-L1 
adipocyte. Taken together, for the first time, using 3T3-L1 cell model, valerate has been 
shown to stimulate adipogenesis and exert its anti-lipolytic property in adipocyte. These 
findings suggest the potential role of valerate in regulating lipid metabolism and adipocyte 
differentiation, thus highlight its potential to be used in the treatment of dyslipidaemia.   
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CHAPTER 7 
 
7. GENERAL DISCUSSION 
Although SCFAs have been heavily studied, there are still gaps in the knowledge of 
their biological effects. The aim of this PhD is to characterise the subtle metabolic and 
pharmacological effects of SCFAs on important metabolic tissues which are liver and 
adipose tissue. To address this, a set of hypothesis has been set up; 1) SCFAs may act as 
substrates for energy metabolism of the cell, 2) SCFAs may act as ligands in activating 
GPCRs (i.e., FFAR2, FFAR3, GPR109A), 3) SCFAs may play important role in regulating 
adipocytes differentiation and mature adipocyte function. Based on the results of the first 
study (Chapter 3), the effect of SCFAs (propionate and butyrate) on HepG2 cells is then 
investigated by identifying the metabolic signature of the exposure (Chapter 4). As SCFAs 
have been shown to act as agonist for GPCRs, the pharmacological assessment of a 
comprehensive SCFAs panel on their GPCRs, i.e., FFAR2, FFAR3, GPR109A is then 
implemented (Chapter 5). Finally, the cellular response of a comprehensive panel of SCFAs 
in regulating adipocyte differentiation and function by using 3T3-L1 cell model is assessed 
(Chapter 6). 
 
7.1 Key findings 
The gut microbiota influences human health through a number of mechanisms. One 
of the highlight of its benefits is from the microbial metabolites that have been shown to 
have major influence on host physiology. Here in this PhD thesis, the effect of several SCFAs 
on two important metabolic tissues were investigated. Two cell culture models were used 
which are HepG2 hepatocarcinoma cell line (hepatocyte) and 3T3-L1 cell line (adipocyte).  
Sodium is one of the most important electrolytes in human body as it regulates 
extracellular fluid as well as essential in balancing the concentration gradient for the signal 
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transmission in nerve and muscle (Bouchard et al., 1993). Sodium chloride (NaCl) is the 
most commonly used salt in the molecular biology and cell biology, and is the essential 
micronutrient for living cell (Pohl et al., 2013). As SCFAs (propionate and butyrate) were 
used in the form on sodium salt (chapter 4), the effect of NaCl on HepG2 cell was first 
investigated (chapter 3). High concentration of NaCl can be genotoxic as evidenced by the 
increase in DNA damage in cell culture study (Kultz and Chakravarty, 2001). Consistent with 
the previous observation made by Dmitrieva et al., (2003) that only at ~200 mM of NaCl 
cell growth was affected and DNA damage was observed, here in this study the highest 
dose of NaCl tested (1.0 mM) shows no effect on HepG2 cell viability. Multivariate data 
analysis on the data generated from 1H NMR metabolic profiling of HepG2 cell media 
further confirmed that no significant modulation of HepG2 cell metabolism occur when the 
cells were treated with NaCl all tested doses when compared to the control. 
Out of the SCFAs produced in the colon, butyrate has caught most attention and 
has been studied widely. It has been demonstrated previously that butyrate at certain 
concentrations plays role in protecting against colon cancer and colitis by supressing 
colonic inflammation, which then causing cell cycle arrest and inducing apoptosis 
(Ganapathy et al., 2013; Roediger, 1990). SCFAs (C3, C4, and C5) at 5 mM dose have been 
shown to inhibit colorectal adenocarcinoma cell line, HT-29. The anti-proliferative effects 
of SCFAs, propionate and butyrate in particularly, have been suggested due to their histone 
deacetylases inhibitor (HDAC) properties (Aoyama et al., 2010; Hinnebusch et al., 2002).  In 
this study, using HepG2 hepatocarcinoma cell line, dosing the cell with 10 mM and 100 mM 
of sodium propionate and sodium butyrate decrease the cell viability and proliferation 
(Chapter 4). Although no attempt has been made to measure the histone hyperacetylation, 
the results of this study suggest that the anti-proliferative effect of propionate and 
butyrate appears to be dependent upon their histone hyperacetylation effects as 
evidenced by Hinnebusch et al., (2002). HDAC inhibitors provide a great potential for the 
development of anti-cancer drugs (Jung, 2001).  
It has be known for some time that SCFAs is used as a source energy which  accounts 
for ~10% of the daily caloric requirement in humans (Bergman, 1990b). Based on the 
relatively high affinity of colonocytes for butyrate, these cells prefer butyrate as their main 
energy source. Approximately 60-70% of the colonocytes energy supply comes from 
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butyrate oxidation (Roediger, 1982), whilst others (propionate and butyrate) will be 
transported by hepatic vein to the liver to get metabolised (den Besten et al., 2013). In 
order to investigate the effect of SCFAs on hepatic cancer metabolism and to identify dose-
response metabolic signature associated with the exposure of HepG2 cells to sodium 
propionate and sodium butyrate, 1H-NMR metabolic profiling approach was carried out. 
Decrease in the cell media concentration of propionate and butyrate after 72 hours 
treatment of HepG2 cell when compared to the control, and at the same time increase in 
alanine, lactate, and α-keto-β-methylvalerate suggest the possibility of the HepG2 cell in 
metabolising these SCFAs as substitute to glucose for their energy source (Chapter 4).  
Butyrate enters the mitochondria, and undergoes β-oxidation to acetyl-CoA, which 
then enters the TCA cycle generating NADH. NADH enters electron transport chain 
producing ATP as the main product and CO2 as a by-product (Roediger, 1980b). As a 
glucogenic compound, propionate might undergo gluconeogenesis in the event of high 
glucose demand. It has been shown recently that propionate increased the rate of 
intestinal gluconeogenesis (IGN) which has beneficial effects on glucose and energy 
homeostasis (De Vadder et al., 2014). Glucose released by IGN is detected by portal glucose 
sensor, sodium glucose co-transporter (SGLT), which sends signal to the brain thus inducing 
satiety and regulating glucose homeostasis (Delaere et al., 2013). Cytosolic pyruvate 
produced by glycolysis has a number of fates. Primarily, pyruvate can be 
transported/diffused from the cell. In low oxygen conditions (hypoxia) and in high 
proliferating cell such as in cancer cell, pyruvate is reduced to lactate to recover NAD+. It 
also can undergo oxidation via TCA cycle in mitochondria or is converted to alanine via 
transamination with glutamate. In addition to pyruvate, we also observed extracellular 
accumulation of lactate and alanine. As HepG2 cell is a hepatic cancer cell line, the 
accumulation of lactate is expected due to the ‘Warburg effects’ (Cairns et al., 2011).  
A number of studies have demonstrated that the increase in protein turn over 
produces gluconeogenic amino acids, which in turn increases the gluconeogenesis rate in 
T2D patients (Gastaldelli et al., 2000). α-keto-β-methylvalerate is an intermediate 
metabolite of isoleucine catabolism. The accumulation of this metabolite suggests that the 
activity of BCAT enzyme in the early step of BCAA catabolism exceed the downstream 
enzymes responsible in incorporating this keto-acid into TCA cycle. BCAA have been shown 
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to play role in the development of obesity-associated insulin resistance. Accumulation of 
BCAA catabolism intermediates cause incomplete oxidation of glucose and fatty acids, 
leading to an increase in mitochondrial stress, impaired glucose homeostasis, and insulin 
resistance (Newgard, 2012; Newgard et al., 2009). The metabolomics analysis also 
highlighted α-keto-β-methylvalerate, a BCAA isoleucine catabolism intermediate as a 
candidate marker of both propionate and butyrate dose-response, though the significant 
modulation of this metabolite only observed at 24-hr time point. The increase in 
accumulation of this metabolite throughout the study suggests that HepG2 cells might 
prefer SCFAs for their energy source, and less incorporation of isoleucine catabolism 
intermediate into the TCA cycle. Although the highest tested dose for propionate and 
butyrate used in this study are not physiologically observed in this tissue (hepatic), these 
data provide insight into the potential role of propionate and butyrate in modulating 
hepatic cancer cell metabolism that relate to the energy production, thus adding new 
knowledge on the biological effects of SCFAs.  
Apart from their role as fuel substrates, SCFAs also act as signalling molecules at the 
cell-surface level. FFAR3 (GPR41) and FFAR2 (GPR43) along with GPR40, are a small family 
of GPCRs that are able to respond to fatty acids (Covington et al., 2006). While GPR40 
responds to medium and long chain fatty acids (Briscoe et al., 2003), FFAR2 (GPR43) and 
FFAR3 (GPR41) are activated by short-chain fatty acids (Brown et al., 2003; Le Poul et al., 
2003). Using short-chain carboxylic acids to reduce the intracellular cAMP by activating 
FFAR2 and FFAR3 allowed the pharmacology of a variety of SCFAs to be determined 
(Chapter 5). Consistent with the observations made by other groups, data from this study 
demonstrate the agonist activity of SCFAs were in agreement with potencies measured in 
different assay systems (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003). FFAR2 
has a preference for acetate and propionate (2 and 3 carbons), whereas longer SCFAs (≥3 
carbons) are preferred by FFAR3. Furthermore, niacin or nicotinic acid has been found to 
act as partial agonist for FFAR3 with relatively low EC50 value (EC50=1465 µM) and much 
lower for FFAR2. Although niacin is a week agonist for these receptors, interestingly, this is 
the first study to report on the activation of FFAR2 by niacin, at least based on the 
experiments conducted in this study. 
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The highest expression of FFAR2 is in immune cells, especially in neutrophils (Brown 
et al., 2003), where its activation by SCFAs plays a crucial role in regulating immune 
responses (Maslowski et al., 2009). FFAR3 expression is more widespread than FFAR2, with 
the highest expression found in adipose tissue (Brown et al., 2003). FFAR3 activation by 
SCFAs has been shown to increase leptin secretion, thus increases satiety, and suppresses 
food intake (Cohen et al., 2001a). Moreover, it has also been shown that both FFAR2 and 
FFAR3 activation by SCFAs in L cells promotes the release of a potent anorectic hormone, 
GLP-1, which then regulates insulin secretion from pancreatic β-cells, and increases insulin 
sensitivity in target tissues (Tolhurst et al., 2012). The metabolic function of FFAR2 and 
FFAR3 makes them an attractive target for drug development. Thus, the new agonists for 
these receptor as revealed in this study could potentially be used in the treatment of 
obesity.  
Previous study demonstrated that butyrate is a ligand for GPR109A in the colon 
(Thangaraju et al., 2009a), and that the activation of this receptor by butyrate suppresses 
inflammation and carcinogenesis in colon (Singh et al., 2014a). Based on these findings, I 
hypothesised that other SCFAs might also activate GPR109A the same way as butyrate and 
niacin. Indeed, consistent with the data reported by Taggart et al., (2005), I found that 
niacin, butyrate, and valerate are able to activate GPR109A receptor. Interestingly, in this 
study, isobutyrate and isovalerate have been identified as the partial agonist for GPR109A, 
which is a novel findings. These branched chain fatty acids are produced in small amount 
by gut microbiota that are capable in breaking down protein and fermenting amino acid 
(Macfarlane et al., 1986). However, due to its low physiological concentrations, BCFA are 
not likely to reach the desired concentration to activate the receptor. In contrast, butyrate 
concentration, but not valerate, can reach up to ~20 mmol/L in colon (Thangaraju et al., 
2009b). GPR109A has been shown to express in abundance on the luminal membrane of 
colonic epithelial cells in human and mouse, where its activation by butyrate induces 
tumour suppression (Thangaraju et al., 2009a). In addition, GPR109A activation also has 
been shown to mediate the anti-lipolytic effect of niacin in adipocyte, thus revealing the 
underlying mechanism of its lipid-lowering effect (Tunaru et al., 2003; Wise et al., 2003). 
Together, data obtained from this study (Chapter 5) on the novel agonists (isobutyrate and 
isovalerate) of GPR109A expand the knowledge on the pharmacological effects of SCFAs 
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and new therapies specifically targeting this receptor could be used for the treatment of 
metabolic syndrome related diseases, as well as for the protection against inflammation 
and carcinogenesis.  
Adipose tissue is one of the important metabolic tissues in human body. In normal 
condition, excess energy is stored in adipocytes in the form of TGs and only low amount of 
TGs are found in non-adipocytes. The dysregulation of adipocytes has been shown to play 
a major role in the development of T2D and many metabolic abnormalities (Frayn et al., 
2007). Ectopic lipid deposition in non-adipocytes such as liver, pancreas, and muscle as a 
result of the limited number of adipocytes decrease insulin sensitivity (Unger et al., 2010). 
This condition may be caused by the limited number of hypertrophic adipocytes that 
unable to store lipid efficiently in a high caloric environment (Unger et al., 2010). A good 
understanding of adipocytes differentiation and development is therefore important in 
maintaining metabolic health. In this study (Chapter 6), the effect of SCFAs on adipocyte 
differentiation in murine 3T3-L1 cell was investigated. Out of the tested SCFAs, only 
isobutyrate, valerate, and isovalerate have been found to significantly enhance the 
formation of Oil Red O-stained cells. These results indicate that these SCFAs promote 
adipocyte differentiation in 3T3-L1 adipocyte cell model. The findings of this study 
however, are not consistent with what have been reported previously on the positive role 
of acetate and propionate in promoting adipogenesis in 3T3-L1 cell (Hong, 2005). This study 
failed to observe any significant changes in intracellular TG content as revealed by the Oil 
Red-O staining as well as in gross cellular morphology when the 3T3-L1 cells were 
incubated with acetate, butyrate, and propionate during the differentiation to adipocyte.  
While it has been demonstrated that SCFAs (isobutyrate, valerate, and isovalerate) 
stimulate adipocyte differentiation in 3T3-L1 cell, SCFAs has no effect on adipocyte 
differentiation in human stromal vascular fraction (SVF) (Dewulf et al., 2013). In addition, 
the differentiation of human bone marrow-derived mesenchymal stem cells into 
adipocytes has been shown to be inhibited by butyrate (Chen et al., 2003). The inconsistent 
findings on the effect of SCFAs on adipocyte differentiation may be related to the use of 
different cell line and different cell culture condition among the research groups.  
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SCFA is a ligand for FFAR2 and FFAR3. The stimulatory effect of acetate and 
propionate on adipocyte differentiation in 3T3-L1 cells has been suggested to be mediated 
by FFAR2 and not via FFAR3 as the Ffar3 mRNA was not expressed in this cell culture model 
(Hong, 2005). In this study however, the adipogenic effect of SCFAs (isobutyrate, valerate, 
and isovalerate) on 3T3-L1 cell has been shown to be FFAR2-independant. Exposing 3T3-L1 
preadipocytes to SCFAs throughout the differentiation process made no difference to the 
Ffar2 mRNA expression pattern as the control group also displayed similar pattern of 
expression of this gene over the time course studied. The observation of the mRNA 
expression pattern however, was obtained from only one single experiment. Thus, more 
data needed before any conclusions can be made on the role of FFAR2 in mediating SCFAs 
effect on 3T3-L1 adipogenesis.  
As the accumulation of TG in the cells is determined by the balance between fat 
synthesis and fat breakdown (lipolysis), next, the role of SCFAs in inhibiting basal 
adipocytes lipolysis is assessed. Propionate, butyrate, and valerate have been found to 
significantly inhibit lipolysis in 3T3-L1 adipocyte as evidenced by the reduction of glycerol 
release to the cell culture media. It is interesting to note that there have been a reports on 
the anti—lipolytic activity of both propionate and butyrate (Ge et al., 2008; Ohira et al., 
2013), but as far as our knowledge is concerned, the anti-lipolytic activity shown by 
valerate is a novel finding. As mentioned previously, valerate has been shown to promote 
3T3-L1 differentiation. Due to its pronounce anti-lipolytic activity, it is possible that the 
stimulatory effect of SCFA in adipocyte differentiation is based on its ability in inhibiting 
lipolysis, thus allowing more fat storage in the cell. These properties could present a great 
potential for the treatment of dyslipidaemia. As niacin also inhibits lipolysis and has been 
shown to raise the level of HDL and at the same time reducing VLDL and LDL, it is of interest 
to see if SCFAs could also have the same properties as niacin in reducing the risk factor of 
atherosclerosis. Given the fact that adipocytes development plays an important role in 
maintaining energy homeostasis, SCFAs could potentially serve as a good regulator in 
regulating energy storage and expenditure in adipose tissue.  
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Future research 
To take this thesis further, the role of GPCRs in mediating the effect of SCFAs on 
hepatic metabolism could be explored by carrying out receptor knockdown experiment. By 
doing this, it is interesting to see if we can decipher between metabolic response and 
signalling response via GPCRs in hepatic tissue, and assessing this effect on the metabolic 
signature. Selection for the most suitable hepatic model that expressing the interested 
GPCRs and has a close properties as primary hepatocytes also important. It is also 
interesting to compare the metabolic signatures that we have identified in our study with 
signatures obtained in livers from mice treated with butyrate or propionate. In addition, 
the assessment of the pharmacological role of a comprehensive SCFAs panel in activating 
GPCRs also can be improved by repeating this study using different assay to confirm the 
agonist activity for the novel agonists. Due to the time constrain, we were only managed 
to generate a small number of sample with only one biological replicate in assessing 
adipogenic and GPCRs gene expression profiles using qPCR array. This lack of power of test 
has resulted in non-conclusive observation, as we were not able to draw a link between 
the role of GPCRs and adipogenesis (no significant effect of SCFAs on gene expression). 
With more time, we would generate a follow-up 3T3-L1 experiment including more 
biological replicates to assess the adipogenic gene expression profiles related to SCFA 
treatment during adipocytes differentiation. It is also interesting to measure the level of 
cAMP as a complement method to confirm the activation of the GPCRs during the 
adipogenesis. In order to confirm the clinical significance of the observations made in this 
study, these effects need to be tested using other in vitro adipocytes model such as human 
primary hepatocytes. 
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Conclusion 
As a conclusion, in this PhD, considerable effort has been made in assessing the 
biological effects of SCFAs on important metabolic target tissues, which are hepatic and 
adipose tissue. We have successfully applied a novel approach, using 1H NMR 
metabonomics to investigate hepatocyte-specific metabolic signature related to SCFA 
exposure and demonstrated that the effect of SCFAs in this cell model are mainly 
metabolic. Furthermore, the pharmacological assessment of a comprehensive SCFA panel 
on related GPCRs revealed a new agonists for GPR109A. Our cell-based assays of a 
comprehensive SCFA panel reveal the role of SCFAs in promoting adipogenesis and 
inhibiting adipocytes lipolysis. In general, the results reported in this thesis provide a new 
knowledge on the biological effects of SCFAs, and signify the gut-microbial metabolites-
host interaction. 
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APPENDIX:  
Table S.1: List of p value obtained from pair-wise comparison between propionate-treated and 
control group at 24-, 48-, and 72-hr time points using non parametric Wilcoxon-Mann-Whitney test. 
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Table S.2: List of p value obtained from pair-wise comparison between butyrate-treated and 
control group at 24-, 48-, and 72-hr time points using non parametric Wilcoxon-Mann-Whitney test. 
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Un-normalised Oil Red-O data. 
 
Figure S.1: Valerate, isobutyrate, and isovalerate at 100 µM dose increase lipogenesis in 3T3-L1 
cells. After 10 days incubation, cells were fixed and stained with Oil Red-O and O.D.520 nm was 
measured. Results are expressed as mean ± SEM and a Mann-Whitney two-tailed test was 
performed; * p<0.05, **p<0.01, ***p<0.001. 
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Expression of the GPCRs and markers for adipogenesis genes during 3T3-L1 
differentiation. 
 
 
Figure S.2: RT-qPCR analysis of the gene expression during 3T3-L1 cell differentiation. The RT-qPCR 
results are expressed as fold change relative to control-treated group from day 2 samples. 
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Table S.3: p-values for the slope coefficient comparison between SCFAs-treated and control groups 
on the gene expression analysis. 
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Supplementary data. 
Table S.4: Minimum Essential Medium (MEM) formulation (ThermoFisher Scientific) 
Components Molecular Weight Concentration (mg/L) mM 
Amino Acids 
L-Arginine hydrochloride 211.0 126.0 0.5971564 
L-Cystine 240.0 24.0 0.1 
L-Histidine hydrochloride-H2O 210.0 42.0 0.2 
L-Isoleucine 131.0 52.0 0.39694658 
L-Leucine 131.0 52.0 0.39694658 
L-Lysine hydrochloride 183.0 73.0 0.3989071 
L-Methionine 149.0 15.0 0.10067114 
L-Phenylalanine 165.0 32.0 0.19393939 
L-Threonine 119.0 48.0 0.40336135 
L-Tryptophan 204.0 10.0 0.04901961 
L-Tyrosine 181.0 36.0 0.19889502 
L-Valine 117.0 46.0 0.3931624 
Vitamins 
Choline chloride 140.0 1.0 0.007142857 
D-Calcium pantothenate 477.0 1.0 0.002096436 
Folic Acid 441.0 1.0 0.0022675737 
Niacinamide 122.0 1.0 0.008196721 
Pyridoxal hydrochloride 204.0 1.0 0.004901961 
Riboflavin 376.0 0.1 2.6595744E-4 
Thiamine hydrochloride 337.0 1.0 0.002967359 
i-Inositol 180.0 2.0 0.011111111 
Inorganic Salts 
Calcium Chloride (CaCl2-2H2O) 147.0 264.0 1.7959183 
Magnesium Sulfate (MgSO4-7H2O) 246.0 200.0 0.8130081 
Potassium Chloride (KCl) 75.0 400.0 5.3333335 
Sodium Bicarbonate (NaHCO3) 84.0 2200.0 26.190475 
Sodium Chloride (NaCl) 58.0 6800.0 117.24138 
Sodium Phosphate monobasic (NaH2PO4-
2H2O) 
156.0 158.0 1.0128205 
Other Components 
D-Glucose (Dextrose) 180.0 1000.0 5.5555553 
Phenol Red 376.4 10.0 0.026567481 
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